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ABSTRACT 
The study objective was to compare the response of bone markers to an exercise 
session consisting of high mechanical loading (144 jumps) between boys (n=12, 10.2 ± 
0.4 years) and men (n=18, 22.5 ± 0.7 years). Blood samples were collected at pre-, 5, 60 
minutes post-, and 24 hours post-exercise) to measure bone-specific alkaline phosphatase 
(BAP), amino-terminal cross-linking telopeptide (NTx), osteoprotegrin (OPG) and 
receptor activator of nuclear factor kb ligand (RANKL). Boys had higher BAP levels at 
all time points, with an increase 24 hours post-exercise. No such increase was observed in 
men. Likewise, NTx levels were higher in boys, with a greater increase over time than in 
men. OPG and RANKL levels were similar in boys and men at all times. In summary, 
even one session of exercise stimulates bone turnover, as reflected in the increase in both 
BAP and NTx, in boys (but not men) within 24 hours.    
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Chapter 1: Introduction 
1.1 Rationale 
Physical activity (PA) plays a vital role in the development and maintenance of 
skeletal mass throughout the life span, as shown in several meta-analyses (Behringer, 
Gruetzner, McCourt, & Mester, 2013; Marques, Mota, & Carvalho, 2012; Wolff, van 
Croonenborg, Kemper, Kostense, & Twisk, 1999). The positive effects of PA can vary 
throughout life’s different stages, where the most evident benefits can be seen during 
prepubescent and pubescent skeletal growth and development (K. B. Gunter, Almstedt, & 
Janz, 2012). During childhood and adolescence, high impact exercise, such as jumping, 
appears to have the greatest benefits on bone structure and mineralization. There are 
several impact exercise intervention studies, such as jumping, in prepubescent, pubescent 
and young adult populations which demonstrate the beneficial effect of high impact 
exercise training on bones, in terms of the changes in the amount of bone mineral over 
time (bone mineral accrual) and bone structure (Fuchs, Bauer, & Snow, 2001; K. Gunter, 
Baxter-Jones, Mirwald, Almstedt, Fuchs et al., 2008; K. Gunter, Baxter-Jones, Mirwald, 
Almstedt, Fuller et al., 2008; Janz et al., 2004; Mackelvie, McKay, Khan, & Crocker, 
2001; MacKelvie, McKay, Petit, Moran, & Khan, 2002; MacKelvie, Khan, Petit, Janssen, 
& McKay, 2003; MacKelvie, Petit, Khan, Beck, & McKay, 2004; Petit et al., 2002; 
Warden & Fuchs, 2009; Weeks, Young, & Beck, 2008). In terms of bone mineral density 
(BMD) in children it has been shown that non-impact sports, such as swimming, results 
in lower BMD in comparison to high impact sports, such as gymnastics (Cassell, 
Benedict, & Specker, 1996; Courteix et al., 1998). Therefore, not only is the timing of 
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physical activity a very important determining factor but also the type of physical activity 
(K. B. Gunter et al., 2012).  
While there is a clear correlation between physical activity and either increased BMD 
in children and adolescents or prevention of bone loss in adults, the particular 
mechanism(s) responsible for the increase or maintenance in BMD are not well 
understood. More specifically, it is not clear how physical activity affects bone cell 
activity that, in time, results in differences in BMC and BMD. The use of biochemical 
measurements of bone turnover provides information on bone cell activity, specifically 
bone formation by the osteoblast and bone resorption by the osteoclast. The use of 
markers of bone turnover allows for an estimation of the bone metabolic processes and 
any changes in bone turnover.  
While PA is a known contributor to bone turnover, the response of bone markers to 
exercise depends on the magnitude, intensity and duration of exercise. Short- and long-
term training appears to have beneficial effects on markers of bone formation and bone 
resorption (Banfi, Lombardi, Colombini, & Lippi, 2010). According to these studies, 
there appears to be a pattern of increased levels of markers of bone formation and 
decreased levels or stabilization of markers of bone resorption as a response to exercise 
training in adults and adolescents but there is limited research in children. Most studies 
which examined the effect of training on bone turnover involve a protocol in which blood 
sampling takes place 24-48 hours following the last exercise session. However, it is 
possible that this protocol precludes the detection of an acute exercise effect. 
Studies that examined the acute effects of exercise on markers of bone turnover in 
adults, have used various forms of exercise and blood sample timings and are therefore, 
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highly inconsistent (Banfi et al., 2010). Resistance training typically resulted in decreased 
bone resorption markers and unchanged bone formation markers, whereas endurance 
running typically resulted in increased markers of both bone formation and bone 
resorption  (Ashizawa et al., 1998; Brahm, Piehl-Aulin, & Ljunghall, 1997; Langberg, 
Skovgaard, Asp, & Kjaer, 2000; Lippi et al., 2008; Malm, Ronni-Sivula, Viinikka, & 
Ylikorkala, 1993; Nishiyama, Tomoeda, Ohta, Higuchi, & Matsuda, 1988; R. S. Rogers, 
Dawson, Wang, Thyfault, & Hinton, 2011; Scott et al., 2010; Scott et al., 2011; Scott et 
al., 2013; Thorsen, Kristoffersson, Hultdin, & Lorentzon, 1997; Welsh et al., 1997; 
Whipple et al., 2004; Ziegler et al., 2005). Non-weight bearing exercise, such as cycling, 
and plyometric exercise do not appear to have a clear pattern or trend (Guillemant, 
Accarie, Peres, & Guillemant, 2004; Herrmann et al., 2007; Kristoffersson, Hultdin, 
Holmlund, Thorsen, & Lorentzon, 1995; Lin et al., 2012; Pomerants et al., 2008; R. S. 
Rogers et al., 2011; Rong et al., 1997; Rudberg, Magnusson, Larsson, & Joborn, 2000; 
Wallace et al., 2000). In children, there is one study, by Pomerants et al. (2008), who 
examined the acute effects of 60 minutes of high intensity cycling on markers of bone 
turnover in boys of different pubertal stages. The authors reported no changes in markers 
of bone metabolism 30 minutes following the cycling bout (Pomerants, Tillmann, 
Karelson, Jurimae, & Jurimae, 2008).  
Therefore, the purpose of this study was to compare the acute response and recovery 
of bone metabolism induced by a high-impact, plyometric exercise protocol over a period 
of 24 hours between pre-pubertal children and adults.  This study will help to standardize 
the timing of sampling in terms of when the effects of exercise occur and whether or not 
the effect lasts longer than 24 hours.  From a methodological perspective, this 
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information will aid researchers in determining the appropriate timing to examine the 
effects of an intervention on bone metabolism, without contamination of a prior exercise 
session. Aside from the methodological purpose, a more practical aspect involves the 
determination of whether bone markers measurement in serum is sensitive enough to 
detect changes in bone metabolism following a single bout of exercise, as well as provide 
insight into the timeline of these changes. This is important information as it can 
elucidate the early phase of bone response to mechanical loading.  
1.2 Objectives and Hypotheses 
The objective of this study was three-fold. First, to determine the acute effects of a 
single bout of impact exercise on bone formation markers over 24 hours in both boys and 
men. The second objective was to determine the acute effects of a single bout of impact 
exercise on bone resorption markers over 24 hours in both boys and men. The third 
objective was to determine whether or not there was a difference in the effect of exercise 
on bone markers between boys and men. 
It was hypothesized that: (1) markers of bone formation would increase 1 hour post 
exercise and subsequently decrease 24 hours post exercise, (2) markers of bone 
resorption would increase 5 minutes post exercise and subsequently decrease to baseline 
values 24 hours post exercise and (3) children would have higher values for both markers 
of bone formation and resorption in comparison to the adults but both groups will follow 
the same trend with respect to the timing of the alterations.  
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Chapter 2: Review of Literature 
2.1 Bone 
2.1.1 Bone Anatomy, Development and Turnover 
The human skeleton contains 206 individual bones that provide the body with a 
multitude of important functions: support for the body, protection for vital structures, 
mineral reservoir composed mainly of calcium and phosphatase, and the mechanical basis 
for muscle movements. Skeletal tissue is predominantly composed of collagen fibers and 
minerals in the form of hydroxyapatite, derived mostly from calcium and phosphate 
(Bailey et al. 1996). The skeleton can be divided into the axial skeleton that includes the 
skull, vertebral column, sternum and ribs and the appendicular skeleton that includes the 
upper and lower extremities, as well as the shoulder and pelvic girdle (Moore, K.L. and 
Agur, A.M.R., 2007). Bone tissues can be mineralized into two forms: (1) cortical bone 
and (2) trabecular bone. Approximately 75-80% of the total skeletal mass is comprised of 
cortical bone and the remaining 20-25% of the mass is trabecular bone (Moore, K.L. and 
Agur, A.M.R., 2007). Cortical bone forms the outer surface of all bones, including the 
diaphysis of long bones, and is densely compacted tissue. Trabecular bone is comprised 
of a meshwork of thin, boney horizontal and vertical plates giving it a porous structure 
and is located on the inside of the cortical shell of flat bones, vertebral bodies and the 
epiphysis of long bones (Moore, K.L. and Agur, A.M.R., 2007). Because trabecular bone 
has a relatively larger surface area to volume ratio than cortical bone, it is suggested that 
this form of bone is more susceptible to hormonal changes and that it also has a higher 
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turnover rate. Cortical bone alternatively provides more protective, biomechanical and 
supportive properties (Moore, K.L. and Agur, A.M.R., 2007).  
Bone development is comprised of two very distinct phases; (1) skeletal 
patterning and (2) mineralization. Skeletal patterning occurs during the embryonic period, 
when the shape and position of various skeletal components are determined through local 
growth factors and numerous regulatory gene expressions. The second phase, 
mineralization, is highly influenced by mechanical stress and strain (Davies, Evans, & 
Gregory, 2005). Heredity is known to be a major determining factor of bone mineral 
status although there has been increasing supporting evidence to show that a large portion 
of the variance in BMD may be attributable to non-hereditary factors such as exercise and 
nutrition (Bailey et al. 1996). 
Bone turnover consists of three simultaneous processes each functioning 
differently; activation, resorption and formation (Bailey et al. 2006).  Activation is the 
first stage in bone turnover, where pre-osteoclasts are attracted to the modeling sites and 
fuse to form multinucleated osteoclasts (Bailey, Faulkner, & McKay, 1996). Bone 
resorption involves the cells that resorb bone, which are known as osteoclasts. Bone 
formation involves the bone-forming cells found on the surfaces of bone and in bone 
cavities, which are known as osteoblasts. If the rate of bone formation exceeds that of 
bone resorption the expectant result is bone mineral accrual, as seen during the growth 
years. In fact, during the adolescent growth spurt approximately half of the peak bone 
mineral content is attained (Malina et al. 2004; Seibel et al. 2002). Therefore, childhood 
through to late adolescence is considered a critical period of bone accrual (Seibel, 2002). 
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Once skeletal maturity is reached, bone tissue continues the process of constant 
renewal of old bone and its replacement by new bone, through coordinated activity of 
osteoblasts and osteoclasts. Bone turnover allows the body to respond to external 
mechanical forces and molecular signals, in addition to providing a mechanism for the 
maintenance of calcium homeostasis (Calvo, Eyre, & Gundberg, 1996). Osteoclasts 
initiate bone turnover by eroding mineralized surfaces, forming a cavity where 
osteoblasts can deposit new bone (Calvo et al., 1996). During steady state, the “coupling” 
of bone formation and bone resorption maintains bone mass but if bone resorption 
exceeds bone formation this may result in debilitating bone diseases such as osteoporosis 
(Calvo et al., 1996). 
The age of the onset of the accelerated rate of bone mineral accrual and the age of 
attainment of peak bone mineral content may vary between sexes (Bailey et al. 1996). In 
childhood, bone mineral content increases linearly with age, with no evident sex 
differences until puberty. However, during the course of growth and maturation, females 
undergo their growth spurt prior to males and as a result have a slightly higher bone 
mineral content during early adolescence. Since males experience their growth spurt later 
on, their bone mineral content continues to increase in late adolescence. Bone mineral 
content continues to increase in males throughout and into the third decade, whereas the 
total-body bone mineral content reaches a plateau, with only small increases at 
approximately 20 years of age in females. The sex differences will thus be established in 
late adolescence (Bailey et al., 1996; Malina, R.M., Bouchard, C. & Bar-Or, O., 2004; 
Theintz et al., 1992). 
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2.2 Bone Assessment Techniques 
The state of the skeleton and any changes in bone mineralization can be evaluated 
through several different techniques. Typically, dual-energy x-ray absorptiometry 
(DEXA) is used to measure bone mineral content from childhood right through to 
adulthood as it is quick, precise and the amount of radiation exposure is generally viewed 
as acceptable. This method provides an estimate of areal bone mineral density (g/cm
2
) 
acquired from the ratio of bone mineral content to bone area (Malina, R.M., Bouchard, C. 
& Bar-Or, O., 2004). BMD assessed through DEXA is only considered an estimation of 
‘true’ bone density as this method is measured in two dimensions and a true volumetric 
density is measured 3-dimensionally (Fulkerson et al., 2004). BMD measured by DEXA 
may not properly reflect true BMD as DEXA does not take into account the depth of the 
bones. 
For growing children, the preferred method of use for research purposes is often 
quantitative computed tomography (QCT) or peripheral QCT (pQCT), which provides a 
true measurement of volumetric bone mineral density. It also provides measures of bone 
size and geometry, both of which can affect bone strength. However, like DEXA, there is 
exposure to radiation, and the levels of exposure are higher than with DEXA and in a 
more focused region (Schoenau et al., 2004). QCT is also relatively expensive and does 
not provide a reference database for children.  
Quantitative ultrasound (QUS) has recently been developed for the assessment of 
bone strength and fracture risk in cortical bone. The advantage of transaxial QUS is that it 
measures the speed of sound (SOS), reflecting bone properties without being influenced 
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by bone size (Barkmann et al., 2000; Schoenau et al., 2004). QUS is also relatively 
inexpensive, non-invasive, radiation-free and portable. SOS can be measured either 
transversally, at trabecular bone sites or transaxially, along cortical bone. Transaxial 
assessments are limited to peripheral sites of the body, such as the radius and tibia, as the 
method involves transmission of sound waves along the length of the bone. The SOS 
values are a reflection of not only bone mineral but also structure and elasticity 
(Barkmann et al., 2000; Njeh et al., 1999; Schoenau et al., 2004).  
2.3 Biochemical Markers of Bone Turnover 
Because the previously mentioned bone assessment techniques do not allow for 
dynamic bone examination or are slow to reveal any intervention-induced changes,  
biochemical markers of bone turnover are useful for measuring acute changes in bone 
cell activity (Calvo et al., 1996; Watts, 1999). Biochemical markers of bone turnover can 
be measured via blood or urine and can be divided into two categories; (1) enzymes or 
proteins involved in bone formation (generated by osteoblasts) and resorption (generated 
by osteoclasts) and (2) the formation and degradation products of bone matrix 
metabolism (primarily type I collagen (Figure 1.) (Calvo et al., 1996; Watts, 1999). A 
limitation of these markers is that systemic biochemical markers cannot be narrowed to 
specific skeletal sites (Calvo et al., 1996; Christenson, 1997; Watts, 1999). 
2.3.1 Markers of Bone Formation 
The traditional markers of bone formation are either direct or indirect products of 
osteoblast activity and include one enzyme, bone-specific alkaline phosphatase and three 
byproducts of bone matrix synthesis, osteocalcin and carboxy and amino procollagen 
10 
 
extension peptides; all of which can be measured in the blood (Figure 1.)  (Banfi et al., 
2010; Calvo et al., 1996; Watts, 1999).  
2.3.1.a Bone-Specific Alkaline Phosphatase (BAP) 
Alkaline phosphatase (AP) is an enzyme associated with plasma membranes of 
bone, liver, intestines and placenta, all of which can contribute to the amount of AP found 
in the blood (Banfi et al., 2010; Calvo et al., 1996; Watts, 1999). Bone-specific alkaline 
phosphatase (BAP) is an enzyme localized to the membrane of osteoblasts and plays an 
important role in bone mineralization thereby providing a specific indicator for osteoblast 
activity (van Straalen, Sanders, Prummel, & Sanders, 1991). BAP has been used as a 
diagnostic marker in various bone pathologies such as osteomalacia, rickets, Paget’s 
disease and for monitoring the healing of new fractures (Calvo et al., 1996; Watts, 1999). 
In adults, BAP appears to be a more sensitive diagnostic tool when compared to total AP 
activity, as small increases are detectable and it is tissue-specific (Delmas & Garnero, 
1998). BAP is highly predominant throughout childhood, and even more so during and 
up until mid-puberty and is then followed by a decrease in late puberty or, post menarche 
for females (Mora, Pitukcheewanont, Kaufman, Nelson, & Gilsanz, 1999; Szulc, Seeman, 
& Delmas, 2000; van Coeverden et al., 2002). Nutritional intake does not typically 
influence BAP levels and the intra-individual variability over time is comparatively low 
(Seibel, 2002).  
2.3.1.b Osteocalcin (OC) 
Osteocalcin (OC) or GLA protein is a small protein that is synthesized by mature 
osteoblasts, odontoblasts and hypertrophic chondrocytes and has been studied extensively 
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as a marker of bone formation (Calvo et al., 1996). An abundance of evidence suggests 
that OC, the major noncollagen protein of bone matrix, is a sensitive and specific marker 
for osteoblast activity. The dynamic marker of bone formation is primarily deposited in 
the extracellular matrix of bone with fragments circulating in the blood (Ivaska et al., 
2004; Watts, 1999). Because OC is incorporated into the skeletal matrix and is released 
during bone resorption it can also be used as a measurement of bone turnover (Ivaska et 
al., 2004). In growing children, there appears to be a correlation between OC levels, 
height and height velocity, where OC propeptide levels parallel the height velocity curve. 
The concentration varies with pubertal level, age and time of day; where the highest 
levels are observed in the mornings. Nutritional intake does not typically have any 
influence on OC (Mora et al., 1999; Seibel, 2002; Szulc et al., 2000; van Coeverden et 
al., 2002).  
2.3.1.c Procollagen I Extension Peptides 
Procollagen I Extension Peptides, carboxy (PICP) and amino (PINP), constitutes 
approximately 90-95% of bone collagen with the remaining 5-10% coming from types III 
and IV. Type I collagen also has a minor component in the extracellular matrix of tissues 
aside from bone, such as skin, dentin, cornea, vessels and tendons (Banfi et al., 2010; 
Calvo et al., 1996). PINP and PICP result from the extracellular enzymatic cleavage at 
the carboxy and amino termini, following the synthesis of new collagen molecules. 
Because these peptides are generated with collagen synthesis they are considered to be a 
quantitative reflection of bone formation (Banfi et al., 2010; Seibel, 2002). Although 
most type I collagen is found in bone, it is not specific for bone and is therefore not the 
most sensitive index of bone formation (Seibel, 2002; Szulc et al., 2000). Similar to OC, 
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PICP and PINP are correlated with the growth velocity, peak values occur early in the 
morning and values are not usually influenced by food intake (Szulc et al., 2000). 
2.3.2 Markers of Bone Resorption 
The traditional markers of bone resorption typically measure the collagen 
degradation products from osteoclast activity, with one osteoclast-specific enzyme. Both 
blood and urine samples can be analyzed, reflecting bone resorption (Figure 1.) (Banfi et 
al., 2010; Calvo et al., 1996; Seibel, 2002). 
2.3.2.a Collagen Pyridinium Crosslinks 
Collagen cross-links, pyridinoline (Pyr) and deoxypiridinonine (Dpd), function to 
cross-link several collagen molecules via molecular bridges, thereby mechanically 
stabilizing the collagen molecule. They are non-reducible cross-links of bony and 
cartilaginous collagens that can also be found in the extracellular matrix of other 
connective tissues. During bone resorption, the cross-linked collagens are broken down 
with the cross-link components being released into the circulation and urine (Banfi et al., 
2010; Seibel, 2002). Pyr is predominantly found in cartilage but can also be found in 
bone, ligaments and vessels, whereas Dpd is almost exclusively found in bone and dentin. 
Because bone has a much higher turnover rate in comparison to cartilage, ligaments or 
tendons, the quantity of Pyr and Dpd found in either the blood or urine can be termed 
skeleton derived (Seibel, 2002). In children, there is a marked age-related variation in 
urinary Pyr and Dpd. As with many bone markers Pyr and Dpd correlate with the growth 
velocity, in that females experience an increase in the early stages of puberty and males 
experience that increase in the later stages of puberty (Mora et al., 1999; Szulc et al., 
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2000). Pyr and Dpd are highest in the morning, lowest in the evening and are not 
influenced by dietary intake (Watts, 1999).  
2.3.2.b Cross-linked Telopeptides 
Cross-linked telopeptides of type I collagen are measurements of osteoclast-
mediated collagen degradation products that are released with cross-links still attached at 
both ends. Currently, there are three markers with cross-links still attached; carboxy-
terminal collagen cross-links (CTx), amino-terminal cross-linking telopeptide (NTx) and 
carboxy-terminal telopeptide of collagen type I (ICTP). Both CTx and NTx can be 
measured in the blood and urine, whereas ICTP can only be measured in the blood 
(Seibel, 2002; Szulc et al., 2000; Watts, 1999). Similar to the majority of the 
aforementioned markers of bone turnover the peptide bound resorption markers CTx, 
NTx and ICTP correlate with growth velocity. Following the growth spurt, urinary and 
serum levels decrease to the level seen in adults (Marowska et al., 1996). Each 
telopeptide marker is subject to circadian variations and CTx can be powerfully 
influenced by food intake, therefore requiring fasting samples (Herrmann & Seibel, 2008; 
Seibel, 2002; Szulc et al., 2000). Although it has been suggested that most markers are 
unaffected by nutritional intake, there are no comparable studies that have been published 
for NTx (Hannon & Eastell, 2000; Herrmann & Seibel, 2008). 
2.3.2.c Plasma Tartrate-Resistant Acid Phosphatase (TRAP5b) 
Acid phosphatase is comprised of six different isoenzymes, of which only five are 
resistant to tartrate inhibition, including bone acid phosphatase; also known as tartrate-
resistant acid phosphatase (TRAP5b). TRAP5b is synthesized and secreted into the blood 
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by osteoclasts during bone resorption and is a reflection of the rate of bone resorption 
(Calvo et al., 1996; Seibel, 2002; Watts, 1999). Unfortunately, TRAP5b does lack 
specificity for osteoclasts, the presence of enzyme inhibitors in serum and does not 
provide stable frozen samples (Szulc et al., 2000). Both children, up until menarche in 
females, and postmenopausal women experience higher levels of TRAP5b. There is very 
little circadian variation demonstrated and it is not influenced by food intake (Seibel, 
2002). 
2.3.3 Osteoprotegerin and Receptor Activator of Nuclear Factor κB Ligand Ratio 
Osteoprotegrin (OPG), Receptor Activator of Nuclear Factor κB Ligand 
(RANKL) and Receptor Activator of Nuclear Factor κB (RANK) have been established 
as the essential cytokines, as new members of the tumor necrosis factor (TNF) ligand and 
receptor family, for osteoclast life span and as mediators of skeletal diseases (Hofbauer & 
Heufelder, 2001).  
2.3.3.a Osteoprotegerin (OPG) 
 OPG is considered a key regulator of osteoclastogenesis and is a soluble factor 
produced by osteoblasts. The effects that OPG has on bone, as shown in vitro, include 
inhibition of differentiation, survival and fusion of osteoclastic precursor cells, 
suppression of osteoclast activation and promotion of osteoclast apoptosis (Hofbauer & 
Heufelder, 2001; Khosla, 2001). Using OPG-deleted knock-out mice, it was established 
that without this certain molecule severe osteoporosis is developed as there is a marked 
increase in osteoclast formation, leading to a marked increase in bone resorption (Bucay 
et al., 1998; Mizuno et al., 1998). The levels of OPG appear to be maintained relatively 
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stable in children older than the age of 4 years old up until the ages of approximately 40-
45 years old, where they typically increase (Khosla, 2001; Wasilewska, Rybi-Szuminska, 
& Zoch-Zwierz, 2009). Buzi et al.(2004)  and Wasilewska et al. (2009) both showed 
higher values in children between the ages of 1 and 4 years old (Buzi et al., 2004; 
Wasilewska et al., 2009).  
2.3.3.b Receptor Activator of Nuclear Factor κB Ligand (RANKL) 
Receptor Activator of Nuclear Factor κB Ligand (RANKL) is well known for its 
activity on the immune system. With respect to bone metabolism, it has been established 
that RANKL is a pre-resorptive factor, acting to stimulate osteoclast differentiation, 
activity and inhibition of osteoclast apoptosis (Hofbauer & Heufelder, 2001; Khosla, 
2001). Kong et al. (1999) has demonstrated through RANKL knock-out mice that without 
the presence of RANKL the end result is severe osteopetrosis and a complete absence of 
osteoclasts (Kong et al., 1999). On the other hand, when mice were parenterally 
administered RANKL, a marked enhancement in the generation and activation of 
osteoclasts was present. Because of this enhancement, the mice demonstrated increases in 
osteoclast formation and activation, a marked decrease in bone mass resulting in 
osteoporosis and life threatening hypercalcemia (Lacey et al., 1998). Wasilewska et al. 
(2009) found differences in serum concentration of RANKL between sexes and among 
age groups. The level of RANKL was much higher in males when compared to females. 
This finding was also reported in adults by Kerschan-Schindl et al. (2008). A statistically 
significant difference in children younger than 9 years old versus children older than 9 
years old was also apparent with the older children having higher levels (Wasilewska et 
al. 2009). However, the age correlation in children was not apparent in other studies 
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(Kerschan-Schindl et al., 2008; Wasilewska et al., 2009). An age-dependent reduction of 
serum RANKL levels has been suggested in post-menopausal women, which may help to 
counteract the reduction in bone formation for the elderly population (Liu et al., 2005). 
2.3.3.c Receptor Activator of Nuclear Factor κB (RANK) 
Receptor Activator of Nuclear Factor κB (RANK) is the receptor for RANKL. The 
functional expression of RANK is found mainly in osteoclasts and dendritic cells. It was 
demonstrated in RANK knock-out mice that RANK was the exclusive receptor and was 
expressed on preosteoblastic cells as the mice experienced severe osteopetrosis due to the 
absence of osteoclasts, similar to the RANKL knock-out mice (Hofbauer & Heufelder, 
2001; Khosla, 2001; Liu et al., 2005).  
2.3.3.d OPG/RANKL/RANK 
Osteoblasts and stem cells within the bone marrow produce RANKL, which is 
able to bind with a transmembranic receptor, RANK, which is found on preosteoclastic 
cells. The interaction between RANKL and RANK results in the activation of the nuclear 
factor κ B, which helps to promote the formation of preosteoclasts into active osteoclasts. 
If however, there is a reduction in RANKL the result is the inactivation of its receptor, 
RANK, and bone resorption is reduced. RANKL is a very strong activator of osteoclasts 
but can be counteracted by OPG, the protector cytokine of bone. OPG competitively 
binds to RANKL, which reduces the impact that RANKL has on its receptor, RANK and 
preosteoclasts. In doing so, a reduction of the transformation of preosteoclasts to 
osteoclasts is achieved which enhances the formation of bone. The importance of the 
ratio between OPG and RANKL then becomes highly apparent. It has been suggested 
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that OPG and RANKL play an essential role in a variety of metabolic bone diseases such 
as, osteoporosis, rheumatoid arthritis, Paget’s disease and periodontal disease (Figure 1.) 
(Khosla, 2001; Ziegler et al., 2005).  
 
Figure 1. Bone Turnover.  Bone turnover is an ongoing dynamic process that consists of bone resorption, 
achieved by osteoclasts, and bone formation, achieved by osteoblasts. The initiation of bone turnover can 
take several forms, direct mechanical stress on the bone or systemic changes in homeostasis (e.g. 
endocrine, metabolic, nutritional). Osteoclasts are responsible for the resorption of the bone matrix 
(osteoid) which results in collagen degradation products such as tartrate resistant isoenzyme of acid 
phosphatase (TRAP 5b), pyridinoline (Pyr), deoxypiridinonine (Dpd), carboxy-terminal collagen cross-
links (CTx), amino-terminal collagen cross-links (NTx) and carboxy-terminal telopeptide of collagen type 
I (ICTP). Osteoblasts are responsible for the formation and organization of the extracellular matrix of 
bone and its subsequent mineralization, as well as the synthesis of collagen and other bone proteins. The 
direct or indirect products of this osteoblastic activity can be classified as bone-specific alkaline 
phosphatase (BAP), Osteocalcin and procollagen I Extension Peptides, carboxy (PICP) and amino 
(PINP). As osteoblasts form new bone tissue many become embedded within the matrix and differentiate 
into osteoctytes. Osteoprotegerin (OPG), secreted by many cell types, including osteoblasts, is the decoy 
receptor that inhibits the differentiation and activation of osteoclasts. Soluble receptor activator of nuclear 
factor κB ligand (sRANKL) also secreted by osteoblasts, is a main stimulator for the formation of mature 
osteoclasts. Receptor activator of nuclear factor κB (RANK), expressed by mature osteoclasts, is the 
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membrane receptor for RANKL. The binding interaction between RANKL and RANK promotes the 
formation of preosteoclasts into active osteoclasts. 
(Datta, Ng, Walker, Tuck, & Varanasi, 2008; Kular, Tickner, Chim, & Xu, 2012; Raggatt 
& Partridge, 2010; Teco Medical Group, 2009) 
2.4 Biological Variability 
Biochemical markers of bone turnover are used as indirect indices of skeletal 
metabolism. The analyses of biochemical bone markers need to be standardized and 
stable to account for any biological variability. There are a number of contributing 
sources to biological variability and they can be divided into two categories: (1) 
uncontrollable factors, and (2) controllable factors (Hannon & Eastell, 2000). The 
uncontrollable factors include age, sex, menopausal status, menstrual cycle, pregnancy, 
ethnicity, fractures, seasonal, disease, bed rest or immobility, circadian rhythm and 
hormones. These factors cannot be altered, but by using age-appropriate and sex-specific 
reference ranges alongside with recent published information regarding fractures and 
diseases, they can be accounted for.  The controllable factors include drugs, oral 
contraception, diet and exercise, and if standardization and appropriate timing and 
conditions of the samples are undergone then these factors can be manipulated to reduce 
the effects of variability (Hannon & Eastell, 2000).  
2.4.1 Uncontrollable Factors 
2.4.1.a Age, Sex, Puberty 
Age can affect biochemical markers of bone turnover, specifically at three stages 
of the life cycle: infancy, puberty and for women, menopause. At birth, all markers of 
bone formation and resorption are high and it is not until between the third month and 
third year of life that they decrease, in correspondence to the slowing of linear growth 
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(Szulc et al., 2000). Bone markers then remain at constant levels until the initiation of 
puberty, at which time major fluctuations occur, in accordance with the growth velocity 
or changes in secondary sex characteristics. In terms of chronological age, females reach 
their peak in bone turnover markers at an approximate age of 12 and boys at an age of 14. 
Because the growth velocity and onset of puberty takes place at an earlier age in females 
then it does in males, the peak bone mineral density is obtained earlier in females. 
Following the period of accelerated growth, the biochemical bone markers undergo a 
decrease in both males and females (Hannon & Eastell, 2000; Szulc et al., 2000).  
Once women reach menopause, there is a marked increase in bone turnover 
markers, with the increase in bone resorption markers being greater than the increases in 
bone formation markers.  These markers generally remain elevated throughout the aging 
process. In men, most bone turnover markers do not change until the fifth or sixth decade 
is reached, at which time both resorption and formation  markers reach their lowest levels 
with no subsequent change (Hannon & Eastell, 2000). 
Premature infants and low birth-weight infants may suffer the adverse effects of 
having low markers of bone formation (Mora, Weber, Bellini, Bianchi, & Chiumello, 
1994; Namgung, Tsang, Specker, Sierra, & Ho, 1993). This reduction may in part be due 
to reduced vitamin D, vitamin K, insulin-like growth factor 1 (IGF-I) or growth hormone 
(GH) biological activity (Namgung et al., 1993). An increase in bone resorption markers 
may also be present in preterm infants. In most cases children catch up with regards to 
body size but skeletal maturation and the attainment of peak BMD may be delayed and 
GH therapy may sometimes be implemented (Namgung et al., 1993; Szulc et al., 2000).  
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2.4.1.b Menstruation 
The menstrual cycle induces very minor, if any, changes to levels of bone 
turnover markers (Chiu et al., 1999). During the luteal phase, markers of bone formation 
appear to be elevated in comparison to the follicular phase, where both BAP and OC 
reach the highest levels in the mid-luteal phase and PICP reaching the highest levels in 
the early luteal phase (Nielsen, Brixen, Bouillon, & Mosekilde, 1990). On the other hand, 
changes in the levels of bone resorption markers throughout the menstrual cycle are 
inconsistent. Because the changes are considered small the effect of the menstrual cycle 
on markers of bone turnover can be termed insignificant (Hannon & Eastell, 2000). 
2.4.1.c Pregnancy 
Pregnancy and lactation result in a growing calcium demand for the fetus or infant 
in part provided by an increase in all but one bone turnover markers. OC shows a 
significant decrease, almost to the point of being undetectable, during pregnancy and this 
may be due to the placental clearance of OC. Once lactation is discontinued bone 
turnover markers should return to premenopausal levels (Naylor, Iqbal, Fledelius, Fraser, 
& Eastell, 2000). 
2.4.1.d Ethnicity and Race 
Ethnic differences have been reported between black and white populations, with 
a trend for markers of bone resorption (TRAP5b and Pyr) and formation (OC) to be lower 
in black children and young adults suggesting that bone turnover was slower (Pratt, 
Manatunga, & Peacock, 1996). These differences may elucidate why black populations 
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have a higher bone mineral density and lower fracture incidence (Hannon & Eastell, 
2000). 
2.4.1.e Fractures 
During the healing process of a fracture, markers of bone formation and 
resorption are significantly increased. This increase may begin as early as the first or 
second week after the fracture and can continue up until one year after. These factors 
should be taken into account when analyzing and interpreting bone markers (Hannon & 
Eastell, 2000; Ingle, Hay, Bottjer, & Eastell, 1999). 
2.4.1.f Disease 
Metabolic bone diseases are the primary, but not only, pathologies that can impact 
biochemical markers of bone turnover. Paget’s disease is a reflection of increased bone 
formation markers, BAP and OC. Other diseases such as diabetes and thyroid disease can 
also alter the levels of bone markers (Hannon & Eastell, 2000). For instance, 
hyperparathyroidism can cause an increase of up to 3- fold the normal level or remain 
unchanged in markers of bone resorption. Similarly, markers of bone formation can 
increase up to 2- to 3-fold the normal level or also remain unchanged (Cortet et al., 
2000). The bone marker alterations in nonskeletal diseases may imply metabolic 
disturbances or extraskeletal production (Delmas et al. 2000). 
For those children who suffer from a GH deficiency, stunted skeletal maturation 
and stature is often present. The bone mass accumulation is typically slower and this may 
be in part due to the suppression of bone turnover. Markers of bone formation (BAP, OC 
and PICP) appear to be either lower or normal and markers of bone resorption (Pyr, Dpd 
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and ICTP) also appear to be lower. GH treatment stimulates the activation of bone 
turnover resulting in an increase in all biochemical markers of bone formation and 
resorption, BMC and height (Kubo, Tanaka, Inoue, Kanzaki, & Seino, 1995; Szulc et al., 
2000).  
2.4.1.g Bed Rest and Immobility 
The consequence of bed rest or immobility is a very rapid increase in bone 
resorption markers. Several cross-sectional studies have revealed that after only 2 days of 
bed rest Pyr and Dpd significantly increase, with an additional 30-50% increase by one 
week (van der Wiel, Lips, Nauta, Netelenbos, & Hazenberg, 1991; Zerwekh, Ruml, 
Gottschalk, & Pak, 1998). Bone formation markers remain unchanged and once 
remobilization takes place the markers of bone resorption gradually decline to normal 
levels (Hannon & Eastell, 2000). 
2.4.1.h Seasonal 
Seasonal changes have been suggested to have low effect on the markers of bone 
turnover, with a minor difference apparent between the winter and summer months 
(Woitge, Scheidt-Nave et al., 1998). Most markers of bone resorption are elevated during 
the winter, with the exception of Pyr excretion being elevated in the summer (Douglas et 
al., 1996). BAP levels appear to be decreased in the winter and spring, whereas OC may 
be elevated during those seasons; the results are inconsistent (Douglas et al., 1996). The 
seasonal variations are small but may be explained by the vitamin D deficiency often 
seen throughout the winter months, but in areas of low latitude this may be less marked 
as exposure to sunlight tends to be higher (Hannon & Eastell, 2000; McKenna, 1992). 
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2.4.1.i Circadian Rhythm 
The impact of circadian variability is greater than most other contributing factors 
of variability. Both urinary and serum markers of bone turnover have significant 
circadian rhythms. Most markers experience high fluctuations at night/early morning and 
rapidly decline to reach a nadir between 1300 and 2300hrs, although each marker appears 
to be different. It is also important to note that nightly calcium supplementation and 
bisphosphonate treatment can suppress both the circadian rhythm and bone resorption 
markers. Circadian rhythms and the factors that can affect it can be very substantial and 
precise timing of sample collection is of utmost importance for accurate interpretation of 
the results as outlined in table 1. (Delmas et al., 2000; Hannon & Eastell, 2000). The 
rhythms of OPG and RANKL have not been well-studied and the results appear to be 
inconsistent. Both Dovio et al. (2008) and Ohta et al. (2006) demonstrated that neither 
OPG nor RANKL have a significant circadian rhythm in premenopausal women whereas 
Joseph et al. (2006) did find a rhythmicity in OPG in women between the ages of 25 and 
65 years (Dovio et al., 2008). 
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Table 1. Peak and nadir timing for markers of bone formation and bone resorption. 
Reference Bone Marker Medium Peak Nadir 
Hassager et al., 
1992 ; 
Schlemmer et 
al., 1992 
Pyr Urine 0200hrs – 0800hrs 1400hrs – 2300hrs 
Dpd Urine 0200hrs – 0800hrs 1400hrs – 2300hrs 
Aoshima et al., 
1998; Wichers 
et al., 1999 
CTX Serum 0130hrs – 0430hrs 1100hrs – 1500hrs 
NTX Serum 0130hrs – 0430hrs 1100hrs – 1500hrs 
Greendspan et 
al., 1997  
BAP Serum 1140hrs –  1245hrs 0630hrs 
Gundberg et 
al., 1985 
OC Serum 0203hrs – 0400hrs 1200hrs – 1600hrs 
Hassager et al., 
1992 
PICP Serum 0200hrs – 0500hrs ~1400hrs 
PINP Serum 0200hrs – 0500hrs ~1400hrs 
(Aoshima et al., 1998; Greenspan, Dresner-Pollak, Parker, London, & Ferguson, 1997; Gundberg, 
Markowitz, Mizruchi, & Rosen, 1985; Hassager et al., 1992; Hassager, Risteli, Risteli, Jensen, & 
Christiansen, 1992; Schlemmer, Hassager, Jensen, & Christiansen, 1992) 
2.4.1.j Hormones 
Certain hormones can play an essential role in the maintenance of skeletal health 
throughout one’s lifespan. Hormone deficiencies can occur in both sexes throughout 
childhood or adulthood, thereby having potentially adverse effects on children and adults. 
The main hormones involved in the maintenance of bone health include growth hormone 
(GH), parathyroid hormone (PTH), testosterone, estrogen and IGF-1. These hormones 
and growth-factors also experience fluctuations throughout the day and the peak times 
and nadir times need to be taken  into consideration for the timing of samples so to avoid 
any impact on the analyzed results (Compston, JE. 2001). To reduce the effect of 
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hormonal fluctuations  it is essential that the timing of sample collection is tightly 
controlled outside of the peak and nadir timings.The various timing is outlined in Table 2.   
Table 2. Peak and nadir timing of bone-related hormones and growth factors 
Reference Hormone/ 
Growth-factor 
Sex Medium Peak Nadir 
Surya et al., 
2006 
GH M Plasma 2400hrs*, 1200hrs 
& 1800hrs 
0800hrs (waking 
hours) 
F 2400hrs*, 1100hrs 
& 1600hrs 
Jubiz et al., 
1972 
PTH M/F Serum 0200hrs – 0400hrs 0800hrs 
Ahokoski et 
al., 1998; 
Plymate et 
al., 1989 
Testosterone M Serum 0800hrs (early 
morning hours) 
1600hrs – 
2000hrs 
Ahokoski et 
al, 1998;  
Estrogen M Serum 1200hrs 2000hrs 
Heuck et al., 
1999 
IGF-1 M/F Serum 0900hrs & 1200hrs 0700hrs 
*Signifies the maximum occurrence 
(Ahokoski et al., 1998; Heuck, Skjaerbaek, Orskov, & Wolthers, 1999; Jubiz, 
Canterbury, Reiss, & Tyler, 1972; Plymate, Tenover, & Bremner, 1989; Surya, Symons, 
Rothman, & Barkan, 2006)  
2.4.2 Controllable Factors 
2.4.2.a Drugs 
The main forms of pharmaceuticals that can have a direct impact on biochemical 
bone turnover are antiresorptive drugs. These drugs are typically used for the treatment of 
osteoporosis but there are also other medicinal treatment methods for various metabolic 
bone diseases. Bisphosphonates are widely known to promptly reduce markers of bone 
turnover by up to 70% (Hannon & Eastell, 2000). Oral corticosteroid use can reduce OC 
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and PICP by up to 40-50% after a few days (Oikarinen et al., 1992). Anticonvulsant 
medication can also affect markers of bone turnover. Large increases in Pyr and Dpd and 
moderate increases in markers of bone formation have been shown following a long-term 
treatment plan of anticonvulsant medication (Ohishi et al., 1996). Similarly, GnRH 
agonist treatment has been shown to increase bone turnover significantly, whereas the use 
of thiazide diuretics can significantly decrease markers of bone turnover (Delmas et al. 
2000). Rheumatoid arthritis often requires the use of long-term corticosteroid therapy, 
which acts to subdue bone formation. The use of corticosteroids in children, often used 
for the treatment of asthma, not only reduces bone turnover but also growth and BMD 
(Boot, de Jongste, Verberne, Pols, & de Muinck Keizer-Schrama, 1997). Corticosteroids 
act to inhibit bone resorption which is shown through the reduced levels of Pyr, Dpd and 
ICTP. Corticosteroids also have a direct suppressive effect on osteoblasts and because 
bone resorption precedes bone formation, this may also impact bone formation markers 
(Sorva, Turpeinen, Juntunen-Backman, Karonen, & Sorva, 1992).  
2.4.2.b Oral Contraceptives 
The effect of oral contraceptives is not entirely known but is suggested to be age-
dependent. Significant decreases in markers of bone formation and resorption have been 
shown in women between the ages of 35 and 49, which is not the typical age group for 
oral contraceptive consumption (Garnero, Sornay-Rendu, & Delmas, 1995). However, 
there is little to no effect in younger women (Hannon & Eastell, 2000). 
 
 
27 
 
2.4.2.c Dietary Intake 
Dietary intake does not typically affect markers of bone turnover, aside from 
serum CTx (Seibel, 2002). As aforementioned, CTx is strongly influenced by food intake 
and to ensure accuracy an overnight fasting sample should be implemented (Seibel, 
2002).  Mineral dietary supplementation, such as zinc, copper or magnesium, does seem 
to impact markers of bone turnover (Hannon & Eastell, 2000). Calcium supplementation 
can suppress markers of bone turnover, especially in pre- and post-menopausal women. 
This may depend on the time of day the supplement is taken (Ginty, Flynn, & Cashman, 
1998).  Long-term vitamin D supplementation, of either 5 or 10µg/day has been shown to 
decrease bone resorption markers, while having no effect on bone formation markers 
(Rossini et al., 2012). The short-term effects of a high dose of vitamin D (600 000 IU) are 
an increase bone resorption markers with no effect on bone formation markers 
(Viljakainen et al., 2006). Protein intervention studies on markers of bone turnover 
indicate mixed results, with a trend towards a reduction in bone resorption markers with 
high protein consumption (Darling, Millward, Torgerson, Hewitt, & Lanham-New, 
2009).  
Malnutrition can impact approximately half of the children around the world, 
often occurring in underprivileged societies (Szulc et al., 2000).  The lack of nutrients 
often results in a reduction of bone turnover, which can easily be corrected upon weight 
gain (Branca, Robins, Ferro-Luzzi, & Golden, 1992). In extreme cases, 
hyperparathyroidism is brought on as a secondary characteristic and results in high 
biochemical bone markers, where elevated ICTP reflects the increased breakdown of the 
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bone matrix and elevated levels of total AP and PICP reflect the increase in bone 
formation (Szulc et al., 2000). 
2.4.2.d Exercise 
It has been well established that PA plays a vital role in the development and 
maintenance of skeletal mass. Adequate amounts of PA have been shown to increase 
peak bone mass in youth and decrease bone loss in the elderly (Forwood & Burr, 1993). 
While there is a clear correlation between PA and increased BMD, the particular 
mechanism for the increase in BMD remains uncertain. The positive effects can vary 
throughout life’s different stages; where the most evident benefits can be seen in pre-
pubertal and pubertal skeletal growth and development (K. B. Gunter et al., 2012). Before 
puberty, gains in bone mass due to exercise can range between 1-6% and are 
considerably smaller post-puberty, thereby illustrating another beneficial aspect of 
incorporating PA into children’s daily life (Hind & Burrows, 2007). 
According to the Mechanostat Theory (Frost, 1987), bone will only respond to 
exercise within certain ranges of loading. This must be above or below threshold levels in 
order to have the adaptive response. If an adequate amount of overload is applied the load 
will stimulate a modeling response, in which bone is added and a new level of 
mechanical loading is met. This theory is based on the principle of mechanical stimuli 
dependence (Bailey et al., 1996). 
Therefore, it is important to note that not only is the timing of PA important but 
also the type of activity or intensity of loading (K. B. Gunter et al., 2012). Exercise can 
range from leisure activities to intense and vigorous physical activities. The osteogenic 
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potential of exercise is dependent on the magnitude of the applied load, the rate at which 
the load is applied, the duration and frequency of the loading bout (J. J. Bauer & Snow, 
2003).  
2.5 Exercise and Bone 
2.5.1 Exercise and BMD 
The effects of weight bearing exercise on bone mineral acquisition in children has 
been studied extensively. Bonjour et al. (2009) estimated that for a 1 SD increase in 
population peak bone mass, fracture risk could be reduced by approximately 50%, 
demonstrating the importance of attaining a relatively high peak bone mass (Bonjour, 
Chevalley, Ferrari, & Rizzoli, 2009). Large forces applied at a very rapid rate, also 
known as weight bearing and high impact; appear to express the greatest benefits on bone 
structure and mineralization in children. Several impact exercise intervention studies 
during pre-puberty and puberty have elucidated this concept nicely. Gunter et al. (2008) 
and Fuchs et al. (2001) both showed gains in bone mass of 3.5%-8.5% following a high-
impact jumping intervention; revealing some of the highest gains observed over a school 
year (Fuchs et al., 2001; K. Gunter, Baxter-Jones, Mirwald, Almstedt, Fuchs et al., 2008; 
K. Gunter, Baxter-Jones, Mirwald, Almstedt, Fuller et al., 2008). MacKelvie et al. (2001) 
also reported significant benefits in BMC accrual, although not as high, following a 
school-based impact program. An additive effect was apparent from repeated exercise 
exposure. BMC gains at the femoral neck and lumbar spine in early pubertal females 
increased from 1.5% and 3.1% to 3.7% and 4.6% following the two year jumping 
protocol (Mackelvie et al., 2001; MacKelvie et al., 2002). In pre-pubertal males there was 
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an increase in the femoral neck and total body BMC, resulting in a 4.3% difference in 
BMC accrual comparison to the control group following the two year jumping protocol 
(MacKelvie et al., 2003; MacKelvie et al., 2004). Petit et al. (2002) examined changes in 
bone structural properties in pre- and early- pubertal girls randomized to a jumping group 
in comparison to a control group. Following the 7 month program the early-pubertal 
jumping group showed increases in bone cross-sectional area and increased cortical 
thickness at the femoral neck in comparison to the control group. These structural 
changes led to a greater increase in the bending strength (Petit et al., 2002). 
In order for older adolescents to benefit from weight-bearing, high impact 
exercises, a sufficiently high load and time period per session is required. Resistance 
training, plyometric training and step aerobics have been shown to be inadequate loads on 
the skeleton as there were no significant improvements in bone mass in late- and post-
pubertal female adolescents (Blimkie et al., 1996; Heinonen et al., 2000; Witzke & Snow, 
2000). However, improvements in the femoral neck, lumbar spine and total body BMC 
were evident following an 8 month jumping protocol involving approximately 300 jumps 
per session (Weeks et al., 2008). These results suggest that jumping protocols may 
provide a unique and beneficial stimulus for skeletal tissue throughout the growing years, 
if the load is sufficiently high. Resistance training or step aerobics may not have had a 
sufficiently high load that was maintained for a sufficient period of time in the adolescent 
age group (K.B. Gunter, Almatedt & Janz, 2012). 
Although exercise is known to be a major determinant of skeletal mass, the 
mechanism by which the changes in bone metabolism occur is not well understood. The 
use of various markers of bone turnover allow for an estimation of the bone metabolic 
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processes and any changes in bone turnover. Inconsistencies in bone turnover may be 
found if the effects of short and long periods of exercise are compared, if different 
intensities are being compared or if preanalytical variability, uncontrollable and 
controllable factors, is not taken into account.  
2.5.2 Exercise and Bone Turnover 
2.5.2.a Long-term Exercise Training or Competitions (≥6 months) and Bone Turnover 
in Adults 
The effect of regular exercise training or competitions on markers of bone 
turnover is not well studied (Table 4). Marques et al. (2011) is one of the very few studies 
that examined the effects of a long-term training protocol on the ratio of OPG and 
RANKL. Following 8 months of either resistance exercise or aerobic exercise no changes 
were demonstrated for either cytokine in older women (Marques et al., 2011).  
Vainionpaa et al. (2009) examined the effects of an impact exercise training protocol, 3 
times a week, over a period of 12 months in middle-aged women. The results indicated 
that the impact exercise did not influence either markers of bone formation or bone 
resorption (Vainionpaa et al., 2009). However, Jurimae et al. (2006) and Shibata et al. 
(2003) both found increases in specific markers of bone formation (Jurimae, Purge, 
Jurimae, & von Duvillard, 2006; Shibata, Ohsawa, Watanabe, Miura, & Sato, 2003). 
Jurimae et al. (2006) investigated the effects of 6 months of heavy training on OC in 
nationally and internationally ranked male rowers. It was found that the levels of OC 
increased over the 6 month period of training (Jurimae et al., 2006). Shibata et al. (2006) 
found there to be no changes in OC or NTx following 12 months of walking or walking + 
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jumping protocol. There was an increase in BAP for both groups but was much more 
pronounced in the walking + jumping group (Shibata et al., 2003). From this limited 
number of studies, a pattern of the effect of long-term training on bone markers is 
unclear. The apparent inconsistencies may be due to the fact that different populations 
were studied, following different modes and intensities of exercise training. 
2.5.2.b Short-term Exercise Training (≤6 months) and Bone Turnover in Adults 
The effects of short-term training on bone metabolism markers have been 
investigated in several studies (Table 4), including jumping, aerobic and anaerobic type 
of exercise (Banfi et al., 2010). Erickson et al. (2010) examined the changes in bone 
markers in young, resistance trained males during a jumping protocol of either once a 
day, 3 times a week for 8 weeks (J1) or twice a day, 3 times a week for 8 weeks (J2), both 
resulting in the same total number of jumps. The results indicated a trend towards the J2 
group to have higher levels of bone formation markers and lower levels of bone 
resorption markers in comparison to the J1 group, suggesting that a recovery period may 
restore mechanosensitivity to allow for an osteogenic effect (Erickson & Vukovich, 
2010). Woitge et al. 1998 examined, in young male adults, the effects of aerobic and 
anaerobic running after 8 weeks of endurance or sprint training on different markers of 
bone resorption and formation. For the markers of bone formation, it was found that after 
4 weeks of endurance training there was a significant reduction but after 8 weeks the 
levels had returned to baseline levels.  The markers of bone resorption showed significant 
decreases at the 4 week point and continued to further decrease at the 8 week mark. 
These observations indicate that an 8 week aerobic training program may be associated 
with an overall suppression of bone turnover. Sprint training showed no differences in 
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either bone formation or resorption markers after 4 weeks of training (Woitge et al., 
1998). However, by the end of the 8 weeks there were significant increases in both 
markers of bone formation and resorption, suggesting that there was a considerable 
acceleration of bone metabolism. The authors concluded that the two types of training 
affect bone metabolism; aerobic training exhibited decreased bone resorption thereby 
resulting in a net increase in bone formation, whereas anaerobic training exhibited an 
overall increase in bone turnover with a less marked increase in bone formation (Woitge 
et al., 1998). From the studies summarized in Table 4 it can be concluded that short-term 
training has beneficial effects on markers of bone turnover. Bone formation markers tend 
to increase and bone resorption markers either remain unchanged or decrease.  
2.5.2.c Short-term Exercise Training (≤6 months) and Bone Turnover in Adolescents 
With respect to children and adolescents Eliakim et al. (1996, 1997) examined the 
effects of endurance-type training in both adolescent males and females. In adolescent 
males, the 5-weeks of training resulted in an increase in bone formation markers and a 
less pronounced decrease in bone resorption markers. In adolescent females the only 
marker of bone turnover measured was OC and after the 5-weeks of endurance-type 
training there was a significant increase. From both of these studies the most important 
result is that a moderate intensity 5-week training protocol led to increases in bone 
formation markers (Eliakim et al., 1996; Eliakim, Raisz, Brasel, & Cooper, 1997). 
2.5.2.d Acute Exercise and Bone Turnover 
The acute effects of exercise are not as well understood (Table 5). There is 
inconsistency in the effects of resistance exercise, aerobic exercise and plyometric 
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exercise on changes in bone biomarkers. There are a limited number of studies examining 
the acute effects of resistance training studies on bone turnover markers. There is an 
apparent trend for bone resorption markers to decrease and for bone formation markers to 
remain unchanged (Ashizawa et al., 1998; R. S. Rogers, Dawson, Wang, Thyfault, & 
Hinton, 2011; Whipple et al., 2004). Endurance running, ranging from 30 minutes to full 
marathons, typically resulted in increased markers of bone formation and bone resorption 
(Brahm, Piehl-Aulin, & Ljunghall, 1997; Langberg, Skovgaard, Asp, & Kjaer, 2000; 
Lippi et al., 2008; Malm, Ronni-Sivula, Viinikka, & Ylikorkala, 1993; Nishiyama, 
Tomoeda, Ohta, Higuchi, & Matsuda, 1988; Scott et al., 2010; Scott et al., 2011; Scott et 
al., 2013; Thorsen, Kristoffersson, Hultdin, & Lorentzon, 1997; Welsh et al., 1997; 
Ziegler et al., 2005). Non-weight bearing exercise, such as cycling, does not result in a 
clear pattern, with some studies demonstrating increases in bone formation markers 
alongside increases in bone resorption markers, and others demonstrating no changes at 
all (Guillemant, Accarie, Peres, & Guillemant, 2004; Herrmann et al., 2007; 
Kristoffersson, Hultdin, Holmlund, Thorsen, & Lorentzon, 1995; Pomerants et al., 2008; 
Rong et al., 1997; Rudberg, Magnusson, Larsson, & Joborn, 2000; Wallace et al., 2000). 
Two studies examined the effects of a single session of plyometric exercise on markers of 
bone turnover, with no clear pattern:  Lin et al. (2012) observed an increase in bone 
formation marker (OC) and no change in bone resorption marker (TRAP), while Rogers 
et al. (2011) observed no change in bone formation markers (BAP and OC)  and an 
increase in bone resorption markers (TRAP5b and CTx) (Lin et al., 2012; R. S. Rogers et 
al., 2011).  
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The results of the studies summarized in Table 5 are strongly dependent on the 
type, intensity and duration of the exercise protocol. It is known that exercise stimulates 
osteoblast and osteoclast functioning but immediate and delayed responses need to be 
distinguished, suggesting that multiple samples are required throughout the recovery 
period (Banfi et al., 2010).  
Thus far, only one study examined the effects of an acute bout of exercise on the 
ratio between OPG and RANKL. Ziegler et al. (2005) measured the serum levels of OPG 
and RANKL in middle-aged males and females following either a 15km run or a 42km 
run and it was found that OPG increased in the runners of the longer distance and 
RANKL decreased in both groups but to a further extent in the longer distance (Ziegler et 
al., 2005).  
In several studies an acute bout of exercise was not sufficient to alter bone 
metabolism (Banfi et al., 2010). However, when alterations were noted, the tendency was 
for markers of bone formation to decrease and markers of bone resorption to increase 
(Banfi et al., 2010). The changes may depend on the type and duration of exercise or 
even the fitness status or age of participants. Because the timing of sampling is quite 
variable it is difficult to determine the immediate or delayed effects of acute exercise on 
markers of bone turnover.  
The majority of the studies have included adult participants of various ages, 
fitness levels and both sexes. However, there is very little research examining the effects 
of an acute bout of exercise on bone turnover markers in children. To date there is one 
study by Pomerants et al. (2008) who examined the impact of acute cycling on serum 
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markers of bone turnover in boys at different pubertal stages. Unfortunately, this exercise 
mode does not elicit high external mechanical loading on the skeleton, as it is not weight 
bearing. Additionally, only a small number of bone markers were measured. 
Nevertheless, the results revealed that there were no changes in PINP or ICTP following 
the continuous cycle ergometer protocol at ~95% of their ventilatory threshold for 60 
minutes. The highest values were seen in the early-pubertal and mid-pubertal group of 
boys (Pomerants et al., 2008).  
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Table 3.  Effects of long term training or competition (≥ 6 months) on markers of bone formation and bone resorption 
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Jurimae et al., 
2006 
OC F Plasma n = 12 elite male 
rowers  
 
20.8±3.0 years 
- 6 months of high-
volume, low-intensity 
strength training 
Baseline  
Post Training – 6 months 
- OC ↑ after 6 months 
Marques et al., 
2011 
OPG F Serum n = 71 sedentary 
older women  
 
67.3±5.2 years 
- 3x/week, 60 min, 32 
weeks 
- Resistance (RE) – full 
body, 2 sets, 10-15 reps, 
50-80% 1RM 
- Aerobic (AE) – 
dynamic activities 
(stepping, skipping, 
graded walking, 
jogging, dancing, 
aerobics) 
Baseline  
Post Training  
 
7:30am – 9:30am 
- OPG and RANKL 
no change after 8 
months 
RANKL R 
Shibata et al., 
2003 
OC F Plasma n = 43 women  
 
37±7 years 
- Walking group (WG) – 
10 000 steps/day 
- Jumping group (WJG) – 
10 000 steps + 10 
jumps/day 
- 12 months 
Baseline 
Post training, 12 months 
- OC no change 
- BAP ↑ in both 
groups but was 
higher in the WJG 
group 
- NTx no change 
BAP 
NTx R 
Vainionpaa et al., 
2009 
PINP F Serum RA women 35-
40 years 
n = 37 exercise 
group 
n = 39 control 
group 
- 60 min. impact ex., 
3x/week, 12 months 
- Step patterns, stamping, 
jumping, running and 
walking 
Baseline  
6 months 
12 months  
 
 
8:00am – 11:00am 
- PINP and TRAP5b 
no change 
TRAP5b R 
F – formation, R – resorption, RA – recreationally active 
(Jurimae et al., 2006; Marques et al., 2011; Shibata et al., 2003; Vainionpaa et al., 2009)   
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Table 4.  Effects of short term training or competition (≤ 6 months) on markers of bone formation and bone resorption  
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Eliakim et al., 
1997 
OC F Serum n = 44 late 
pubertal males  
 
15-17 years 
5 weeks endurance type 
training (running, aerobic 
dance, competitive sports, 
occasional weights) 
Baseline – 1 week 
before (early 
morning) 
Post Training – 
During the week after 
completion (early 
morning) 
- OC, BAP and PICP ↑ 
significantly 
- Dpd or CTX no change 
- NTX ↓ significantly 
BAP 
PICP 
Dpd R Urine 
CTX 
NTX 
Eliakim et al., 
1996 
OC F Serum n = 44 late 
pubertal females  
 
15-17 years 
5 weeks endurance type 
training (running, aerobic 
dance, competitive sports, 
occasional weights) 
Baseline 
Post Training 
- OC ↑ significantly 
Erickson & 
Vukovich, 
2010 
BAP F Serum n = 21 resistance 
trained males  
 
24.1±2.5 years 
- Group 1 – jumping 
1/day, 3x/week  
- Group 2 – jumping 
2/day, 3x/week 
Baseline  
4 weeks training 
8 weeks training 
- BAP ↑ significantly in both 
groups after 8 weeks 
- CTX ↓ significantly in both 
groups after 8 weeks 
- Trend for J2 to have ↑ 
formation and ↓ resorption  
CTX R 
Morgan et al., 
2011 
OC F Serum n = 29 female 
athletes 
19.7±0.82 
n = 4 sedentary 
females 
19.3±1.89 
- High Impact  
- Medium Impact  
- Non-impact 
Baseline – 8:00am-
10:00am 
Mid-Season 
Post-Season (within 2 
weeks of completion) 
- OC and BAP ↑ in the high 
and medium group 
compared to control but no 
changes over time 
- NTX no difference between 
groups or change over time 
BAP 
NTX  R 
Woitge et al., 
1998 
OC F Serum n = 22 sedentary  
males  
20-30 years 
- Group 1 – endurance 
running 40-60min , HR 
at 60-85% VO2max 
- Group 2 – sprints at 90-
100% speed 
- Group 3 – control  
Baseline 
4 weeks training 
8 weeks training 
- Group 1 – OC and BAP ↓ at 
4 weeks,  returned to 
baseline by 8 weeks, Pyr 
and Dpd ↓ at 4 weeks and ↓↓ 
at 8 weeks 
- Group 2 – OC, BAP and Pyr 
↑ after 8 weeks 
BAP 
Pyr R Urine 
Dpd 
       -  children, F – formation, R – resorption, HR – Heart rate 
(Eliakim et al., 1996; Eliakim et al., 1996; Eliakim et al., 1997; Erickson & Vukovich, 2010; Morgan & Weiss Jarrett, 2011; Morgan & Weiss Jarrett, 
2011; Woitge et al., 1998; Woitge et al., 1998) 
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Table 5. The acute effects of physical activity on markers of bone formation and bone resorption 
Reference Bone 
Marker 
F/R Medium Sample Exercise type 
and/or intensity 
Sample Timing(s) Comments: 
Ashizawa et 
al., 1998 
OC F Serum n = 14 
UT males  
25±0.7 years 
RE (3 sets of 10 reps 
– 60% of RM for 1st 
set and 80% of RM 
for 2
nd
 and 3
rd
 sets) 
 
Onset of exercise 
4:00pm 
Baseline – 8:00am 
Post ex. – 5 min., 1, 
2 and 3 days 
 
- OC no change 
- ↓ BAP 2 and 3 days post ex. 
- PICP and BAP ↓ ex. day and ↓↓ 1 day 
post ex. – baseline by recovery 
BAP 
PICP R 
TRAP 
Brahm et al., 
1996 
OC F Serum n = 10 active 
males  
22-52 years 
 
n = 10 active 
females  
22-55 years 
Long distance 
running – mean 
distance of 28km 
 
Onset of exercise 
unknown 
Baseline – morning 
24hrs pre ex. 
Post ex. – morning 1 
and 2 days 
- ↑ OC 1 day post ex. in males only 
- BAP no change 
- ↓ PICP post run but returned to 
baseline 2 days post ex. in females 
only 
 
 
BAP 
PICP R 
ICTP 
Banfi et al., 
2012 
OPG F Serum n = 30 
professional 
male rugby 
players  
26±2 years 
Training camp – 
field practice 
Baseline 
Post ex. 
- OPG and RANKL showed non-
significant ↑ post ex. 
RANKL R 
Guillemant et 
al., 2004 
BAP F Serum n = 12 T male 
triathletes  
23-37 years 
1 hour cycle 
ergometer at 80% of 
VO2max 
 
Onset of exercise 
9:30am 
Baseline – 8:30am, 
9:30am 
During ex. – 
10:00am 
Post ex. – 
immediately, 30 
min., 1 hour and 2 
hours 
- BAP no change 
- ↑ CTX 30min post ex. through to 2 
hours post ex. 
- Ingestion of high-calcium mineral 
water suppressed CTX response 
 
 
 
 
CTX R 
F – formation, R – resorption, RE – resistance exercise, RM – repetition maximum, UT – untrained, T – trained, PL – plyometrics, IR – intermittent 
running, CON – control, RA – recreationally active, WBV – whole body vibrations 
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Table 5. The acute effects of physical activity on markers of bone formation and bone resorption continued. 
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Herrmann et 
al., 2007 
OC F Serum n = 32 (MA, male 
athletes 26±4 
years; MCo, male 
controls 36±21 
years; FA, female 
athletes 24±3 
years; FCo, 
female controls 
25±2 years)  
Incremental anaerobic 
threshold cycle 
ergometer – started at 
50W, increase of 5-W 
(males) or 30W 
(females) every 3 
minutes 
 
 
 
Baseline 
Post ex. – 3 hours 
and 24 hours 
- Exercise at 75% intensity↓ 
OC and PINP in all groups 
post ex. 
- CTX and TRAP not 
consistently modified 
PINP 
CTX R 
TRAP 
Kristofferson 
et al., 1995 
OC F Serum n = 7 T males  
22 years 
Modified Wingate test 
– cycle ergometer 
 
Onset 9:00am-1:00pm 
Baseline – 1 hour 
pre ex. 
Post ex. – 5 and 60 
mins. 
- No changes in any of the 
markers PICP 
ICTP R 
Langberg et 
al., 2000 
PICP F Plasma n = 17 male 
runners  
23-48 years 
Marathon running 
(onset of 9:30am) 
Baseline – 7:00am 
(1 week prior) 
Post ex. – 
immediately, 1, 2, 3, 
4, 5, 6  days 
(7:00am) 
- PICP ↓ immediately post ex., 
↑ and peaked day 3, returned 
to baseline day 5 
- ICTP short ↑ immediately 
post ex. but returned to 
baseline by 24 hours  
ICTP R 
Lippi et al., 
2008 
OC F Serum n = 15 T males 
47 years 
Half marathon (21km) 
under competitive 
conditions 
Baseline  
Post ex. – 
immediately, 2, 6 
and 24 hours 
- ↑ OC immediately post ex. 
but returned to baseline by 3 
hours 
Lin et al., 
2012 
OC F Serum n = 24 UT males 
25±0.7 years 
 
(PL group, IR 
group and CON 
group) 
Plyometric jumping – 5 
sets forward jumping 
and lateral jumping 
Baseline – 8:00am  
Post ex. – 5min, 
15min, 1, 3, 6, 24, 
48 and 72 hours 
- ↑ OC vs. CON at 5min and 1 
hour post ex.  
- No significant differences in 
TRAP vs. CON 
TRAP R Interval running – 
200m x 10 
(onset of 9:00am) 
- No significant differences in 
OC or TRAP vs. CON 
F- formation, R – resorption, RE – resistance exercise, RM – repetition maximum, UT – untrained, T – trained, PL – plyometrics, IR – intermittent 
running, CON – control, RA – recreationally active, WBV – whole body vibrations 
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Table 5. The acute effects of physical activity on markers of bone formation and bone resorption continued. 
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Malm et al., 
1993 
OC F Serum n = 8 male 
marathon runners 
25-41 years 
n = 15 female 
marathon runners 
23-55 years 
Marathon run Baseline 
Post ex. – 
immediately, 1, 3 
and 5 days (between 
3:00pm and 
7:00pm) 
- OC ↓ 1 day post ex. and 
continued to day 3 in males 
and remained lower in 
females 
- BAP ↓ in females only 
immediately post ex. and 
remained lower  
- Ca ↓ immediately post ex. but 
returned to baseline by day 1 
in males and females 
 
 
BAP 
Calcium R Urine 
Hyp 
Nishiyama et 
al., 1988 
OC F Serum n = 18 (A, athletic 
male volleyball 
players; NA, non-
athletic sedentary 
males)  
20-24 years 
30 min running 
ergometer at 
approximately 50% of 
maximum capacity 
(onset 5:00pm) 
Baseline – 5:00pm 
Post ex. – 
immediately and 1 
hour 
- A ↑ baseline values vs. NA 
- A OC ↑ 1 hour post ex. 
- NA OC ↑ immediately post 
ex. and returned to baseline 
values by 1 hour 
 
 
Pomerants et 
al., 2008 
PINP F Serum n = 60 boys  
10-18 years 
Acute cycle ergometer 
(30 min ~95% of 
ventilator threshold) 
(onset between 3:00pm 
and 5:00pm) 
Baseline – 3:00pm-
5:00pm 
Post ex. – 
immediately and 30 
min. 
- No change in either PINP or 
ICTP at any time point 
- Pubertal group II (Tanner 2 
and 3) significantly higher 
PINP and ICTP 
concentrations vs. pre-
pubertal (Tanner 1) and 
pubertal group III (Tanner 4 
and 5)  
 
 
ICTP R 
F – formation, R – resorption, RE – resistance exercise, RM – repetition maximum, UT – untrained, T – trained, PL – plyometrics, IR – intermittent 
running, CON – control, RA – recreationally active, WBV – whole body vibrations, A – athletic, NA – non-athletic,        -  children 
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Table 5. The acute effects of physical activity on markers of bone formation and bone resorption continued. 
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Rogers et al., 
2011 
BAP F Plasma n = 12 UT males 
24-62 years 
Plyometric jumping and 
bounding – 1 set, 10 
reps or 2 sets, 5 reps 
 
Resistance –  3 sets, 10 
reps (1
st
 set 60% RM, 
2
nd
 and 3
rd
 set 80% RM) 
 
(Onset  between 
6:00am-7:00am) 
Baseline – 6:00am-
7:00am 
Post ex. – 
immediately, 15 
min., 30min., 1 and 
2 hours 
- BAP unchanged but the 
natural morning ↓ was 
prevented 
- No change in OC 
- TRAP5b ↓ for both PLY and 
RT at 15 min. and 30 min. 
post ex. but returned to 
baseline values 1 hour post 
ex. 
- CTX ↑ at 1 hour, ↓ 2 hour, ↑ 
24 hour post ex. 
 
 
OC 
TRAP5b R 
CTX 
Rong et al., 
1997 
OC F Serum  n = 8 UT males 
23±3 years 
Cycle ergometer – 
E55% or E85%  
VO2max 45 or 15min – 
STR (supine leg press) 
Baseline – 7:00am-
8:00am (fasted) 
Last minute of 
exercise 
Post ex. – 1, 4 and 
24 hours 
- ICTP ↓ 4 hours post ex. after 
all types of exercise 
- OC ↑ 4 hours post ex. after 
E55% 
 
 
 
ICTP R 
Rudberg et 
al., 2000 
OC F Serum n = 15 (CY, cycle 
ergometer group; 
JG, jogging 
group) 
RA 
postmenopausal 
women  
57±4 years 
Cycle ergometer until 
exhaustion – increase of 
30W every 6min 
30-40min of jogging – 
4-6km  
 
(onset – afternoon) 
Baseline – afternoon 
Post ex. – 
immediately and 20 
min. 
- OC no change 
- BAP (isoform B2) ↑ 
immediately post ex. in both 
groups 
- ICTP no change 
 
 
 
 
 
BAP 
ICTP R 
F – formation, R – resorption, RE – resistance exercise, RM – repetition maximum, UT – untrained, T – trained, PL – plyometrics, IR – intermittent 
running, CON – control, RA – recreationally active, WBV – whole body vibrations 
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Table 5. The acute effects of physical activity on markers of bone formation and bone resorption continued. 
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Scott et al., 
2010 
OPG F Plasma n = 21 RA males 
(RA, exercise 
group 30±3 years; 
CON, control 
group 26±3)  
 
n = 10 ET males 
31±3 years 
Intermittent exhaustive 
running 
 
(onset ~8:00am) 
- Baseline – 8:00am 
- During ex. – 20, 
40 and 60min. 
- Post ex. – 
Immediately, 
30min., 1, 1.5 and 
2 hours  
- 1-4 days post ex. – 
fasting 
~8:00am/day 
- OPG ↑ during exercise, 
immediately and 2 hours post 
ex. in both groups 
- BAP and PINP no change  
- β-CTX ↑ 1-4 days post ex. in 
both groups vs. control 
 
 
 
 
BAP  
 
Serum 
PINP 
β-CTX R 
Scott et al., 
2011 
BAP F Serum n = 10 RA males 
28±4 years 
60min treadmill 
running at 55%, 65% 
and 75% of VO2max 
 
(onset 8:15am) 
- Baseline – 8:00am 
- During ex. – 20, 
40 and 60min. 
- Post ex. – 30min., 
1, 2 and 3 hours 
- 1-4 days post ex. – 
fasting 
8:00am/day 
 
- BAP not affected by exercise 
intensity but ↑ at day 3 and 4 
post ex.  
- PINP ↑ during ex. for all 
intensities but ↓ quickly in 
recovery to baseline 
- OC not affected by exercise 
intensity but ↓ 3 days post ex. 
- OPG not affected by exercise 
intensity but ↑ 20 min. during 
ex. and remained ↑ 3 hours 
post ex.   
- β-CTX not ↑ by ex. but was 
higher in 55% and 65% ex. 
 
 
 
 
 
PINP  
Plasma 
OC 
OPG 
β-CTX R 
RE – resistance exercise, RM – repetition maximum, UT – untrained, T – trained, PL – plyometrics, IR – intermittent running, CON – control, RA – 
recreationally active, WBV – whole body vibrations 
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Table 5. The acute effects of physical activity on markers of bone formation and bone resorption continued. 
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Scott et al., 
2013 
β-CTX R Serum n = 10 RA males 
26±5 years 
Two 60 min. bouts of 
treadmill running  at 
65% VO2 max 
separated by a recovery 
of either 23 hours 
(LONG) or 3 hours 
(SHORT)  
 
LONG – onset 2:30pm 
SHORT – onset 
10:30am 
LONG Ex. Day 1: 
- Baseline – 8:00am 
- Pre ex. – 2:15pm 
- Post ex. – 
Immediately, 1, 2 
and 3 hours 
LONG Ex. Day 2: 
- Baseline – 8:00am 
- Pre ex. – 2:15pm 
- Post ex. – 
Immediately, 1, 2 
and 3 hours 
SHORT Ex. Day 1: 
- Baseline – 8:00am 
- Pre ex. – 10:15am 
- Post ex. – 
Immediately, 1, 2 
and 3 hours 
LONG & SHORT  
- 1-4 days post ex. – 
8:00am 
- β-CTX, PINP and BAP no 
change 
- OPG ↑ with all exercise 
bouts, second bout not altered 
by recovery duration 
PINP  F 
OPG 
BAP Plasma 
Sherk et al., 
2013 
BAP F Serum n = 10 RA 
females  
20.7±0.2 years 
 
RE-only – 3 sets of 10 
repetitions at 80% 1RM  
(4 lower body, 2 upper 
body) 
WBV + RE – same 
protocol and 5 one min. 
intervals at 20 Hz 
 
Onset 7:00am 
RE only: 
- Baseline – 7:00am 
- Post-ex. – 
immediately, 30 
min. 
WBV + RE: 
- Baseline – 7:00am 
- Post-ex. – 
immediately 
WBV, 
immediately RE 
and 30 min. RE 
- BAP no change both groups 
- TRAP5b ↑ post WBV but ↓ 
immediately post to 30 min. 
RE in both groups 
- CTX ↓ post WBV and post 
30 min RE in WBV+RE 
group 
TRAP5b R 
CTX 
RE – resistance exercise, RM – repetition maximum, UT – untrained, T – trained, PL – plyometrics, IR – intermittent running, CON – control, RA – 
recreationally active, WBV – whole body vibrations 
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Table 5. The acute effects of physical activity on markers of bone formation and bone resorption continued. 
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Thorsen et al., 
1997 
OC F Serum n = 14 sedentary 
females  
25.2±0.6 years  
Outdoor jogging at 50% 
VO2max, estimated by 
50% heart rate max 
Onset 8:30am-9:30am 
- Baseline – 15 min. 
pre ex. 
- Post ex. – 1, 24 
and 72 hours 
- OC ↑ 1 hour post ex. but 
returned to baseline 24 hours 
post ex. 
- PICP ↓ 1 hour post ex. but ↑ 
24, 72 hours post ex. 
- ICTP ↑ 24, 72 hours post ex. 
 
 
 
  
PICP 
ICTP R 
Tosun et al., 
2006 
OC F Plasma n = 9 sedentary 
females  
28±2.2 years 
- Walking (W) – 30 
min. submax 
treadmill walking 
- Walking with 5kg 
(WE) –  30 min. 
submax treadmill 
walking 
Onset between 9:00am-
11:00am 
- Baseline – 
9:00am-11:00am 
- Post ex. – 
immediately, 45 
min (OC, PINP, 
PICP, ICTP), 1 
hour (Dpd), 24 
hours (BAP, Dpd) 
- OC, PICP, PINP and ICTP no 
changes 
- BAP ↓ 24 hours post ex. in W 
group and ↑ 24 hours post ex. 
in WE group 
 
 
 
 
 
PICP 
PINP 
BAP R 
ICTP 
Dpd Urine 
Wallace et al., 
2000 
OC F Serum n = 17 RA males 
26.9±1.5 years 
Cycle ergometer 
incremental protocol 
 
Onset late afternoon or 
evening 
- Baseline – 3hr 
fasting afternoon-
evening 30min. 
and immediately 
prior to ex. 
- During ex. – 15 
and 30 min. 
- Post ex. – 45, 60, 
75, 90 and 120 
min. 
- OC no change 
- BAP, PICP and ICTP ↑ in 
response to ex. 
 
 
 
 
 
 
 
BAP 
PICP 
ICTP R 
RE – resistance exercise, RM – repetition maximum, UT – untrained, T – trained, PL – plyometrics, IR – intermittent running, CON – control, RA – 
recreationally active, WBV – whole body vibrations 
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Table 5. The acute effects of physical activity on markers of bone formation and bone resorption continued. 
Reference Bone 
Marker 
F/R Medium Sample Exercise type and/or 
intensity 
Sample Timing(s) Comments: 
Welsh et al., 
1997 
OC F Serum n = 10 sedentary 
males  
25.7±4.5 years 
30 min. on motor 
driven treadmill 60% of 
predicted max heart rate  
 
Onset between 8:00am-
8:30am 
Serum: 
- Baseline – 
8:00am-8:30am 
- Post ex. – 30 min., 
1, 8, 24 and 32 
hours 
Urine: 
- 1 day pre ex., ex. 
day and 1 day post 
ex. 
- OC and BAP  no change 
- Pyr and Dpd ↑ day of ex. and 
↑↑ 1 day post ex.  
BAP 
Pyr R Urine 
Dpd 
Whipple et 
al., 2004 
BAP F Serum n = 9 RA males  
21.9±1.2 years 
3 sets of 10 – 50, 75 
and 100% of 10 RM 
(bench press, leg press, 
lateral pull down, 
seated row, leg curl, 
back extension and arm 
curl) 
 
Onset is unknown 
Serum: 
- Baseline  
- Post ex. – 
immediately, 1, 8, 
24 and 48 hours 
Urine: 
- 1 day pre ex., ex. 
day, 1 day post ex. 
and 2 days post 
ex. 
- BAP and PICP no change 
- sNTx ↓ 1 and 8 hours post ex. 
- uNTx no change 
- BAP : sNTx ↑ at 1 and 8 
hours post ex. 
- Returned to baseline 24 hours 
post ex. 
PICP 
sNTx R 
uNTx Urine 
Ziegler et al., 
2005 
OPG F Plasma n = 31 
recreational male 
(43.7±10.9 years) 
and female 
(37.3±8.6 years) 
runners 
Marathon or half 
marathon run 
 
Onset is unknown 
- Baseline – 30min. 
prior to run 
- Post ex. – 30 min. 
within finishing 
run 
- OPG ↑ in full marathon 
runners  
- RANKL ↓ in half and full 
marathon runners RANKL R 
RE – resistance exercise, RM – repetition maximum, UT – untrained, T – trained, PL – plyometrics, IR – intermittent running, CON – control, RA – 
recreationally active, WBV – whole body vibrations, sNTx – serum NTx, uNTx – urinary NTx 
 
(Ashizawa et al., 1998; Banfi, Corsi, & Galliera, 2012; Brahm, Piehl-Aulin, & Ljunghall, 1996; Guillemant et al., 2004; Herrmann et al., 2007; 
Kristoffersson et al., 1995; Langberg et al., 2000; Lin et al., 2012; Malm et al., 1993; Nishiyama et al., 1988; Pomerants et al., 2008; R. S. Rogers et al., 
2011; Rong et al., 1997; Rudberg et al., 2000; Scott et al., 2010; Scott et al., 2011; Scott et al., 2013; Sherk et al., 2013; Thorsen et al., 1997; Tosun, 
Bolukbasi, Cingi, Beyazova, & Unlu, 2006; Welsh et al., 1997; Whipple et al., 2004; Ziegler et al., 2005)
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Chapter 3: Methods 
3.1 Participants 
This study and all related procedures received ethical clearance from the Brock 
University Research Ethics Board. Participants were recruited through poster 
advertisements, flyers and information packages to local elementary schools and 
universities/colleges throughout the Niagara region. Recruitment of the participants 
focused on recreationally active young men and pre-pubescent boys to limit the impact of 
pubertal and post peak bone mass fluctuations in bone markers and bone strength 
measures.  
After showing interest in the study, participants, and their parents for children, 
were provided with a thorough description of the purpose, methods and any potential 
risks of the study. Exclusion criteria included factors that can influence properties of bone 
(1) BMI  ≥ 85th percentile for their age, (2) a body fat percentage ≥ 30%, (3) previous or 
current fracture, (4) premature growth or growth delay and (5) use of pharmaceuticals 
(Antiresorptives, bisphosphonates, corticosteroids, anticonvulsants and GnRH agonists). 
A total of 30 participants completed the study, 12 of which were boys (10.2 ± 0.4 years) 
and 18 young men (22.5 ± 0.7 years). 
3.2 Procedures 
 Participants were instructed to refrain from alcohol and caffeine for a minimum of 
6 hours prior and vigorous or impact exercise for a minimum of 24 hours prior to testing. 
Participants were invited to the Applied Physiology Exercise Physiology Laboratory for 
two separate visits. The first visit took place at 9:00am for all participants, in order to 
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control for circadian rhythm variation. Upon arrival, participants and parents were 
introduced to the purpose of the study, the methods involved and any potential benefits or 
discomforts and an informed consent/assent was then signed by either the participant or 
parent/guardian.  Afterwards, the resting baseline blood sample was drawn, using a 
standard venipuncture technique and a questionnaire package was completed, including  
medical information, maturation, leisure-time physical activity, past-year physical 
activity and dietary intake. Children participants were assisted with the completion of the 
questionnaires by either the investigator or parent/guardian as necessary. The plyometric 
exercise protocol was then completed and followed by two additional blood samples; five 
minutes post-exercise and one hour post exercise. During the second visit, the last blood 
sample 24 hours post-exercise was taken and anthropometric measures of height, sitting 
height (children only), weight and body composition were taken. Subsequently, 
quantitative ultrasound (QUS) was used to determine bone strength of the tibia and radii.   
3.3 Measurements 
3.3.1 Anthropometry 
All measures of height, sitting height, weight and body composition were 
assessed by the same investigator for all participants. Height was measured, using a 
stadiometer, to the nearest 0.1cm with no shoes and light clothing. For maturational 
indications, sitting height was measured to the nearest 0.1cm for the pre-pubescent males 
using the stadiometer and a table. This was measured by subtracting the height of the 
table from the combined height of the table and sitting participant. Body mass (kg) was 
measured using the InBody520 bioelectrical impedance analysis (BIA) system 
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(Biospace.2008.). Body mass index (BMI) was calculated by dividing the participants’ 
mass (kg) by their height squared (m
2
). Percent body fat (PBF) and lean body mass 
(LBM) were assessed using skinfold thickness measurements. PBF was estimated using 
the Slaughter et al. (1988) equations, based on skinfold thickness at two sites, triceps and 
subscapular, using a Harpenden caliper. All skinfold measurements were made on the 
right side of the body. Each site was measured in triplicate and the median was recorded. 
PBF was then calculated using Slaughter’s standardized equations, which are based on 
sex and maturity level (Slaughter et al., 1988).  
3.3.2 Indicators of Maturity 
 Sexual maturity was determined using secondary sexual characteristics, as defined 
by Tanner (1962) (self-assessed using drawings) (Tanner, 1962). Refer to appendix. 
Pubic hair development was used to determine sexual maturity. Skeletal maturity was 
determined by calculating the years from the age of peak height velocity (PHV), using 
height, sitting height, leg length and body mass as suggested by Mirwald et al. 2002 
(Mirwald, Baxter-Jones, Bailey, & Beunen, 2002).   
3.3.3 Habitual Physical Activity and Dietary Intake Measures 
 Habitual physical activity was assessed using three different questionnaires. The 
Godin-Shephard Leisure Time Exercise Questionnaire was designed to evaluate leisure 
time physical activity using intensity indicators such as light, moderate or strenuous 
(Godin & Shephard, 1985). The questionnaire was administered to the participants to 
assess the weekly physical activity metabolic equivalent (WAeq) by indicating the number 
of times they engaged in at least 15 minutes of each intensity level. The number of each 
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intensity level was then multiplied by known energy consumption values to determine the 
metabolic equivalents (Godin & Shephard, 1985). This method of physical activity 
assessment has shown to be a valid and reliable tool in children and adolescents as well 
as in adult male and female populations (Sallis, Buono, Roby, Micale, & Nelson, 1993).   
 The Bone-Specific Physical Activity Questionnaire (BPAQ) was administered to 
the participants to record type, frequency and years of current and historical physical 
activity involvement (Weeks & Beck, 2008). Scoring is based on an algorithm which 
takes into account the osteogenic index principle described by Turner and Robling and 
ground reaction forces (GRF) (Turner & Robling, 2003). It should be noted that this 
questionnaire was developed in a small sample of adults and may not predict bone 
parameters in other populations, such as children (Farr, Lee, Blew, Lohman, & Going, 
2011). 
 The Past Year Physical Activity Questionnaire (PYPAQ) was administered to 
survey the time spent in leisure and sporting activities in the past year (Aaron et al., 
1995). The participants were asked to indicate all of the leisure-time activities that they 
had engaged in over the past year for at least 10 times, followed by details regarding the 
frequency and duration of each activity listed. This physical activity assessment tool has 
been validated in adolescents (Aaron et al., 1995). In addition, it has also been compared 
to the BPAQ in girls and it was shown that the PYPAQ was a stronger predictor of 
indices of bone strength (Farr et al., 2011). Both questionnaires were included to ensure 
all measures of bone-relevant physical activity were taken into consideration.  
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 Dietary intake was evaluated using the 24-hour Nutrition Recall Questionnaire. 
The participants were asked to recall a typical day of eating. With the use of a variety of 
visual aids, the different portion sizes were determined to ensure the most accurate 
representation of each participant’s nutritional intake. Nutritionist ProTM (Axxya 
Systems, USA) was used to analyze each participant’s dietary intake, ultimately 
providing an estimate for total caloric intake (kcal), calcium intake (mg), vitamin D 
intake (µg) as well as caffeine intake (mg).  
3.3.4 Quantitative Ultrasound (QUS)   
 QUS was performed in order to examine overall bone health. The SOS 
measurement is an indicator of bone strength, reflecting bone mineral density, elasticity 
and microarchitectural structure (Barkmann et al., 2000).  The QUS method has been 
shown in several studies to be a sensitive diagnostic tool in bone fragility and changes in 
bone strength. QUS has been used to predict vertebral and hip fractures and in vitro 
studies have indicated the capability of measuring previously unquantified properties of 
bone fragility (D. C. Bauer, Gluer, Genant, & Stone, 1995; Gluer, Wu, & Genant, 1993; 
Njeh, Boivin, & Langton, 1997). It has also been shown to be a sensitive tool to detect 
changes in tibial bone properties among pre-pubertal boys over an 8-month period (Falk 
et al., 2000).  
This method is a simple, inexpensive, non-invasive and radiation-free way of 
investigating and reflecting bone strength. Because QUS is not influenced by the size of 
bone it is advantageous when assessing children (Barkmann et al., 2000; Schoenau et al., 
2004).  
  
52 
 
Skeletal properties were assessed by measuring bone speed of sound (SOS) using 
QUS (Sunlight Omnisense
TM
 7000S, Sunlight Medical, Israel) at the distal 1/3 of the 
radius and the mid-shaft of the tibia, on both the dominant and non-dominant limbs. The 
measurement site of the radius was determined as the midpoint between the olecranon 
process and the tip of the third distal phalanx, while the measurement site for the tibia 
was determined as the midpoint between the bottom of the calcaneous and the top of the 
patella with the knee at a 90 degree angle. The system contains a main unit and a hand-
held probe, which is used to measure the SOS (m/s) of the ultrasound waves along 
cortical bone. Z-scores between -1 and 1 standard deviations indicate healthy bone 
properties in relation to the available norms. Preceding any measurements the system 
underwent calibration procedures according to the manufacturer’s protocol for quality 
control procedures. The probe is positioned to run, at a critical angle, along the bone 
around the arc of the radius and the tibia.  
3.3.5 Exercise Protocol 
 Upon completion of the medical screening questionnaire, participants were asked 
to wear a heart rate monitor and an accelerometer. The heart rate monitor included the 
wrist watch and the transmission strap worn around the chest. Accelerometers were used 
to record accelerations (counts) in the vertical or horizontal axes. The accelerometers 
were programmed to record activity counts at 1 second epochs. The exercise protocol was 
designed to provide high impact, weight-bearing loads in the form of circuit training 
stations and was modified from the protocol used by MacKelvie et al, (2001) in the long-
term school-based interventions (Mackelvie et al., 2001).  
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 The participants began with a warm-up activity that consisted of a 5 minute 
incremental cycle ergometer protocol. The adults started at 120 watts (W) and increased 
by 30W every minute and the children started at 25W and increased by 15W every 
minute.  Upon completion of the warm-up, a thorough explanation and demonstration of 
the exercises was given to the participants who were also able to familiarize themselves 
with the exercises.  
The participants were then instructed to rotate through the five stations, which 
were comprised of, in this order, drop jumps, lunge jumps, hurdle jumps, single-leg hops 
and jumping jacks. The drop jumps were 75cm in height for the adults and 40cm in 
height for the children. The hurdle jumps were 40cm in height for the adults and 15cm in 
height for the children. For both adults and children, 3 sets of 8 repetitions were 
completed with a recovery period of at least three minutes between each set. The 
participants were asked to jump to their highest potential for each individual jump. The 
heart rates were recorded after each exercise and rest period. By following this protocol, 
an approximation of 144 jumps was executed upon completion (Mackelvie et al., 2001). 
McKay et al. (1998) demonstrated that the ground reaction forces involved in these 
circuit stations characteristically involved forces up to 3.5- to 5-times body weight 
(McKay, Bailey, Mirwald, Davison, & Faulkner, 1998). 
3.3.6 Biochemical Markers of Bone Turnover 
 Resting venous blood samples were drawn using a standard venipuncture 
technique from a vein in the antecubital fossa between 9:00am and 9:30am. The morning 
hours were chosen for the baseline measurement to control for circadian rhythm 
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variations. All participants were asked to refrain from physical activity 24 hours prior to 
the resting blood sample. A total of 10ml of blood was drawn per sample and was 
collected using serum tubes (BD Vacutainer®). The blood was centrifuged at 3000rpm, 
4°C for a total of fifteen minutes after waiting at least 1 hour post blood draw at room 
temperature. The waiting time rarely exceeded the 1 hour post draw. The serum was 
separated, removed from the sample tube and aliquoted into six 0.5ml polyethylene tubes. 
The tubes were then stored at -80°C until analysis.  
 Serum was analyzed for biochemical markers of bone turnover. The following 
bone formation markers were measured using enzyme-linked immunosorbent assay 
(ELISA) kits: bone-specific alkaline phosphatase (BAP) and osteoprotegerin (OPG). 
Serum BAP immunoassay appears to be the method of choice due to its high specificity 
and precision and has been shown to be a sensitive indication tool of bone formation 
(Gomez et al., 1995). OPG is a key regulator of osteoclastogenesis and the commercial 
OPG assay precision is within the acceptable ranges with the latest generation having low 
detection limits (Haufbauer & Heufelder, 2001; Kholsa, 2001; A. Rogers & Eastell, 
2005). The following bone resorption markers were measured: N-telopeptides of type I 
collagen (NTx) and receptor activator of nuclear factor κB ligand (RANKL). Serum NTx 
has been shown to provide a responsive index of human bone resorption in healthy 
populations (Clemens, Herrick, Singer, & Eyre, 1997). RANKL is a pre-resorptive factor 
that stimulates osteoclast differentiation (Hofbauer & Heufelder, 2001; Kholsa, 2001). 
RANKL assay sensitivity has recently been improved with the use of a secondary 
antibody and a modified detection method (A. Rogers & Eastell, 2005).  OPG and 
RANKL are not traditional measures of bone turnover but can provide insight into the 
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early phase of bone cellular response to exercise. At present, there are no such data 
related to high impact exercise in children or in adults.   
 All samples were thawed and ELISA kits brought to room temperature prior to 
the onset of the procedures. All analyses were performed in duplicate and the 
absorbencies were read using a microplate reader. 
Bone-specific alkaline phosphatase (BAP) was assayed using four Ostase® BAP 
Immunoenzymetric Assays (Immunodiagnostics Systems, Fountain Hills, AZ, USA). 
Prior to the onset of the analysis, all reagents were thoroughly mixed by gentle agitation 
or swirling, the Wash Solution was prepared and specific samples were diluted. The 
Wash Solution was prepared by adding the Wash Concentrate to 950ml of deionized 
water and mixing it using a magnetic stirrer for a minimum of 5 minutes. Because 
childrens’ values would fall above the standard curve, their samples needed to be diluted 
1:3 and mixed thoroughly using the vortex (Hui et al., 2003).  
Upon completion of the preparatory steps 50µl of each Calibrator, Control and 
sample were pipetted into each assigned well. Using a multichannel pipette, 100µl of 
Conjugate was then pipetted into each well. A plate sealer was applied to the microplate 
which was then incubated for 1 hour at room temperature using a horizontal rotator set at 
500rpm. At the end of the incubation period the microplate was washed 3 times with the 
Wash Solution. After the final wash, the microplate was inverted and tapped strongly 
against paper towel. Using a multichannel pipette, 150µl of Substrate reagent was 
delivered to each well and without delay, was incubated for 13-15 minutes at room 
temperature using a horizontal rotator set at 500rpm. After the incubation period using a 
multichannel pipette, 100µl of Quench Reagent was added to each well. Within 1 hour of 
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adding the Quench Reagent, the microplate absorbance was read using a microwell plate 
reader at 405nm.  
Assay performance can be verified if the following criteria were met: (1) recovery 
of the control concentrations fell within the stated ranges and (2) the coefficient of 
variation (%CV) of the 405nm absorbance readings for each calibrator and control 
sample was less than 10%.  
After the absorbance values were determined, a standard curve was produced 
using the calibrator points.  The concentration values for the controls and samples of 
BAP, expressed in µg/L, were then determined from the calibration curve using a third 
order polynomial equation, with an average r
2
 value of 0.99543(0.9882-0.9999). Because 
the children’s samples were diluted in the preparatory steps, the dilution factor needed to 
be taken into consideration when calculating the values. The ranges of the low and high 
controls set by the kit were 7.6-11.4µg/L and 39.2-58.8µg/L, which all of the assayed 
controls fit within. The intra-assay CVs were 3.3%, 3.2%, 3.3% and 6.9%, averaging 
4.2%. The average inter-assay CV for 4 plates was 1.4%.  
Osteoprotegerin (OPG) was assayed using four Human OPG ELISA kits 
(Biovendor Research and Diagnostics Products, Asheville, NC, USA). Prior to the assay 
procedure the Standards, Controls, Wash Solution Concentrate and samples were all 
prepared. The lyophilized Master Standard was reconstituted with Dilution Buffer and 
was left to dissolve for at least 15 minutes with occasional gentle shaking. The set of 
standards was prepared using the amount of Dilution Buffer stated in the product data 
sheet. Once prepared, the standards were then further diluted 3x with Dilution Buffer, and 
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were ready to be aliquoted. The lyophilized Quality Controls were reconstituted with 
deionized water and were left to dissolve for at least 15 minutes with occasional gentle 
shaking. The prepared Quality Controls were diluted 3x with Dilution Buffer and were 
then ready to be aliquoted. The Wash Solution Concentrate was prepared by diluting it 
10x or ten-fold in deionized water for a 1x working solution. Samples were diluted 3x 
with Dilution Buffer and mixed thoroughly using the vortex.   
Following the preparatory steps, 100µl of the diluted Standards, Quality Controls 
and samples were distributed to the bottom of each assigned well. A plate sealer was 
applied to the microplate, which was then incubated at room temperature for 1 hour, 
shaking at 300rpm on an orbital microplate shaker. At the end of the incubation period 
the wells were washed 3 times using the Wash Solution. After the final wash, the 
microplate was inverted and tapped strongly against paper towel. Using a multichannel 
pipette, 100µl of the Biotin Labelled Antibody was added to each well and was then 
incubated for another hour at room temperature, shaking at 300rpm on an orbital plate 
shaker. Following this incubation period, 100µl of Streptavidin-HRP Conjugate was 
added to each well using the multichannel pipette. The microplate was then incubated for 
30 minutes, shaking at 300rpm on an orbital plate shaker. The last washing step occurred 
after this incubation period, where the microplate was washed 3 times using the Wash 
Solution and was inverted and tapped strongly against paper towel. Using the 
multichannel pipette 100µl of the Substrate Solution was added to each well. The 
microplate was then covered with a plate sealer as well as aluminum foil to avoid 
exposure to direct sunlight. It was incubated for 10 minutes at room temperature and was 
not to be shaken. During this step a blue colour should have formed and to stop the colour 
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development 100µl of Stop Solution was added to each well using the multichannel 
pipette. Within 5 minutes of adding the Stop Solution absorbance was read using a 
microwell reader at 450nm. 
After the microplate was read and the absorbance values were determined the 
concentration values for the controls and samples of OPG (pmol/L) were determined 
from the calibration curve using a second degree polynomial equation.  
After the absorbance values were determined, a standard curve was produced 
using the calibrator points.  The concentration values for the controls and samples of 
OPG, expressed in pmol/L, were then determined from the calibration curve using a third 
order polynomial equation, with an average r
2
 value of 0.9994 (0.9986-0.9998). The 
ranges for the high and low controls were 12.8-19.2pmol/L and 4.4-6.6pmol/L. All of the 
control values for each of the OPG ELISA kits completed fell within the ranges with an 
average of 18pmo/L for the high control and 5.9pmol/L for the low control. The intra-
assay CV’s were 5.7%, 9.1%, 3.9% and 4.3%, averaging 5.7% for all four microplates. 
The average inter-assay CV for 4 plates was 3.2% respectively.  
N-telopeptides of type I collagen (NTx) was assayed using Osteomark® NTx 
Serum kits (Alere Scarborough, Inc., Scarborough, ME, USA). Prior to the 
commencement of the assay procedure the Working Strength Wash Solution, the 
Working Strength Conjugate Solution and the Calibrators, Controls and samples were all 
prepared. The Working Strength Wash Solution was prepared using 1 part 30x Wash 
Concentrate with 29 parts deionized water and was mixed using the magnetic stirrer for a 
minimum of 5 minutes. The working strength conjugate solution was prepared by 
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diluting 120µl of the Antibody Conjugate Concentration with 12ml of Antibody 
Conjugate Diluent. The solution was then mixed gently by inversion only. The 
Calibrators, Controls and samples were diluted 1:5, but because the childrens’ values 
would fall above the standard curve their samples needed to be further diluted to 1:3 (van 
der Sluis, Hop, van Leeuwen, Pols, & de Muinck Keizer-Schrama, 2002). All of the 
diluted samples were mixed thoroughly using the vortex.  
Following these preparations 100µl of each diluted Calibrator, Control and 
sample was pipetted into the microplate according to the plate configuration. Using a 
multichannel pipette, 100µl of the Working Strength Conjugate Solution was added to 
each well. A plate sealer was then applied and the microplate gently swirled on a flat 
surface for 15-20 seconds to ensure mixing. The microplate was incubated for 90 ± 5 
minutes at room temperature. During the last 5 minutes of incubation the Chromagen 
Reagent/Buffered Substrate solution was prepared using a 1:101 of the Chromagen 
Reagent into the Buffered Substrate. The solution was mixed by inversion only. At the 
end of the incubation period the microplate was washed 5 times with the working 
strength wash solution and was blotted on absorbent paper after the final wash. Without 
delay 200µl of the diluted Chromagen Reagent/Buffered Substrate was added to each 
well using a multichannel pipette. A new plate sealer was applied and the microplate was 
then incubated for 30 ± 2 minutes at room temperature. During this time a blue colour 
will develop in the wells containing bound antibody-horseradish peroxidase conjugate. 
After the incubation period 100µl of the Stopping Reagent was added to each well, 
during which time the wells that developed a blue colour now turned yellow. The 
microplate was then swirled for 15-20 seconds on a flat surface and incubated for 5 
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minutes at room temperature before reading the absorbance values. Within 30 minutes of 
adding the Stopping Reagent the microplate absorbance values were read using a 
microwell plate reader that was set at 450nm.  
The assay results were valid if the following criteria were met: (1) mean 
absorbance of the 0 nanomoles Bone Collagen Equivalents (nM BCE) Calibrator is 
greater than or equal to 1.300, (2) the span of the calibrator curve (absorbance difference 
between 0 nM BCE Calibrator and the 40 nM BCE Calibrator) is greater than or equal to 
0.900, (3) the coefficient of variation (% CV) between concentration value (nM BCE) 
duplicates is ≤20% CV otherwise those > 20% CV should be rerun and (4) specimens 
giving absorbance values below the 40 nM BCE Calibrator should be diluted and 
retested.  
After the absorbance values were determined, the concentration values for the 
controls and samples of NTx, expressed in nanomoles BCE/L (nM BCE), were 
determined from the calibration curve using a third order polynomial equation. The 
average r
2
 was 0.995 (0.9862-0.9998). The childrens’ concentration values were 
multiplied by their dilution factor of 3x. All of the mean absorbencies for the OnM BCE 
Calibrator were above 1.300 and the differences between the 0nM BCE and 40nM BCE 
above 0.900, which validates the results of the assays. In addition, all of the control 
values for the NTx ELISA kits fell within the low and high ranges of 6.1-10.3nM BCE. 
The intra-assay CV’s were 2.8%, 2.4%, 2.7% and 3.1%, with an average of 2.8% and the 
average inter-assay CV for 4 plates was 4.9%. 
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Receptor activator of nuclear factor κB ligand (RANKL) was assayed using 
Human sRANKL (TOTAL) ELISA kits (BioVendor Research and Diagnostic Products, 
Candler, NC, USA). Prior to the assay procedure the standards, controls, Wash Solution 
Concentrate and samples were all prepared. The lyophilized Master Standard was 
reconstituted with Dilution Buffer and was left to dissolve for at least fifteen minutes 
with occasional gentle shaking. The set of standards was prepared using the amount of 
Dilution Buffer stated in the product data sheet. The lyophilized Quality Controls were 
reconstituted with deionized water and were left to dissolve for at least fifteen minutes 
with occasional gentle shaking.  The Wash Solution Concentrate was prepared by 
diluting it 10x or ten-fold in deionized water for a 1x working solution. Samples were 
diluted 100x with Dilution Buffer and mixed thoroughly using the vortex.   
Following the preparatory steps, 100µl of the Standards, Quality Controls and 
diluted samples were pipetted into the appropriate wells. A plate sealer was applied to the 
microplate, which was then incubated at 2-8 °C for 16-20 hours, shaking at 300rpm on an 
orbital microplate shaker. At the end of the incubation period the wells were washed 5 
times using the Wash solution. After the final wash, the microplate was inverted and 
tapped strongly against paper towel. Using a multichannel pipette, 100µl of the Biotin 
Labelled Antibody was added to each well and was then incubated for an hour at room 
temperature, shaking at 300rpm on an orbital plate shaker. Following this incubation 
period, the wells were washed 5 times using the Wash Solution. After the final wash, the 
microplate was inverted and tapped strongly against paper towel. Afterwards, 100µl of 
Streptavidin-HRP Conjugate was added to each well using the multichannel pipette. A 
new plate sealer was applied and the microplate was then incubated for another hour at 
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room temperature, shaking at 300rpm on an orbital microplate shaker. At the end of the 
incubation period, the wells were washed 5 times for the final time using the Wash 
Solution. After the final wash, the microplate was inverted and tapped strongly against 
paper towel. Using a multichannel pipette 100µl of the Substrate Solution was distributed 
to each well. The microplate was then covered with a plate sealer as well as aluminum 
foil to avoid exposure to direct sunlight. It was incubated for 25 minutes at room 
temperature and was not to be shaken. During this step a blue colour should have formed 
and to stop the colour development 100µl of Stop Solution was added to each well using 
the multichannel pipette. Within 5 minutes of adding the Stop Solution absorbance was 
read using a microwell reader at 450nm. 
Once the absorbance values were established, a standard curve was formed using 
the calibrator points. From the established curve, the concentration values of the controls 
and samples, expressed in pmol/L, were determined by extrapolating the values through a 
third order polynomial equation, with an average r
2
 value of 0.9992 (0.999-0.9995). The 
measured concentrations of samples, calculated from the standard curve were multiplied 
by their respective dilution factor of 100x as they were diluted prior to the onset of the 
assay. The ranges of the low and high controls set by the kit were 3.9-5.8pmol/L and 9.4-
14.0pmol/L. All of the controls fit within these required ranges. The intra-assay CV’s 
were 11.3%, 6.4%, 4.5%, 7.9% and 6.7%, with an average of 7.4% and the average inter-
assay CV for 5 plates was 9.1%.   
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3.4 Statistical Analysis 
 Statistical analyses were performed using SPSS version 21.0 for Windows. A 
paired t-test was used to examine group differences in physical characteristics, habitual 
physical activity, nutritional intake, time spent in each exercise intensity level, exercising 
heart rates and baseline measures of bone markers. A two-way analysis of variance 
(ANOVA) for repeated measures (RM ANOVA) (between-subject effect: group, within-
subject effect: time) was used to assess group differences over time for the biochemical 
bone turnover markers. Note that a blood sample could not be obtained for one child at 1 
hr post-exercise and for another child at both the 1 hr and 24 hr post-exercise time point 
(i.e. missing values). For these participants, the group’s mean value at each time point 
was used for the purposes of the RM ANOVA analyses. In all cases assumption of 
sphericity was examined. In cases where sphericity could not be assumed the 
Greenhouse-Geisser test of significance was used. These cases are indicated in the 
Results section, where applicable. Bivariate correlations were examined using Pearson 
Product Moment Correlations. Data are reported as means and standard errors. 
Significance was assumed at an alpha level of 0.05. 
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Chapter 4 Results 
4.1 Descriptives 
A total of 30 participants completed the study, 12 of whom were pre- (n=7) and 
early (n=5) pubertal boys and 18 were adult men. Each group’s mean age and 
anthropometric measurements, as well as the years from PHV and pubertal stage, are 
presented in Table 6. As expected, men were older and larger than boys (P<0.001), with 
no difference in adiposity between groups.  The distribution of the sexual maturity levels 
(pubertal stage) in boys is shown in Table 7.  
Table 6. Physical characteristics, body composition for healthy men and boys, as well as 
the boy’s pubertal staging. 
 Men (n=18) Boys (n=12) p-value 
Age (yrs) 22.5 ± 0.7 10.2 ± 0.4 <0.001* 
Height (cm) 180.1 ± 1.6 142.6 ± 2.0 <0.001* 
Body Mass (kg) 78.6 ± 2.6 34.4 ± 1.5 <0.001* 
BMI  24.1 ± 0.5 16.9 ± 0.6 <0.001* 
PBF (%) 15.5 ± 1.5 13.4 ± 1.1 NS 
LBM (kg) 66.0 ± 1.8 30.2 ± 1.2 <0.001* 
Years to PHV - -3.05 ± 0.3 - 
Pubertal Stage PH - 1.67 ± 0.3 - 
All values are expressed as means ± SE. Significance was set at p<0.05 difference between groups. 
BMI = Body mass index, PBF = percent body fat, LBM = lean body mass, PHV = peak height velocity, PH 
= pubic hair 
Table 7. Pubertal stage frequency table for boys (n=12) 
Pubertal Stage PH Boys (n=12) 
1 
2 
3 
7 
2 
3 
The number of children in pubertal stages 1, 2 and 3 respectively 
PH = pubic hair 
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4.2 Physical Activity  
 Table 8 describes the habitual physical activity of the two groups. No group 
differences were observed in physical activity scores, as assessed by the Godin-Shephard 
questionnaire or the PYPAQ (p>0.05), both of which assess general physical activity. 
However, using a bone-specific questionnaire (BPAQ), children demonstrated higher 
scores for both current physical activity and impact frequency scores (p<0.02, p<0.01), 
whereas adults demonstrated higher past activity scores (p<0.01).  
Table 8. Physical activity scores, weekly physical activity metabolic equivalents, current 
and past scores and impact exercise frequency for healthy men and boys. 
 Men (n=18) Boys (n=12) p-value 
Strenuous (times/week) 4.6 ± 0.7 5.3 ± 1.1 NS 
Moderate (times/week) 4.3 ± 0.8 3.3 ± 0.6 NS 
Mild (times/week) 5.6 ± 0.4 4.3 ± 0.8 NS 
Total Leisure Time PA (MET hours/week) 78.8 ± 8.7 77.3 ± 9.0 NS 
PYPAQ Total (MET hours/week) 64.9 ± 16.9 58.5 ± 7.5 NS 
BPAQ – Current 8.9 ± 1.4 18.7 ± 4.2 <0.02* 
BPAQ – Past  85.3 ± 12.7 40.2 ± 5.8 <0.01* 
BPAQ – Impact Frequency (times/week) 6.2 ± 0.8 10.2 ± 1.4 <0.01* 
All values are expressed as means ± SE. Significance was set at p<0.05 difference between groups. 
PYPAQ – Past Year Physical Activity Questionnaire, BPAQ – Bone-specific Physical Activity 
Questionnaire 
4.3 Nutritional Intake 
 Table 9 presents the total daily intake of calories, calcium, vitamin D, caffeine, 
carbohydrates, fat and protein for the men and the boys, as assessed by the 24-hour 
nutrition recall interview. The two groups were similar in terms of their calcium and 
vitamin D intake. However, boys had a higher daily energy intake when corrected for 
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body mass differences (p<0.006). Caffeine intake neared significance with men showing 
a trend towards higher caffeine consumption (p<0.06). Men had significantly higher 
intakes of both fat and protein consumption in comparison to the boys (p<0.02, p<0.001).  
 
Table 9. Total daily energy intake, total dietary consumption of calcium, vitamin D, 
caffeine, CHO, fat and protein for healthy men and boys (n=30). 
 Men (n=18) RDA Boys (n=12) RDA p-value 
Total Energy Intake 
(kcal) 
2775 ± 229 3225 1888 ± 116 2266 <0.006* 
Total Energy Intake 
(kcal/kg) 
36.8 ± 3.7 41 56.4 ± 4.5 65.9 <0.02* 
Calcium (mg) 1213 ± 144 1000 895.1 ± 90.5 1300 NS 
Vitamin D (IU) 231.2 ± 46.1 600 200.2 ± 34.7 600 NS 
Caffeine (mg) 46.3 ± 19.1 ND 1.0 ± 0.3 ND NS 
CHO (g) 354 ± 29.7 130 281 ± 17.0 130 NS 
CHO (g/kg) 4.7 ± 0.5 ND 8.5 ± 2.8 ND <0.001* 
Fat (g) 99 ± 12.2 ND 58.6 ± 7.7 ND <0.02* 
Fat (g/kg) 1.3 ± 0.8 ND 1.7 ± 0.8 ND NS 
Protein (g) 131 ± 10.5 56 68.5 ± 5.3 34 <0.001* 
Protein (g/kg) 1.7 ± 0.7 0.8 2.1 ± 0.7 0.95 NS 
All values are expressed as means ± SE. Significance was set at p<0.05 difference between groups. 
CHO – carbohydrates, RDA – recommended dietary allowance, ND – not determined. RDA were taken 
from (Health Canada, 2010) 
 
4.4 Bone SOS 
 Bone SOS and Z-scores are presented in Table 10. As expected, men has 
significantly higher SOS scores for both dominant and non-dominant radius and tibia 
(p<0.001). There was also a significant difference in the non-dominant tibia Z-score 
(P<0.05). No group differences were observed in the radii Z scores and in the dominant 
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tibia Z score, but boys had a higher non-dominant tibial Z score. Importantly, all mean Z 
scores were between -1 and +1, indicating that bone properties were relatively close to 
the available norms for both age groups. 
Table 10. Participant SOS (m/s) and Z-scores from the QUS measurement for dominant 
limbs for healthy men and boys.  
 Men (n=18) Boys (n=12) p-value 
Dominant Radius SOS (m/s) 4099 ± 25.2 3772 ± 19.4 <0.001* 
Dominant Radius Z-Score 0.4 ± 0.2 -0.1 ± 0.2 NS 
Dominant Tibia SOS (m/s) 3980 ± 20.4 3711 ± 22.4 <0.001* 
Dominant Tibia Z-Score 0.04 ± 0.2 0.5 ± 0.3 NS 
All values are expressed as means ± SE. Significance was set at p<0.05 difference between groups. 
SOS – speed of sound 
4.5 Exercise Protocol Measurements 
The total exercise time for the men was 27.5± 1.5 min while for the children was 
21.4 ± 1.0 min, (p<0.004). The exercising heart rates for each exercise at the completion 
of the required repetitions and for each of the three sets showed no significant differences 
between the two groups. It is evident that the exercise protocol was of high enough 
intensity to produce heart rates of at least 80% of the age-predicted maximum heart rates. 
The exercising heart rates at the completion of each set showed no significant differences 
between the two groups (Mean post-set heart rate: men: 172 ± 1 bpm; boys: 178 ± 1 
bpm). The exercise protocol was of high intensity, resulting in heart rates ≥80% of the 
age-predicted maximum heart rates.  
The accelerometery data revealed that, as expected, both groups experienced 
higher accelerations in the vertical axis than in the horizontal axis during exercise, 
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confirming that the majority of the exercise-related impact was in the vertical axis. Men 
had 6718 ± 581 counts per minute (CPM) in the vertical axis and the boys had 5356 ± 
736 CPM in the vertical axis, with no significant differences between groups. Presented 
in Table 11 are the cut points thresholds between exercise intensities, based on the 
Freedson Adult (1998) and Freedson Children (2005) equations. For both groups, the 
mean CPM in the vertical axis was within the vigorous exercise intensity. Whereas the 
horizontal CPM’s for both groups (men: 3247 ± 327 CPM; boys: 3088 ± 351 CPM) fell 
within the moderate intensity range, verifying that the exercise protocol was indeed 
vertically focused. The Cut Points in Table 13 are based on various activities such as 
walking, running and jumping (P. Freedson, Pober, & Janz, 2005; P. S. Freedson, 
Melanson, & Sirard, 1998).  
 
Table 11. Freedson Adult (1998) and Freedson Children (2005) Cut Points (CPM) 
 Sedentary Light Lifestyle Moderate Vigorous Very 
Vigorous 
Freedson 
Adult 
(1998) 
0 – 99 100 – 759 760 – 1951 1952 – 5724 5725 – 9498 9499 – ∞ 
Freedson 
Children 
(2005)  
0 – 149 150 – 499 NA 500 – 3999 4000 – 7599 7600 – ∞ 
CPM – counts per minute 
 
4.6 Bone Turnover Markers 
4.6.1 Baseline Measurements 
 Table 12 depicts the baseline values for each bone marker measured; BAP, NTx, 
OPG and RANKL, in both adult males and pre-pubescent boys. Both BAP and NTx 
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concentrations were significantly higher in the children. The OPG and RANKL 
concentration were similar in the two groups.  
Table 12. Baseline values for BAP, NTx, OPG and RANKL in healthy men and boys 
 Adults (n=18) Children (n=10) p-value 
BAP (µg/L) 31.4 ± 2.6 112 ± 8.4 <0.001* 
OPG (pmol/L) 3.4 ± 0.2 3.7 ± 0.3 NS 
NTx (nM BCE) 22.5 ± 1.3 52.0 ± 3.9 <0.001* 
RANKL (pmol/L) 322 ± 35.9 317 ± 51.1 NS 
All values are expressed as means ± SE. Significance was set at p<0.05 difference between groups. 
BAP – Bone-specific alkaline phosphatase, NTx – N-telopeptides of type I collagen, OPG – 
Osteoprotegerin, RANKL – Receptor activator of nuclear factor κB ligand 
4.6.2 Bone Formation Markers – Effect of Exercise Session 
4.6.2.a Bone-specific Alkaline Phosphatase (BAP) 
BAP was significantly higher in children compared with adults at all of the time 
points (Group effect, p<0.001) (Figure 2). The RM ANOVA analysis revealed that 
sphericity could not be assumed (p < 0.001). Therefore, the Greenhouse-Geisser test of 
significance was used to examine the Time and Group-by-Time interaction effects 
(within-subject effects). The time effect was significant (p=0.02), reflecting an overall 
increase in BAP over time. The Group-by-Time interaction was significant (p=0.04), 
which reflects a higher increase 24 hr post-exercise in the boys compared with the men. 
Pairwise comparisons revealed significantly higher values 24 h post exercise, compared 
with pre-exercise values in boys only. 
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Figure 2. BAP Concentrations (μg/L) throughout the different time points and their associated p-values. 
All BAP values are expressed as mean ± SE.  
G x T – Group by Time, * = significant difference between pre- and 24 hr post-exercise in boys only. 
 
 
 
4.6.2.b Osteoprotegerin (OPG) 
 The RM ANOVA showed that the OPG concentrations were similar across all 
time points in the men and boys (Group effect, p<0.5) (Figure 3). Because sphericity 
could not be assumed (p<0.003) the Greenhouse-Geisser test of significance was used to 
assess the Time and Group-by-Time interaction effects (within-subject effects). While 
there was a trend towards increased OPG values post exercise, neither the Time (p<0.06) 
nor the Group-by-Time interaction (within-subject effects) were significant (p<0.05). 
 
 
 
 
 Greenhouse
-Geisser 
Time p = 0.04 
G x T p = 0.07 
Sphericity p < 0.001 
Group p < 0.001 
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Figure 3. OPG Concentrations (pmol/L) throughout the different time points and their associated p-values. 
All OPG values are expressed as mean ± SE.  
G x T – Group by Time 
 
4.6.3 Bone Resorption Markers – Effect of Exercise Session 
4.6.3.a N-telopeptides of type I collagen (NTx) 
 NTx concentrations were significantly higher in children in comparison to the 
adults throughout all four time points (Group effect, p<0.001) (Figure 4). The RM 
ANOVA disclosed that sphericity can be assumed (p=0.3). There was no Time effect but 
there was a significant Group-by-Time interaction (p=0.03), with a greater increase over 
time in boys than in men.  Pairwise comparisons revealed significant increases in NTx at 
each time point post-exercise in boys only. 
 
 
 
 
 Greenhouse
-Geisser 
Time p = 0.06 
G x T p = 0.5 
Sphericity p = 0.003 
Group p = 0.4 
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Figure 4. NTx concentrations (nM  BCE)) throughout the different time points and their associated p-
values. All RANKL values are expressed as mean ± SE.  
NTx – N-telopeptides of type I collagen, G x T – Group by Time, * = significant difference between time 
points. 
 
4.6.3.b Receptor activator of nuclear factor κB ligand (RANKL) 
 The RM ANOVA revealed that RANKL concentrations were similar in both 
adults and children across all time points (Group effect, p<0.6) (Figure 5). Because 
sphericity could not be assumed (p<0.001) the Greenhouse-Geisser test of significance 
was implemented to assess the Time and Group-by-Time interaction effects (within-
subject effects) throughout all four time points. There was no significant Time effect 
(p<0.4) or Group-by-Time interaction (p<0.07). 
 
 
 
 
 
 Sphericity 
Assumed 
Time p = 0.1 
G x T p = 0.03 
Sphericity p = 0.3 
Group p < 0.001 
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Figure 5. RANKL Concentrations (pmol/L) throughout the different time points and their associated p-
values. All RANKL values are expressed as mean ± SD.  
G x T – Group by Time 
 
4.7 Habitual Physical Activity and Bone Turnover Response 
 Changes in bone turnover markers did not correlate with the reported physical 
activity in either the boys or the men. 
4.8 Bone Markers at Different Pubertal Stages  
 Table 13 presents the baseline, 5 minutes post-, 1 hour post- and 24 hours post-
exercise values of each bone marker for the boys of different pubertal stages. Because the 
sample size is so small, the results of the statistical analyses should be viewed with 
caution. For the purpose of the analysis, comparison was made between pre-pubertal 
(Tanner stage 1, n=7), and mid-pubertal boys (Tanner stage 2 and 3, n=5). A distinctly 
different pattern of response is not apparent between the maturity groups (Figures 6 – 9). 
 
 Sphericity 
Assumed 
Time p = 0.3 
G x T p = 0.2 
Sphericity p < 0.02 
Group p = 0.9 
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Table 13. Baseline, 5 minutes post-, 1 hour post- and 24 hours post-exercise values for 
boys of different pubertal stages. Tanner 1 (n=7), Tanner 2 (n=2) and Tanner 3 (n=3). 
 Baseline 5 minutes 1 hour 24 hours 
BAP (µg/L) 
Tanner 1 109 ± 14.0 107 ± 15.6 123 ± 13.9 131 ± 13.4 
Tanner 2 111 ±  19.9 77.7 ± 20.1 145 ± 34.0 156 ± 18.7 
Tanner 3 124 ± 4.6 150 ± 23.7 108 ± 43.2 140 ± 29.6 
OPG (pmol/L) 
Tanner 1 3.7 ± 0.4 4.1 ± 0.5 4.1 ± 0.6 3.9 ± 0.5 
Tanner 2 4.0 ± 0.03 4.7 ± 1.0 4.7 ± 0.08 4.5 ± 0.4 
Tanner 3 3.6 ± 0.2 3.8 ± 0.2 4.0 ± 0.3 3.4 ± 0.4 
NTx (nM BCE) 
Tanner 1 47.4 ± 5.8 62.3 ± 6.8 53.5 ± 3.2 47.7 ± 4.0 
Tanner 2 44.5 ± 0.3 63.6 ± 49.0 89.8 ± 10.4 72.6 ± 13.5 
Tanner 3 54.6 ± 9.0 55.4 ± 2.4 54.1 ± 12.3 72.0 ± 8.9 
RANKL (pmol/L) 
Tanner 1 379.0 ± 55.2 403.0 ± 75.9 477.0 ± 73.1 444.0 ± 69.6 
Tanner 2 59.7 ± 10.6 92.1 ± 30.7  77.7 ± 41.0 67.5 ± 26.1 
Tanner 3 366.0 ± 97.9 388.0 ± 116 382.0 ± 132 449.0 ± 148 
All values expressed as means ± SE.  
BAP – Bone-specific alkaline phosphatase, NTx – N-telopeptides of type I collagen, OPG – 
Osteoprotegerin, RANKL – Receptor activator of nuclear factor κB ligand 
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4.8.1 Bone Formation Markers – Effect of exercise session at different pubertal stages 
4.8.1.a Bone-specific Alkaline Phosphatase (BAP) 
 
Figure 6. BAP Concentrations (µg/L) throughout the different time points in pre- and early/mid-pubertal 
boys and their associated p-values. All BAP values are expressed as mean ± SE.  
G x T – Group by Time 
 
4.8.1.b Osteoprotegerin (OPG) 
 
Figure 7. OPG Concentrations (pmol/L) throughout the different time points in pre- and early/mid-puberal 
boys and their associated p-values. All OPG values are expressed as mean ± SE.  
G x T – Group by Time 
 
 
 Sphericity 
Assumed 
Time p = 0.1 
G x T p = 0.8 
 Sphericity 
Assumed 
Time p = 0.03 
G x T p = 0.9 
Sphericity p < 0.3 
Group p = 0.9 
Sphericity p < 0.8 
Group p = 0.9 
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4.8.2 Bone Resorption Markers – Effect of exercise session at different pubertal stages 
4.8.2.a N-telopeptides of type I collagen (NTx) 
 
Figure 8. NTx Concentrations (nM BCE) throughout the different time points in pre- and early/mid-
pubertal boys and their associated p-values. All NTx values are expressed as mean ± SE.  
G x T – Group by Time 
 
4.8.2.b Receptor activator of nuclear factor κB ligand (RANKL)  
 
Figure 9. RANKL Concentrations (pmol/L) throughout the different time points in pre- and early/mid-
pubertal boys and their associated p-values. All RANKL values are expressed as mean ± SE.  
G x T – Group by Time. 
 Sphericity 
Assumed 
Time p = 0.2 
G x T p = 0.2 
 Greenhouse
-Geisser 
Time p = 0.2 
G x T p = 0.1 
Sphericity p < 0.02 
Group p = 0.7 
Sphericity p < 0.8 
Group p = 0.9 
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Chapter 5 Discussion 
5.1 Introduction 
 This is the first study to examine differences in the responses of markers of bone 
formation and bone resorption to an intense session of plyometric exercise between men 
and boys. The response was examined immediately after exercise, as well as 24 hours 
after the exercise session. The main findings of this study include: 1) Boys have greater 
concentrations of BAP (µg/L) and NTx (nM BCE) across all of the time points, whereas 
OPG and RANKL concentrations were similar in boys and men across all time points; 2) 
Impact exercise did not appear to affect the concentration of OPG and RANKL over a 24 
hour time period in either boys nor men; and 3) BAP and NTx were significantly higher 
post-exercise in the boys but not in the men.  
Neither the first or second hypotheses were confirmed in that serum levels of 
OPG and RANKL did not change following exercise. However, BAP and NTx were 
significantly increased after exercise in the boys, but not in the men. Thus, the pattern of 
change over time (third hypothesis) was similar in boys and men for OPG and RANKL, 
but not for BAP or NTx. 
5.2 Habitual Physical Activity 
 When examining the results of the physical activity questionnaires, there were no 
significant group differences in Leisure-Time exercise and in past year PA. However, 
when looking at the BPAQ scores, boys had greater current scores but lower past scores 
compared with the men. The current PA results reflect the fact that children are generally 
more active than adults and the past PA results reflect the age factor in that the score is 
  
78 
 
cumulative. These results are in line with current literature (Caspersen, Pereira, & Curran, 
2000; Livingstone, Robson, Wallace, & McKinley, 2003; Riddoch et al., 2007). 
However, it is surprising that the LTPA and PYPA scores were similar in the two age 
groups. One possible explanation is that the men’s group comprised of individuals who 
were relatively active and therefore more inclined to volunteer for such a study. Indeed, 
the men’s group included two elite athletes. 
5.3 Nutritional Intake 
  The results of the 24 hour nutrition recall interview were used to assess intake of 
bone-related macronutrients and micronutrients including total energy, total relative 
energy, calcium, vitamin D, caffeine and the three macronutrients. Total energy intake 
was significantly higher in the adult group in comparison to the children. The average 
total energy intake fell below the estimated energy requirements for both groups (Health 
Canada, 2010). However, when body mass was taken into consideration the boys had 
higher total energy consumption, as expected, when compared to the men.  
The recommended calcium intake of 1000mg for adults was exceeded in this 
study, whereas the children did not meet the recommended dietary intake of 1300mg. 
Neither group met the dietary requirement for Vitamin D intake (400IU or 10µg), 
although endogenous production was not measured or estimated.  Vitamin D and calcium 
supplementation were inquired about through the subject screening and medical history 
questionnaire (Appendix 3.1). There were only two participants who reported vitamin D 
supplementation, one of which had just started two weeks prior to the test date. The 
supplements were included in the nutrition analysis. Vitamin D intakes for men were 
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similar to those reported in the literature. Rogers et al. (2010) reported a mean calcium 
intake of 1235 ± 219mg/day and vitamin D intake of 6 ± 2µg/day in untrained males 
between the ages of 24 and 62 years old (R. S. Rogers et al., 2011). Scott et al. (2010, 
2011 and 2013) reported calcium intakes of greater than 700mg/day for all of the young 
recreationally active male participants (Scott et al., 2010; Scott et al., 2011; Scott et al., 
2013). The boys, however, appear to have abnormally low values in comparison to the 
literature. Several studies have reported calcium intakes as low as 991 and as high as 
1316mg/day which are higher than the values seen in this study (Falk et al., 2008; Falk et 
al., 2010). The vitamin D intake in the present study (5 ± 3µg/day) are similar to 
previously reported values in 10-16 year old children and adolescents (Falk et al., 2010). 
As would be expected, men consumed greater amounts of carbohydrates and protein in 
comparison to the boys. Both groups exceeded the recommended dietary allowance for 
carbohydrates and protein. The apparent high protein consumption of the men may reflect 
the fact that some of the men (n=4) consumed at least one protein shake daily. It is not 
clear whether the difference in nutritional intake between groups, specifically the fact that 
men’s calcium consumption was above the RDA, while boys’ consumption was below 
the RDA, affected the bone markers’ response to the exercise session. No effects were 
apparent on bone properties (see below). 
Unfortunately, food frequency questionnaires do not always reflect normal daily 
nutritional intake, especially when the data is based on one day (Rockett, Wolf, & 
Colditz, 1995). Nutritional questionnaires are often imprecise for capturing dietary 
intake; issues such as under-reporting do not allow for an accurate reflection. 
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5.4 Bone SOS 
Bone SOS values were significantly higher in men in comparison to the boys, as 
expected. The bone SOS measurement served as an indicator of bone health status.  This 
allowed us to ensure that there were no outliers with regards to bone strength. Despite 
group differences in daily calcium intake (relative to RDA), all of the participants’ bone 
SOS values fell within normal ranges, as reflected by their Z-scores.   
5.5 Exercise Measurements 
 It was evident that both groups were working at high intensity, as reflected by the 
high heart rates (≥80% of the age-predicted maximum heart rate) and accelerometry 
output. When looking at the time spent in moderate, vigorous or very vigorous activity, 
as a percentage of the total time spent exercising (not including resting periods); both 
groups spent the majority of their exercising time in those intensities. The accelerometer 
results indicate high intensity exercise, emphasizing the impact in the vertical axis. The 
Cut Points (CPM) developed by Freedson et al. (1998 and 2005) for adults and children, 
also confirm that both men and boys worked vigorously in the vertical axis as opposed to 
moderately in the horizontal axis (Turner & Robling, 2003).  Therefore, it is assumed that 
the exercise protocol provided a potential osteogenic effect, as defined by others (P. 
Freedson et al., 2005; P. S. Freedson et al., 1998). 
The adult group spent significantly more time completing the exercise protocol, 
which could be attributed to the recovery periods. All of the participants were allotted a 
minimum of 3 minutes recovery between sets. The adults typically exceeded the 3 
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minutes, whereas the children typically did not. Children have been shown to recover 
from short, high intensity exercise substantially faster than adults (Falk & Dotan, 2006).  
5.6 Biochemical Markers of Bone Turnover 
5.6.1 Baseline Values 
 As shown in Table 7, the boys in this study were pre- to mid-pubertal. 
Accordingly, the boys had a higher variability in the levels of bone markers, as reflected 
by the standard deviation values, for each measured bone marker in comparison to the 
men. This variability likely reflects the effects of growth and maturation. As documented, 
major fluctuations in bone markers occur at the onset of puberty, in accordance with the 
growth velocity or changes in secondary sexual characteristics (Hannon & Eastell, 2000; 
Szulc et al., 2000). 
The baseline values of BAP for the children fell within previously reported values 
for healthy pre- and early-pubescent boys of 95µg/L to 114µg/L (Hui et al., 2003). Serum 
BAP reference ranges for men in the literature generally refer to older men than the men 
in this study. Additionally, serum BAP concentrations have been shown to decrease with 
age in older men (Hannon & Eastell, 2000).  Therefore, it is not surprising that the men’s 
baseline values were higher than the suggested values in the literature (6.8µg/L to 
22.4µg/L) (Cavalier et al., 2010; Szulc, Garnero, Munoz, Marchand, & Delmas, 2001; 
Woitge, Scheidt-Nave et al., 1998).  
The NTx baseline concentrations also fell within previously reported values of 
50.6nM BCE to 71.7nM BCE for healthy pre- and early-pubertal (Tanner 1 and Tanner 2) 
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boys (van der Sluis et al., 2002). The only reference values available for serum NTx in 
adults are the ones provided in the package insert of the Osteomark® assay (6.2nM BCE 
to 19nM BCE) (Herrmann & Seibel, 2008). The mean NTx values for the men in this 
study were 22.5nM BCE, which is slightly higher than indicated by Herrman & Seibel 
(2008). However, the male reference range was conducted in men with an average age of 
51 years, whereas the average age in this study was 22.5 years.  
Because OPG and RANKL are relatively new bone markers, reference data in 
relation to age, sex and maturation has not been well established. The reported values for 
serum OPG in healthy children between the ages of 0.5 and 19 years of age ranges 
between 3.89 and 4.24pmol/L (Buzi et al., 2004; Gajewska, Ambroszkiewicz, & 
Laskowska-Klita, 2006; Wasilewska et al., 2009). The baseline values seen in the present 
study are at the lower end of these values at 3.7pmol/L for children. Kudlacek et al. 
(2003) examined the serum levels of OPG with increasing age in adults. The average 
level for men less than 30 years old was 4.9pmol/L and the values increased with 
increasing age. The average baseline value in this study was 3.4pmol/L. Vitamin D 
uptake has been shown to stimulate OPG production in vivo (Kudlacek et al., 2003). The 
participants did not reach their daily recommended intake for vitamin D intake, which 
might contribute to the lower serum OPG concentration. Since serum vitamin D, 
specifically 25-hydroxyvitamin, was not determined, their vitamin D status is not known.  
In the present study, RANKL was analyzed as total RANKL, which is formed 
from the free and bound RANKL. Kerschan-Schindl et al. (2008) evaluated the serum 
levels of both free RANKL and total RANKL in healthy men between the ages of 42 and 
50 years old. The values for these older men were between 41.5pmol/L and 236pmol/L. 
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The serum RANKL values seen in the adult group of this study were 322pmol/L, which 
appear to be much higher than the older adults. Serum levels of RANKL appear to 
decrease with increasing age, which may explain the difference between the two studies 
(Kerschan-Schindl et al., 2008).  Representative values of total RANKL for children are 
not available in the literature. 
5.6.2 Exercise Response 
 Boys displayed higher BAP levels with an increase 24 hours post-exercise (111.9 
± 29.2 vs. 137.6 ± 36.3µg/L, respectively), which was not observed in the men (31.4 ± 
11.1 vs. 33.3 ± 10.5µg/L, respectively). NTx levels were higher in boys before and after 
exercise, with a greater increase over time in boys than in men (boys: 48.7 ± 13.7 vs. 58.8 
± 16.7nM BCE pre- and 24 hours post-exercise, respectively; men: 21.7 ± 5.4 vs. 19.4 ± 
5.0nM BCE pre- and 24 hours post-exercise, respectively). OPG and RANKL levels were 
similar in boys and men before and after exercise, with no change over 24 hours.  
 Two previous studies examined the effect of a plyometric exercise session on 
bone turnover in adults, but not in children (Lin et al., 2012; R. S. Rogers et al., 2011). 
Lin et al. (2012) assessed the response of OC and TRAP5b acutely to plyometric jumping 
in young men. The exercise protocol consisted of approximately 150 jumps with an 
average heart rate of 164 bpm. Blood samples were collected before, 5 minutes, 1, 3, 6, 
24, 48 and 72 hours post exercise trials (Lin et al., 2012). Rogers et al. (2011) assessed 
the response of BAP and TRAPb5 to a single session of plyometric jumping 
(approximately 130 jumps) in young and older men and blood samples were collected 
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before exercise, immediately following exercise, 15, 30 minutes, 1, 2 and 24 hours post-
exercise (R. S. Rogers et al., 2011). 
In terms of bone formation, the results of the two studies are inconsistent in that 
Lin et al. (2012) observed an increase in OC, while Rogers et al. (2011) observed no 
change in BAP levels after exercise. In the present study, no BAP changes were observed 
after exercise in the men, in agreement with Rogers et al. (2011). The latter argue that a 
possible increase in BAP levels may have been masked by the natural morning decrease 
in BAP (Table 3). This decrease typically occurs around 6:30am and our participants 
were tested between 9:00am and 9:30am. Unfortunately, we did not include a time-
matched control session to confirm these assumptions. Nevertheless, taken together, it is 
suggested that high impact exercise induces an acute osteogenic effect in adults, although 
this effect may not be substantial.   
 In terms of bone resorption, TRAP5b did not change in one study (Lin et al. 2011) 
but decreased post-exercise in another study (Rogers et al. 2011). In the present study, no 
significant effect of exercise was observed on NTx or RANKL in the men. This is in line 
with Lin et al. (2012). The discrepancy between the present study (no change in bone 
resorption markers) and the results of Rogers et al. (2011) (decrease in bone resorption 
marker 15 and 30 min post-exercise) may possibly be due to the difference in sampling 
times between the two studies. The decrease in TRAP5b was observed 15 and 30 min 
post-exercise, but at 1 hour, values were not significantly different from pre-exercise. 
Similarly, in the present study, no difference was observed in bone resorption markers 1 
hr post-exercise in the men. It is possible that some increase in bone resorption was 
‘missed’ between 5 min post- and 1 hour post-exercise. 
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 In terms of pediatric bone metabolism responses to single bouts of exercise, the 
research is limited to one study. Pomerants et al. (2008) examined the effect of acute 
exercise on serum markers of bone turnover in 60 healthy schoolboys, 10-18 years old. 
The boys underwent a 30 minute constant load, cycle ergometer bout at approximately 
95% of their ventilatory threshold. The average heart rates achieved were 169bpm, which 
is ≥80% of the age-predicted maximal heart rate. The results revealed that although there 
was a slight increase 30 minutes post exercise in serum PINP and ICTP levels, markers of 
bone formation and resorption, respectively, it did not reach statistical significance. These 
results are in line with the fact that cycling does not provide weight bearing loads and 
therefore, may not provoke a sufficiently high osteogenic effect to induce significant 
effects on bone turnover. By contrast, in the present study, both BAP and NTx, markers 
of bone formation and resorption, respectively, increased following exercise in the boys. 
The inconsistency between the two studies likely reflects the different exercise modes 
(cycling vs. jumping – no-impact vs. high impact), which were used in the two studies.  
The mechanical loads applied to bone generate mechanical signals at the cellular 
level, the nature of which is not known. What is known is that mechanical loads can 
stimulate a response from both osteoblasts and osteoclasts (Frost, 1997; Frost, 1999). It is 
evident that the mechanistic effects differ between the boys and men, as reflected by the 
increased BAP and NTx in the boys, induced by the plyometric exercise, with no effect in 
the men. Children’s bones undergo greater turnover compared with adults (Szulc et al., 
2000). This is supported by the higher baseline BAP and NTx values in the boys 
observed in this study. The higher turnover rate in the children may render their cellular 
bone activities more responsive to mechanical stimuli. Indeed, Frost (1997,1999) 
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described an age-related decline in bone cellular responsiveness in aging adults (Frost, 
1997; Frost, 1999).  Thus, the higher responsiveness may explain the greater increase in 
BAP and NTx markers after exercise in the boys. Notably, the mechanical stimulus in 
this study was designed to be similar in the boys and the men (similar number of jumps 
from size-adjusted height). 
Although there was no clear immediate change post-exercise in bone markers in 
the men, it is known that exercise has a long-term maintenance effect on bone in adults. 
Therefore, the mechanism remains unclear. 
Because OPG and RANKL are considered essential cytokines rather than 
enzymes or degradation products of bone resorption and formation, it may be possible 
that their response to exercise differs from that of BAP or NTx. It has been suggested that 
mechanical stimuli can directly affect osteoblasts and indirectly affect osteoclasts 
(Robling, Castillo, & Turner, 2006). The indirect osteoclastic response reduces the 
expression of RANKL and increases the expression of OPG, which in turn decreases the 
number of osteoclasts (Robling, Castillo, & Turner, 2006). However, the timeline of this 
process in response to exercise is not known. Ziegler et al. (2005) studied the effects of 
either a half marathon or full marathon on OPG and RANKL in recreational male and 
female middle-aged runners. In both groups, a significant decrease in RANKL was 
observed, whereas a significant increase in OPG was only apparent in the full marathon 
group. The results of this study suggest that the running distance and duration play an 
important role in OPG and RANKL changes (Ziegler et al., 2005). Although the exercise 
protocol in the present study involved very high mechanical stimuli, the duration was 
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relatively short. It is possible that multiple sessions or a larger duration of exercise would 
induce a change in OPG and RANKL values.  
It has been suggested that acute exercise may not be sufficient to modify serum 
concentrations of markers of bone turnover (Banfi et al., 2010). In fact, the effects of 
exercise may not be apparent until 2 or 3 days post exercise. Scott et al. (2013) 
demonstrated that increases in serum OPG levels did not appear until 2 days post exercise 
of two 60 minute treadmill running bouts (Scott et al., 2013). In previous studies also 
done by Scott et al. in 2011 and 2010 there were also increases in bone metabolism 
markers following the 24 hour post exercise time period. When recreationally active 
young males completed a 60 minute running treadmill protocol increases in BAP were 
seen 3 and 4 days post exercise and decreases in OC 3 days post exercise (Scott et al., 
2011). When recreationally active young males completed an intermittent exhaustive 
running protocol, increases in β-CTx were evident 1-4 days post exercise (Scott et al., 
2010). Ashizawa et al. (1998) also demonstrated delayed bone marker responses with 
young, untrained males executing a resistance exercise protocol. BAP decreased 2 and 3 
days post exercise (Ashizawa et al., 1998). Therefore, it is possible that the plyometric 
exercise in the present study induced changes in bone turnover markers in the men but 
that these changes would be evident after more than 24 hours. Although the exercise 
protocols described above are not plyometric, nor do they involve children, it is 
suggested that in the future, post-exercise blood samples should exceed the 24 hour time 
point as it may take several hours and up to several days to show changes (Banfi et al., 
2010). 
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Chapter 6 Conclusion 
6.1 General Conclusions 
 The present study aimed to compare the acute response of markers of bone 
turnover following a single session of plyometric exercise in adult males and young boys. 
The results demonstrated that children had higher levels of both BAP and NTx at baseline 
as well as throughout the post-exercise period. This was not the case with the levels of 
OPG and RANKL which were similar in adults and children. In addition, boys showed an 
increase in BAP and NTx 24 hours post-exercise, which was not seen in the men. Thus, it 
can be concluded that a single session of plyometric exercise may stimulate bone 
turnover, as reflected by the increase in both BAP and NTx levels, in boys but not in men 
suggesting that children are more responsive to the effects of plyometric exercise. This is 
in line with the previously described enhanced bone accretion rate during childhood and 
especially, during the early pubertal period (Malina, R.M., Bouchard, C. & Bar-Or, O., 
2004; Seibel, 2002).  
6.2 Implications 
 It is known that high impact exercise has the greatest benefits on bone but the 
timing of response is not well known or understood. From a methodological perspective, 
this information could aid researchers in determining appropriate timing to examine the 
effects of an intervention on bone turnover without contamination of a prior exercise 
session, The results of the present study indicate that 24 hours is an insufficient time 
period to exclude the effects of the last training session of a plyometric exercise protocol 
in boys. In men, no changes with time were evident. This may indicate that changes in 
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biochemical markers of bone turnover are apparent after a longer time period, or that 
these changes are more apparent on a different time line than the boys (e.g., possibly after 
60 min but before 24 hrs). Further research is necessary to examine these possibilities.  
 Aside from the methodological perspective, a more practical approach involves 
the determination of whether measurement of serum bone markers is sensitive enough to 
detect changes in bone turnover markers following a single bout of exercise. There was 
an obvious osteogenic effect in the boys, as reflected by the increase in both BAP and 
NTx, which may suggest that their bone cellular activities are more responsive than 
men’s to mechanical stimuli. The lack of an apparent effect in OPG and RANKL may 
indicate that the measurement of these markers in serum is not sensitive to the effects of 
exercise in boys or in men.   
6.3 Strengths 
 The present study has numerous strengths. First, this study was the first to 
examine the acute response of bone markers to a plyometric exercise session in children. 
In addition, it was also the first to compare the acute response of serum markers of bone 
turnover in men and boys. The present study incorporated several questionnaires 
regarding habitual physical activity and nutritional intake as well as bone health status 
which provided insight into whether habitual physical activity or bone strength affects the 
bone turnover markers’ response in boys or in men. The plyometric exercise protocol was 
designed to provide ground reaction forces high enough to induce an osteogenic effect, as 
reflected by the long-term changes in bone structure and mineralization. All participants 
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were tested consistently at the same time to minimize the circadian rhythm variation of 
the various bone markers. 
6.4 Limitations 
 The participants in each of the groups were physically active to various degrees. 
None of the participants were competitive athletes but habitual physical activity and 
training varied considerably. It is possible that with a more homogenous group, the 
variability in our results would have been reduced, thus increasing the power to detect 
significant differences over time or between groups. Along these lines, the small sample 
size of the boys’ group may have resulted in reduced power to detect significant group 
differences. 
Additionally, all testing took place at the same time of day. However, we did not 
include a time-matched control session. This would have allowed us to take into account 
the circadian rhythms of the measured bone markers by following the same blood 
collection schedule without the exercise protocol in the same participants.  
 It is known that the majority of bone markers are present in other tissues aside 
from bone, and the measured levels may be influenced by non-skeletal properties. 
Therefore, it is important to note that the measured quantity of each bone marker may not 
be solely skeletally derived. Moreover, conclusions based on changes of bone marker 
concentrations alone may not be entirely accurate since the deviations may be a reflection 
of plasma volume shifts. Exercise is accompanied by hemoconcentration and during 
recovery plasma volume expansion occurs. Therefore, it is sometimes recommended to 
interpret the changes in bone marker concentrations alongside the changes in plasma 
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volume. This may result in a truer indication of the changes in bone metabolism 
(Fellmann, 1992). Brahm et al. (1997) studied the influence of plasma volume and 
physical fitness with regards to bone metabolism and exercise. Significant reductions in 
plasma volume during exercise were evident and there was a marked expansion following 
24 hours of recovery. However, Rogers et al. (2011) who examined the acute response of 
markers of bone turnover to a single bout of plyometric exercise, also examined changes 
in plasma volume at all of the time points. These changes in plasma volume were 
minimal and the concentrations of the analytes did not need to be adjusted (R. S. Rogers 
et al., 2011).  
 Finally, plyometric exercise was used as a stimulus for bone turnover in the 
present study, assuming that the high impact of the jumping has a local effect. However, 
exercise may also have a systemic, whole-body effect, which may be better reflected in 
hormonal changes. Thus, one limitation of this study is that hormonal changes of GH, 
PTH. Testosterone, estrogen and IGF-1 were not examined, which would provide further 
information on the anabolic effects exercise exerts on bones and muscles. 
6.3 Future Directions 
 In the present study, two markers of bone formation and two markers of bone 
resorption were examined before and after exercise. The pattern of response was 
dissimilar in the measured markers. That is, while one marker of bone formation (BAP) 
and one marker of bone resorption (NTx) increased, in the boys, the other markers did 
not. Thus, the mechanism by which exercise affects bone metabolism is still unclear. 
Future studies should examine the local and systemic effects that exercise has on bone 
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turnover. For example, numerous hormones may affect bone turnover. These hormones 
generally have a systemic effect. However, the mechanical effect of plyometric or high-
impact exercise presumably has a local effect. The interaction between the systemic 
(hormonal) and local (mechanical) effects on bone turnover needs to be further examined 
in children and adults, males and females. This can be achieved by measuring the 
baseline values of the aforementioned hormones and their response to an exercise 
protocol such as the one used in the present study as well as in response to an exercise 
protocol which does not involve high impact (e.g., cycling, swimming).  
 A different response pattern was observed between children and adults. Future 
studies should examine children of different ages and especially, of different maturity 
status, in order to elucidate the period during which children’s response becomes more 
adult-like. 
 In the present study, BAP and NTx were elevated 24 h after exercise in the boys. 
Future studies are important to determine the timeline for the return of levels to resting 
values. That is, future studies are needed to examine the response of these bone turnover 
markers over a period longer than 24 hours. 
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Appendix 1 Recruitment  
1.1 Posters 
1.1.1 Recruitment Poster for Children 
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1.1.2 Recruitment Poster for Adults 
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1.2 Newspaper Advertisement 
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1.3 Letters of Invitation 
1.3.1 Letter of Invitation for Children 
Invitation Letter 
Bone Turnover Following Exercise in Children and Adults 
Principal Investigator: Dr. Bareket Falk, Department of Physical Education and 
Kinesiology, Brock University 
 
Principal Student Investigator: Kimberly Kish, Msc. Candidate, Department of 
Kinesiology, Brock University 
If you have a male child between the ages of 8 and 11 years, we would like to invite you 
and your child(ren) to participate in this study.  
The purpose of this research project is to investigate the acute response and recovery 
of bone metabolism induced by a variety of jumping exercises over a period of 24 hours 
in children and adults.  
Tests and measurements will require approximately 1.5 hours on one day and 15 
minutes on the post-exercise day. Briefly, measurements include filling out several 
questionnaires, completing a 30 minute exercise routine, measurements of bone 
turnover (using blood samples) and bone strength (using ultrasound).  
Participation in this project will provide information on your child’s bone strength, as well 
as other information, such as height, weight and percent body fat.  
There is a $20 honorarium for participating. 
 
This research is being performed by Brock University researchers in the Applied 
Physiology Laboratory 
If you are interested in participation or if you would like some more information, 
please fill out the form on the next page and return it in the enclosed envelope. 
You can also e-mail the requested information to Kim Kish (Project Coordinator) 
at kk11om@brocku.ca, or to Bareket Falk (Principal Investigator) at 
bfalk@brocku.ca. 
If you have any pertinent questions about your rights as a research participant, please 
contact the Brock University Research Ethics Officer (905 688-5550 ext 3035, 
reb@brocku.ca)  
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Thank you, 
Dr. Bareket Falk and Kimberly Kish 
Department of Physical Education and Kinesiology 
Faculty of Applied Health Science 
Brock University 
Tel: 905-688-5550 ext: 4979 or 5623 
Email: bfalk@brocku.ca or kk11om@brocku.ca 
If you are willing to be contacted to discuss having your child participate in this 
study, please complete one of the two following options: 
 
OPTION 1: Fill out the information below and return this form in the enclosed envelope 
 
OPTION 2: Send the information below to Kim Kish (Project Coordinator) at 
kk11om@brocku.ca 
 
Child’s first and last name: 
_______________________________________________________________ 
 
Child’s age:               _____________________________________________ 
Child’s sex:               ______________________________________________ 
 
Parent’s first and last name: 
___________________________________________________________________ 
 
Please contact me at: 
____________________________________________________________________ 
 
At the following days and times:  
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1.3.2 Letter of Invitation for Adults 
Invitation Letter 
Bone Turnover Following Exercise in Children and Adults 
Principal Investigator: Dr. Bareket Falk, Department of Physical Education and 
Kinesiology, Brock University 
Principal Student Investigator: Kimberly Kish, Msc. Candidate, Department of 
Kinesiology, Brock University 
We would like to invite you to participate in the present study, which investigates bone turnover 
following an acute bout of exercise.  
The purpose of this research project is to investigate the acute response and recovery of bone 
metabolism induced by a variety of jumping exercises over a period of 24 hours in children and 
adults.  
Tests and measurements will require approximately 1.5 hours on one day and 30 minutes on 
the post-exercise day. Briefly, measurements include filling out several questionnaires, 
completing a 30 minute exercise routine, measurements of bone turnover (using blood samples) 
and bone strength (using ultrasound). 
Participation in this project will allow you to have personal information on your bone strength as 
well as other information, such as height, weight and percent body fat.  
This research is being performed by Brock University researchers in the Applied 
Physiology Laboratory 
If you have any pertinent questions about your rights as a research participant, please contact the 
Brock University Research Ethics Officer (905 688-5550 ext 3035, reb@brocku.ca)  
If you are interested in finding out more about this study, please contact us by email 
(kk11om@brocku.ca, or bfalk@brocku.ca) or by phone (905-688-5550 ext: 4979 or 5623).  
Thank you, 
Principal Investigators: 
Dr. Bareket Falk and Kimberly Kish 
Department of Physical Education and Kinesiology 
Faculty of Applied Health Science 
Brock University 
Tel: 905-688-5550 ext: 4979 or 5623 
Email: bfalk@brocku.ca or kk11om@brocku.ca  
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Appendix 2 Consent Forms 
2.1 Consent Form for Children 
INFORMATION AND CONSENT TO PARTICIPATE IN RESEARCH 
Exercise and Bone Turnover 
You are being invited to participate in a research study being conducted by the 
investigators listed below. Prior to participating in this study please read this form to find 
out about the purpose and the tests of this study. For the tests you will have to visit the 
Exercise Physiology Laboratory (WH 23, Brock University). This study is part of the 
Faculty of Applied Health Sciences of Brock University.  
INVESTIGATORS:  DEPARTMENT:   CONTACT: 
Dr. Bareket Falk  FAHS, Brock University  (905) 688-5550 ex. 
4979 
Kimberly Kish   FAHS, Brock University  (905) 688-5550 ex. 
5623 
 
PURPOSE: 
 
The purpose of the study is to investigate the acute response and recovery of bone 
metabolism induced by jumping exercise over a period of 24 hours in children and 
adults.  
 
DESCRIPTION OF TESTING PROCEDURES: 
 
If you agree to volunteer for this study, you will visit our laboratory for one session of 
testing, lasting approximately 1.5 hours and another session, 24 hours later, lasting 
approximately 30 min. At the end of the study, you will be given a summary of the 
findings, upon request. It is recommended that you come for the measurements in shorts 
and a short sleeved shirt. Parents may be present at all stages of the study. 
 
Your child will undergo the measurements and procedures listed below; please note that 
in all questionnaires, you may choose not to answer any question.  
 
A. Pre-exercise Assessments: 
 
1. Your child will be asked to complete several questionnaires, outlining their 
medical history, physical activities, nutritional habits and pubertal status. The 
questionnaire used to measure pubertal status involves your child looking at 
drawings of genitalia and deciding which stage of puberty they best match. This 
will be carried out in a private room to avoid any uneasiness. Also, please be 
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aware that the medical history questionnaire includes questions about drug use, 
alcohol use and smoking. In all questionnaires, your child may choose not to 
answer any question without penalty.  
 
2. Body Composition: we will measure your height, weight and percent body fat. 
Percent body fat will be estimated using skinfold thicknesses and bioelectrical 
impedance analysis (BIA). The BIA assessment requires your child to stand on a 
weight scale and grasp handles. A mild electrical current (50kHz, 800µA) will 
pass through your hands to your feet. This current cannot be felt and causes no 
harm. Valid measurements require abstinence from exercise, alcohol 
consumption, and eating/drinking for at least 12, 24 and 4 hours, respectively, 
prior to testing.  
 
3. We will determine your child’s bone strength using the Sunlight Omnisense™ 
ultrasound system. This procedure involves the application of gel to the forearms 
and the lower legs and moving an ultrasound probe over these regions. This 
procedure is quick and causes no discomfort.  
 
4. Blood Analysis: A total of 4 blood samples will be collected to determine 
biochemical markers affecting bone turnover: pre-exercise, immediately after 
exercise, 60 min and 24 hours post exercise. The blood samples will be drawn 
using a standard venipuncture technique performed by a certified lab assistant. 
Up to 10ml will be withdrawn. It should be noted that the venous blood drawing 
procedure is a routine procedure performed by a certified technician and offers 
minimal risk to participants.  In rare instances, participants may experience slight 
pain and/or tingling in the area and/or a minor bruise from the needle. However, 
with the use of anaesthetic creams (e.g., Emla), which we use in the laboratory, 
any sensation of pain is minimal. 
 
B. Exericse Protocol: 
 
Participants will begin with a warm-up activity that will consist of 5 minutes of low 
intensity jogging with a series of stretching exercises. The exercise protocol will 
be designed to provide high impact, weight-bearing loads in the form of circuit 
training stations. Participants will be instructed to rotate through the five stations, 
which will be composed of jumping jacks, lunge jumps hopping, jumping over 
various obstacles (ie, hurdles) and drop jumps, for a total of 3 sets. Each station 
will take 2 minutes and the participants will then be instructed to progress to the 
next one. A recovery period of 2 minutes will be given between each set.    
 
CONFIDENTIALITY: 
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All data collected during this study will remain confidential and will be stored in offices 
and on secured computers to which only the principal and co-investigators have access. 
You should be aware that the results of this study will be made available to scientists, 
through publication in a scientific journal but your name and any personal data will not 
appear in compiling or publishing these results. Data will be kept for 5 years after the 
date of publication, at which time all information will be destroyed. Additionally, you will 
have access to your own data, as well as group data when it becomes available and if 
you are interested. This can be provided to you by simply contacting the principal 
investigators.  
PARTICIPATION AND WITHDRAWL: 
You and your child can choose whether to participate in this study or not and may 
remove your data from the study if you wish. Your child may also refuse to answer any 
questions posed to them during the study and still remain as a subject in the study. The 
investigators reserve the right to withdraw you from the study if they believe that it is 
necessary.  
RISKS AND BENEFITS: 
Participation will allow your child to become exposed to a research protocol, contribute 
to the advancement of science and, gain personal and general knowledge about their 
own body. All results will be provided to you upon request. 
The only foreseeable risks involved in participation include: 
a) Possible muscle soreness within 48 hours of the test. If this occurs, it will only be 
temporary. 
b) In rare instances, participants may experience slight pain and/or tingling in the 
area and/or a minor bruise from the venous blood draw.  
 
RIGHTS OF RESEARCH PARTICIPANTS: 
 
You will receive a signed copy of this consent form. You may withdraw your consent to 
participate in this study at any time, and you may also discontinue participation at any 
time without penalty. In signing this consent form or in participating in this study you are 
not waiving any legal claims or remedies. This study has been reviewed and received 
clearance from the Brock University Research Ethics Board (file # 12-051) If you have 
any pertinent questions about your rights as a research participant, please contact the 
Brock University Research Ethics Officer (905 688-5550 ext 3035, reb@brocku.ca).  
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INFORMATION: 
 
Please contact Dr. Bareket Falk at 905 688-5550 (ext. 4979), bfalk@brocku.ca or 
Kimberly Kish at 905 688-5550 (ext. 5623), kk11om@brocku.ca if you have any 
questions about the study.  
I HAVE READ AND UNDERSTAND THE ABOVE EXPLANATION OF THE PURPOSE 
AND PROCEDURES OF THE PROJECT.  I HAVE ALSO RECEIVED A SIGNED 
COPY OF THE INFORMATION AND CONSENT FORM. MY QUESTIONS HAVE 
BEEN ANSWERED TO MY SATISFACTION AND I AGREE TO PARTICIPATE IN 
THIS STUDY. 
 
 
SIGNATURE OF PARENT/GUARDIAN     DATE 
 
 
PRINTED NAME OF PARTICIPANT 
 
 
WITNESS         DATE 
 
In my judgment the participant is voluntarily and knowingly giving informed consent and 
possesses the legal capacity to give informed consent and participate in this research 
study. 
 
 
SIGNATURE OF INVESTIGATOR     DATE 
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2.2 Consent Forms for Adults 
INFORMATION AND CONSENT TO PARTICIPATE IN RESEARCH 
Exercise and Bone Turnover 
You are being invited to participate in a research study being conducted by the 
investigators listed below. Prior to participating in this study please read this form to find 
out about the purpose and the tests of this study. For the tests you will have to visit the 
Exercise Physiology Laboratory (WH 23, Brock University). This study is part of the 
Faculty of Applied Health Sciences of Brock University.  
INVESTIGATORS:  DEPARTMENT:   CONTACT: 
Dr. Bareket Falk  FAHS, Brock University  (905) 688-5550 ex. 
4979 
Kimberly Kish   FAHS, Brock University  (905) 688-5550 ex. 
5623 
 
PURPOSE: 
 
The purpose of the study is to investigate the acute response and recovery of bone 
metabolism induced by jumping exercise over a period of 24 hours in children and 
adults.  
DESCRIPTION OF TESTING PROCEDURES: 
 
If you agree to volunteer for this study, you will visit our laboratory for one session of 
testing, lasting approximately 1.5 hours and another session, 24 hours later, lasting 
approximately 30 min. At the end of the study, you will be given a summary of the 
findings, upon request. It is recommended that you come for the measurements in shorts 
and a short sleeved shirt.  
 
You will undergo the measurements and procedures listed below; please note that in all 
questionnaires, you may choose not to answer any question.  
 
C. Pre-exercise Assessments: 
 
5. You will complete several questionnaires, outlining your medical history, physical 
activities and nutritional habits. Please be aware that the medical history 
questionnaire includes questions about drug use, alcohol use and smoking. In all 
questionnaires, you may choose not to answer any question without penalty.  
 
6. Body Composition: we will measure your height, weight and percent body fat. 
Percent body fat will be estimated using skinfold thicknesses and bioelectrical 
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impedance analysis (BIA). The BIA assessment requires you to stand on a 
weight scale and grasp handles. A mild electrical current (50kHz, 800µA) will 
pass through your hands to your feet. This current cannot be felt and causes no 
harm. Valid measurements require abstinence from exercise, alcohol 
consumption, and eating/drinking for at least 12, 24 and 4 hours, respectively, 
prior to testing.  
 
7. We will determine your bone strength using the Sunlight Omnisense™ 
ultrasound system. This procedure involves the application of gel to the forearms 
and the lower legs and moving an ultrasound probe over these regions. This 
procedure is quick and causes no discomfort.  
 
 
8. Blood Analysis: A total of 4 blood samples will be collected to determine 
biochemical markers affecting bone turnover: pre-exercise, immediately after 
exercise, 60 min and 24 hours post exercise. The blood samples will be drawn 
using a standard venipuncture technique performed by a certified lab assistant. 
Up to 10ml will be withdrawn. It should be noted that the venous blood drawing 
procedure is a routine procedure performed by a certified technician and offers 
minimal risk to participants.  In rare instances, participants may experience slight 
pain and/or tingling in the area and/or a minor bruise from the needle. However, 
with the use of anaesthetic creams (e.g., Emla), which we use in the laboratory, 
any sensation of pain is minimal. 
 
D. Exercise Protocol: 
 
Participants will begin with a warm-up activity that will consist of 5 minutes of low 
intensity jogging with a series of stretching exercises. The exercise protocol will 
be designed to provide high impact, weight-bearing loads in the form of circuit 
training stations. Participants will be instructed to rotate through the five stations, 
which will be composed of jumping jacks, lunge jumps hopping, jumping over 
various obstacles (ie, hurdles) and drop jumps, for a total of 3 sets. Each station 
will take 2 minutes and the participants will then be instructed to progress to the 
next one. A recovery period of 2 minutes will be given between each set.    
CONFIDENTIALITY: 
All your data collected during this study will remain confidential and will be stored in 
offices and on secured computers to which only the principal and co-investigators have 
access. You should be aware that the results of this study will be made available to 
scientists, through publication in a scientific journal but your name and any personal data 
will not appear in compiling or publishing these results. Data will be kept for 5 years after 
the date of publication, at which time all information will be destroyed. Additionally, you 
will have access to your own data, as well as group data when it becomes available and 
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if you are interested. This can be provided to you by simply contacting the principal 
investigators.  
PARTICIPATION AND WITHDRAWL: 
You can choose whether to participate in this study or not and may remove your data 
from the study if you wish. You may also refuse to answer any questions posed to you 
during the study and still remain as a subject in the study. The investigators reserve the 
right to withdraw you from the study if they believe that it is necessary.  
RISKS AND BENEFITS: 
Participation will allow you to become exposed to a research protocol, contribute to the 
advancement of science and, gain personal and general knowledge about the human 
body. All results will be provided to you upon request. 
The only foreseeable risks involved in participation include: 
c) Possible muscle soreness within 48 hours of the test. If this occurs, it will only be 
temporary. 
d) In rare instances, participants may experience slight pain and/or tingling in the 
area and/or a minor bruise from the venous blood draw.  
 
RIGHTS OF RESEARCH PARTICIPANTS: 
 
You will receive a signed copy of this consent form. You may withdraw your consent to 
participate in this study at any time, and you may also discontinue participation at any 
time without penalty. In signing this consent form or in participating in this study you are 
not waiving any legal claims or remedies. This study has been reviewed and received 
clearance from the Brock University Research Ethics Board (file # 12-051). If you have 
any pertinent questions about your rights as a research participant, please contact the 
Brock University Research Ethics Officer (905 688-5550 ext 3035, reb@brocku.ca).  
 
INFORMATION: 
 
Please contact Dr. Bareket Falk at 905 688-5550 (ext. 4979), bfalk@brocku.ca or 
Kimberly Kish at 905 688-5550 (ext. 5623), kk11om@brocku.ca if you have any 
questions about the study.  
 
I HAVE READ AND UNDERSTAND THE ABOVE EXPLANATION OF THE PURPOSE 
AND PROCEDURES OF THE PROJECT. I HAVE ALSO RECEIVED A SIGNED COPY 
OF THE INFORMATION AND CONSENT FORM. MY QUESTIONS HAVE BEEN 
ANSWERED TO MY SATISFACTION AND I AGREE TO PARTICIPATE IN THIS 
STUDY. 
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SIGNATURE OF PARTICIPANT     DATE 
 
 
PRINTED NAME OF PARTICIPANT 
 
In my judgment the participant is voluntarily and knowingly giving informed consent and 
possesses the legal capacity to give informed consent and participate in this research 
study. 
 
 
SIGNATURE OF INVESTIGATOR     DATE 
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Appendix 3 Questionnaires 
3.1 Subject Screening and Medical History Questionnaire  
SUBJECT SCREENING AND MEDICAL HISTORY QUESTIONNAIRE 
Name: ___________________________________________         Date: _______________  
 
Date of Birth: __________________________________ 
 
Dominant Hand: ___________           Dominant Leg: _____________   
Your responses to this questionnaire are confidential.  If you answer “YES” to any of the 
following questions, please give additional details in the space provided and discuss the matter 
with one of the investigators.  You may refuse to answer any of the following questions. 
1. Have you ever had any major joint instability or ongoing chronic pain such 
as in the knee, back or elbow? 
 
YES NO 
2. Are you currently taking any medication (including aspirin) or have you 
taken any medication in the last two days? 
 
YES NO 
3. Have you taken any medication in the past six months? 
 
YES NO 
4. Is there any medical condition with which you have been diagnosed and 
are under the care of a physician (e.g. asthma, diabetes, anorexia)? 
 
YES NO 
5. Do you, or have you in the past, consumed any alcohol on a regular basis? 
 
YES NO 
6. Do you, or have you in the past, smoked on a regular basis? 
 
YES NO 
7. Are you, or have you in the past, engaged in any extreme diet? 
 
YES NO 
8. Do you, or have you in the past, consumed any nutritional supplements 
(e.g. calcium, multi-vitamin) on a regular basis? 
 
YES NO 
9. Do you, or have you in the past, engaged in physical activity on a regular 
basis? 
 
YES NO 
10. Have you had any fractures? 
 
YES NO 
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3.2 Sexual Maturation  
Male Pubertal Stage 
FACULTY OF APPLIED HEALTH SCIENCES - BROCK UNIVERSITY 
 
NAME: _________________________________________________ 
This scale is to assess your maturational level. For both columns, please choose the appropriate 
stage and write the corresponding number on this piece of paper. 
Column #1: __________________ (corresponding number) 
 
Column #2: __________________ (corresponding number) 
 
# 1: PLEASE LOOK AT PENIS SIZE ONLY  2: PLEASE LOOK AT PUBIC HAIR ONLY
1 2 
3 4 
5 
1 2 
3 4 
5 6 
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3.3 Physical Activity 
 
3.3.1 Godin-Shepherd Leisure-Time Exercise Questionnaire 
GODIN-SHEPHARD LEISURE-TIME EXERCISE QUESTIONNAIRE 
 
 
1. Considering a 7-day period (a week), how many times on the average do you do the 
following kinds of exercise for more than 15 minutes during your free-time (write 
on each line the appropriate number)? 
  
Times PerWeek 
 
(a) STRENUOUS EXERCISE (HEART BEATS RAPIDLY)    ______________                    
     
 (i.e. running, jogging, hockey, football, soccer, squash, basketball,  
cross country skiing, judo, roller skating, vigorous swimming,  
vigorous long distance bicycling) 
 
(b) MODERATE EXERCISE (NOT EXHAUSTING)   ______________ 
    
(i.e. fast walking, baseball, tennis, easy bicycling, volleyball,  
badminton, easy swimming, alpine skiing, popular and folk dancing) 
 
(b) MILD EXERCISE (MINIMAL EFFORT)                           ______________ 
     
 (i.e. yoga, archery, fishing from river bank, bowling, horseshoes,  
golf, snow-mobiling, easy walking) 
 
 
 
2. Considering a 7-day period (a week), during your leisure-time, how often do you 
engage in any regular activity long enough to work up a sweat (heart beats rapidly)?  
 
1. OFTEN    2. SOMETIMES  3. NEVER/RARELY 
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3.3.2 Past Year Physical Activity Questionnaire 
PHYSICAL ACTIVITY AND EXERCISE 
 
NAME ___________________________________ DATE _____________ 
ID ____________ CLASS _____________ GRADE ____________ 
 
1. How many of the past 14 days have you done at least 20 minutes od 
exercise hard enough to make you breath heavily and make your 
heart beat fast? (Hard exercise includes, for example, playing 
basketball, jogging, fast dancing or bicycling; include time in 
physical education class) 
 
1. None   4. 6 to 8 days 
2. 1 to 2 days  5. 9 or more days 
3. 3 to 5 days 
 
2. How many of the past 14 days have you done at least 20 minutes of 
light exercise that was not hard enough to make you breath 
heavily and make your heart beat fast? (Light exercise includes, 
for example, playing baseball, walking or slow bicycling; include 
time in physical education class) 
 
1. None   4. 6 to 8 days 
2. 1 to 2 days  5. 9 or more days 
3. 3 to 5 days 
 
4. During a normal week, how many hours a day do you watch 
television and videos, or play computer or video games before and 
after school? 
 
1. None   4. 4 to 5 hours 
2. 1 hour or less 5. 6 or more hours 
3. 2 to 3 hours 
5. During the last 12 months, how many team or individual sports or 
activities did you participate in on a competitive level, such as 
varsity or junior varsity sports, intramurals, YMCA or other out-
of-school programs. 
  1. None   4. 3 activities 
  2. 1 activity  5. 4 or more activities 
  3. 2 activities 
 
What activities did you compete in?  1. _______________ 
       2. _______________ 
       3. _______________ 
       4. _______________ 
       5. _______________ 
       6. _______________ 
       7. _______________ 
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3.3.3 Bone-Specific Physical Activity Questionnaire 
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3.4 24-hour Nutritional Recall Questionnaire 
24 HOUR NUTRITIONAL RECALL 
 
Name: _________________________________________   Date:  _________________ 
 
24 Hour Recall Date: ________________ 
 
Nutritional Intake: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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Appendix 4 Data Collection Sheets 
EXERCISE AND BONE TURNOVER ID: ______________              
 
SECTION 1: PARTICIPANT INFORMATION 
Participant ID #: 
 
________________________ 
First and Last Name: 
 
________________________ 
Date of Birth: 
 
______ / ______ / _______ 
(month)      (day)        (year) 
Visit Date: 
 
________________________ 
Age: 
 
________________________ 
Dominant Limbs: 
 
________           __________ 
(Arm)                            (Leg) 
 
SECTION 2: CONSENTS, QUESTIONNAIRES AND DATA COLLECTION 
1.Consent form: ______ 
2. Subject Screening and Medical History Questionnaire: ______ 
3. Anthropometric Measurements: ______ 
4. 24 Hour Nutrition Recall: ______ 
5. Godin-Shephard Leisure-Time Exercise Questionnaire: ______ 
6. Past Year Physical Activity Questionnaire: ______ 
7. Bone-Specific Physical Activity Questionnaire: ______ 
8. Tanner Staging: ______ 
9. Bone QUS: _____ 
10. Blood Sample #1 – Pre-Exercise: _____ 
11. Plyometric Exercise: _____ 
12. Accelerometer Worn: ______ 
13. Blood Sample #2 – 5min Post-Exericse: _____ 
14. Blood Sample #3 – 1 hour Post-Exercise: _____ 
15. Blood Sample #4 – 24 hour Post-Exercise: _____ 
16. Incentive Given: _____ 
 
SECTION 3: COMMENTS 
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EXERCISE AND BONE TURNOVER ID:            
 
NAME: _______________________________  DATE: ______________________ 
DOB: ________________________________________  AGE: ________________ 
DOMINANT ARM: _________________   DOMINANT LEG: _____________ 
WEIGHT: ________ HEIGHT: ________ BMI: ________  BF%: _________ 
 
ARM AND LEG LENGTH (CM): 
 TRIAL 1 TRIAL 2 TRIAL 3 TRIAL 4 (>1cm 
difference) 
MEDIAN 
UPPER ARM      
     
UPPER LEG      
     
 
SKINFOLD THICKNESS (MM): 
 
 TRIAL 1 TRIAL 2 TRIAL 3 TRIAL 4 
(>1mm 
difference) 
MEDIAN 
TRICEPS      
     
     
SUBSCAPULA      
     
     
ANTERIOR 
THIGH 
     
     
     
 
  
136 
 
EXERCISE AND BONE TURNOVER ID:            
 
Bone Strength Data: 
Sunlight Omniscence™ 
DOMINANT: 
Side (circle) Site SOS T-Score Z-Score 
L or R Dominant Radius    
   
   
L or R Dominant Tibia    
   
   
 
NON-DOMINANT: 
Side (circle) Site SOS T-Score Z-Score 
L or R Non-Dominant 
Radius 
   
   
   
L or R Non-Dominant 
Tibia 
   
   
   
 
WARM-UP PROTOCOL: 
TIME (minutes) WATTS HEART RATE (bpm) 
1:00   
2:00   
3:00   
4:00   
5:00   
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EXERCISE AND BONE TURNOVER ID:            
 
ONSET OF EXERCISE: ___________________ COMPLETION OF EXERCISE: ________________ 
SET #1 
 START TIME END TIME HEART RATE 
DROP JUMPS    
LUNGE JUMPS    
HURDLES    
1 FOOT HOPS    
JUMPING JACKS    
FINAL HEART RATE   
SET #2 
 START TIME END TIME HEART RATE 
DROP JUMPS    
LUNGE JUMPS    
HURDLES    
1 FOOT HOPS    
JUMPING JACKS    
FINAL HEART RATE  
SET #3 
 START TIME END TIME HEART RATE 
DROP JUMPS    
LUNGE JUMPS    
HURDLES    
1 FOOT HOPS    
JUMPING JACKS    
FINAL HEART RATE  
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EXERCISE AND BONE TURNOVER ID:            
 
Blood Sample Timing: 
 TIME OF SAMPLE TIME TO CENTRIFUGE 
SAMPLE #1 – PRE-EXERCISE   
SAMPLE #2 – 5MIN POST-EXERCISE   
SAMPLE #3 – 1HR POST-EXERCISE   
SAMPLE #4 – 24HR POST-EXERCISE   
 
 
 
 
 
 
 
 
COMMENTS: 
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Appendix 5 Additional Data, not appearing in main body of thesis 
 
Table 12. Participant SOS (m/s) and Z-scores from the QUS measurement for the non-
dominant limbs for men and boys.  
 Adults (n=18) Children (n=12) p-value 
Non-Dominant Radius SOS 4153.6 ± 115.8 3794.5 ± 116.1 <0.001* 
Non-Dominant Radius Z-Score 0.8 ± 1.0 0.1 ± 1.2 NS 
Non-Dominant Tibia SOS 3963.1 ± 85 3706.3 ± 72.4 <0.001* 
Non-Dominant Tibia Z-Score -0.1 ± 0.8 0.5 ± 0.7 <0.05* 
All values are expressed as means ± SD. Significance was set at p<0.05 difference between groups. 
SOS – speed of sound 
 
Table 13. Time spent in moderate, vigorous or very vigorous activity (minutes), the 
counts in the vertical and horizontal axis and the total time for the exercise protocol  
 Adults (n=18) Children (n=12) p-value 
Moderate Activity  3.3 ± 1.3 5.0 ± 1.4 <0.002* 
Vigorous Activity  1.5 ± 0.5 1.9 ± 0.5 NS 
Very Vigorous Activity  6.4 ± 2.2 4.6 ± 0.6 <0.007* 
Vertical Axis Count 140519 ± 46266 82840 ± 12751 <0.001* 
Horizontal Axis Count 65849 ± 20202 49911 ± 10488 <0.02* 
Total Exercise Time  27.5 ± 6.1 21.4 ± 3.4 <0.004* 
All values are expressed as means ± SD. Significance was set at p<0.05 difference between groups. 
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Table 11. Heart rates (bpm) after each exercise throughout each set  
 Adults (n=18) Children (n=12) 
#1 DJ  165 ± 10.6 170 ± 16.2 
#1 LJ 170 ± 13.8 178 ± 14.2 
#1 HJ 167 ± 14.8 173 ± 11.0 
#1 S-L Hop 178 ± 10.4 183 ± 10.5 
#1 JJ 174 ± 13.1 180 ± 14.5 
#2 DJ  164 ± 11.4 172 ± 10.3 
#2  LJ 172 ± 11.5 178 ± 14.3 
#2 HJ 169 ± 13.6 174 ± 13.9 
#2 S-L Hop 178 ± 10.5 185 ± 10.7 
#2 JJ 176 ± 9.8 182 ± 9.5 
#3 DJ  166 ± 11.0 173 ± 13.2 
#3 LJ 172 ± 11.5 180 ± 16.0 
#3 HJ 173 ± 13.4 174 ± 16.5 
#3 S-L Hop 181 ± 11.4 185 ± 10.5 
#3 JJ 177 ± 9.6 183 ± 12.9 
All values are expressed as means ± SD. Significance was set at p<0.05 difference between groups. 
DJ – drop jump, LJ – lunge jump, HJ – hurdle jump, S-L – single-leg, JJ – jumping jacks 
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Raw Data - Men 
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001 07/08/90 11/07/12 8158 22.35 2 1 1 0 0 0 1 0 0 0 
  002 02/28/89 11/12/12 8658 23.7 2 1 0 0 0 0 1 0 0 0 
  003 08/19/89 11/21/12 8495 23.3 2 1 0 0 0 0 0 0 0 0 
  004 07/02/84 11/27/12 10375 28.4 2 1 0 0 0 0 0 0 1 0 
  005 11/17/90 11/29/12 8048 22.0 2 1 0 0 0 0 0 0 0 0 
  
006 08/01/93 11/29/12 7060 19.3 2 1 0 0 0 0 0 0 0 1 
Ventolin &
Flovent 2 
007 01/23/89 12/03/12 8715 23.9 2 1 0 0 0 0 0 0 0 1 Thyroxine 
 009 06/15/93 12/06/12 7114 19.5 2 1 1 0 0 0 0 0 0 0 
  0010 12/11/93 01/22/13 6982 19.1 2 1 1 0 0 0 0 0 0 0 
  0011 05/23/88 01/28/13 9016 24.7 2 1 0 
 
0 0 0 0 0 0 
  0012 03/27/89 02/04/13 8715 23.9 2 1 1 0 0 0 1 0 0 0 
  0013 06/02/93 02/07/13 7190 19.7 2 1 1 1 0 0 0 0 0 0 
  0014 01/15/91 02/11/13 8063 22.1 2 1 1 
 
0 0 1 0 1 0 
  0015 06/17/94 02/27/13 6830 18.7 2 1 0 0 0 0 0 0 0 1 
  0016 11/25/93 02/27/13 7034 19.3 2 1 1 0 0 1 0 0 0 0 
  
0017 02/16/88 03/07/13 9151 25.1 2 1 1 
 
0 0 0 0 0 1 
Amoxacillan,
cyprofloxacin  0 
0018 03/18/91 03/18/13 8036 22.0 2 1 1 
 
0 0 0 0 0 1 Clonazepam  0 
0019 05/19/85 04/13/13 10191 27.9 2 1 1 
 
0 0 0 0 0 0 
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001 82.30 182.30 1.82 24.85 9.10 11.30 20.40 15.85 69.26 15.10       
002 106.3 191.10 1.91 29.11 22.30 25.20 47.50 33.93 70.23 27.90       
003 71.25 169.30 1.69 24.86 4.40 7.30 11.70 7.56 65.86 9.90       
004 89.10 192.60 1.93 24.02 7.00 10.00 17.00 12.76 77.73 9.8       
005 67.50 173.10 1.73 22.53 6.40 6.80 13.20 9.08 61.37 9.40       
006 86.90 186.50 1.87 24.98 9.80 10.20 20.00 15.50 73.43 9.40       
007 75.90 175.30 1.75 24.70 6.80 8.00 14.80 10.66 67.81 11.30       
009 71.40 175.40 1.75 23.21 6.90 7.80 14.70 10.56 63.86 11.40       
0010 60.70 173.10 1.73 20.26 13.60 10.60 24.20 19.10 49.11 14.60       
0011 87.80 183.20 1.83 26.16 8.00 9.00 17.00 12.76 76.60 12.50       
0012 70.1 180.00 1.800 21.64 10.20 10.40 20.60 16.031 58.88 21.60       
0013 82.40 180.10 1.80 25.40 7.00 9.20 16.20 12.002 72.51 16.20       
0014 75.30 176.80 1.77 24.09 9.20 9.80 19.00 14.602 64.31 14.80       
0015 67.60 173.00 1.73 22.59 11.40 10.40 21.80 17.076 56.04 14.90       
0016 88.70 188.50 1.89 24.96 9.40 9.80 19.20 14.783 75.57 15.80       
0017 73.30 180.50 1.81 22.50 8.80 9.20 18.00 13.688 63.26 14.40       
0018 69.20 178.90 1.79 21.62 10.80 13.20 24.00 18.932 56.12 12.30       
0019 88.40 182.70 1.83 26.48 17.40 14.50 31.90 24.958 66.30 22.90       
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001 3 2 4 49 3 4 5 5 4 2 3 
 
1 0.740 6.0 4.440 
002 8 8 8 128 4 3 3 1 
    
6 1.323 5.0 6.615 
003 14 7 7 182 5 5 3 3 3 14 
  
11 1.985 7.3 14.488 
004 5 5 7 91 4 5 3 4 15 2 23 
 
15 2.977 9.8 29.174 
005 5 6 7 96 5 5 2 2 24 
   
17 0.496 6.5 3.225 
006 5 1 4 62 4 4 3 5 2 4 3 
 
7 0.207 7.5 1.550 
007 3 15 7 123 5 3 1 2 19 
   
19 19.846 12.5 248.077 
009 7 1 3 77 3 2 4 3 20 3 
  
11 0.496 7.3 3.622 
0010 2 1 1 26 3 3 3 2 3 
   
6 0.413 5.0 2.067 
0011 2 5 6 61 
        
17 3.969 6.5 25.800 
0012 2 2 7 49 3 3 3 1 
    
11 0.620 7.3 4.527 
0013 5 3 7 81 4 3 5 2 23 
   
20 0.992 8.0 7.938 
0014 3 4 4 59 
        
17 0.413 6.5 2.687 
0015 4 2 6 64 2 3 4 3 2 17 
  
17 0.496 6.5 3.225 
0016 4 4 4 68 4 5 3 3 2 4 
  
17 0.165 6.5 1.075 
0017 5 5 7 91 2 5 3 4 21 5 7 
 
7 1.488 7.5 11.163 
0018 3 4 7 68 3 5 3 2 19 
   
7 5.292 7.5 39.692 
0019 2 2 5 43 3 4 4 3 3 21 
  
3 1.985 8.0 15.877 
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001 2 0.660 10.0 6.620 3 0.280 8.0 2.205 4 0.124 4.0 0.496 5.0 0.248 11.8 2.927 
002 7 3.184 7.5 23.877 8 3.473 4.0 13.892 9 7.442 6.0 44.652 10.0 1.158 3.5 4.052 
003 7 1.240 7.5 9.303 12 2.315 3.8 8.798 9 0.662 6.0 3.969 13.0 1.158 7.0 8.104 
004 16 1.819 5.0 9.096 
            005 7 0.827 7.5 6.202 5 2.481 11.8 29.273 16 0.992 5.0 4.962 
    006 8 1.488 4.0 5.954 3 0.930 8.0 7.442 5 0.248 11.8 2.927 18.0 1.654 7.0 11.577 
007 7 7.938 7.5 59.538 16 3.473 5.0 17.365 
        009 17 0.662 6.5 4.300 20 0.413 8.0 3.308 3 2.977 8.0 23.815 5.0 0.827 11.8 9.758 
0010 8 0.413 4.0 1.654 9 0.992 6.0 5.954 13 0.248 7.0 1.737 5.0 0.496 11.8 5.855 
0011 7 1.654 7.5 12.404 5 1.654 11.8 19.515 18 0.620 7.0 4.341 16.0 5.954 5.0 29.769 
0012 17 0.413 6.5 2.687 5 0.248 11.8 2.927 18 0.310 7.0 2.171 1.0 0.145 6.0 0.868 
0013 8 4.962 4.0 19.846 5 2.481 11.8 29.273 21 0.662 7.8 5.160 16.0 7.442 5.0 37.212 
0014 7 1.985 7.5 14.885 8 0.744 4.0 2.978 9 3.969 6.0 23.815 5.0 2.233 11.8 26.346 
0015 8 0.207 4.0 0.827 9 0.248 6.0 1.488 13 0.248 7.0 1.737 5.0 0.868 11.8 10.246 
0016 7 0.248 7.5 1.861 8 0.331 4.0 1.323 5 0.551 11.8 6.505 18.0 1.985 7.0 13.892 
0017 9 0.496 6.0 2.977 13 0.248 7.0 1.737 5 0.827 11.8 9.758 30.0 0.413 5.3 2.191 
0018 5 2.646 11.8 31.225 9 2.315 6.0 13.892 15 4.465 9.8 43.761 
    0019 21 0.331 7.8 2.580 
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                002 
                003 5.0 1.9 11.8 23.418 3.0 0.554 8.0 4.431 14.0 2.977 6.0 17.862 
    004 
                005 
                006 1.0 0.3 6.0 1.675 4.0 0.372 3.0 1.116 16.0 0.992 5.0 4.962 
    007 
                009 18.0 0.3 7.0 1.737 21.0 0.372 7.8 2.902 1.0 1.240 6.0 7.442 22.0 1.323 7.3 9.658 
0010 22.0 0.3 7.3 2.415 10.0 0.992 3.5 3.473 3.0 0.744 8.0 5.954 
    0011 
                0012 4.0 0.1 3.0 0.372 10.0 3.473 3.5 12.156 
        0013 3.0 0.7 8.0 5.292 
            0014 18.0 0.3 7.0 1.929 21.0 0.413 7.8 3.225 4.0 0.662 3.0 1.985 14.0 4.465 6.0 26.792 
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        0018 
                0019 
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c
y
 
001 
        
13.761 9.026 188.57 98.797 1 8 
002 
        
89.036 0.537 47.128 23.833 1 1 
003 
        
77.838 19.193 65.313 42.253 1 8 
004 
        
38.270 0.485 17.657 9.071 0 0 
005 
        
43.661 7.165 91.451 49.308 1 6 
006 
        
24.510 13.533 123.08 68.308 1 10 
007 
        
324.981 0.497 51.12 25.809 1 2 
009 16.0 13.892 5.0 69.462 
    
53.882 7.891 63.204 35.547 1 12 
0010 
        
19.780 12.451 96.01 54.231 1 4 
0011 
        
62.061 8.556 91.566 50.061 1 8 
0012 
        
12.685 9.41 88.506 48.958 1 6 
0013 
        
67.510 9.004 151.03 80.019 1 12 
0014 
        
75.072 17.09 75.509 46.299 1 8 
0015 
        
33.470 11.101 56.084 33.593 1 7 
0016 
        
48.141 20.132 38.735 29.434 1 4 
0017 
        
37.245 4.953 42.224 23.589 1 9 
0018 
        
128.570 3.819 215.27 109.55 1 3 
0019 
        
18.457 5.756 33.527 19.642 1 3 
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C
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W
U
 M
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#
4
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R
 
C
y
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e
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m
e
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W
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#
5
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R
 
001 5.92 3.07 2.17 2.28 1.13 8.43 180079 69621 
     002 18.58 4.95 4.32 4.70 2.32 8.13 167383 71823 147 144 166 170 174 
003 10.68 2.80 2.12 4.17 1.08 8.15 173157 83602 139 147 151 163 169 
004 6.97 3.27 3.22 3.13 1.23 5.18 119752 49292 
  
126 136 148 
005 17.65 6.07 5.33 7.30 2.32 13.33 292909 132894 131 147 159 167 173 
006 8.13 2.27 1.68 2.37 1.10 5.45 123059 54322 115 126 133 141 147 
007 4.20 1.00 1.57 2.83 1.13 5.27 126232 49837 
     009 9.03 3.17 3.47 4.75 2.42 7.17 154942 72517 127 139 149 151 161 
0010 14.65 1.90 2.02 2.53 1.37 5.53 112480 43579 128 149 162 174 182 
0011 62.48 3.82 2.05 3.52 1.32 7.05 157668 55579 116 124 124 136 144 
0012 15.13 4.47 2.13 1.95 0.90 5.42 126841 50794 133 157 169 176 181 
0013 9.08 2.55 2.48 2.68 1.37 5.28 116890 56381 136 155 164 171 177 
0014 6.13 4.68 3.02 3.65 1.93 6.60 151494 78653 113 132 139 146 154 
0015 17.50 2.07 1.78 3.60 1.40 5.15 119293 76601 123 140 160 181 193 
0016 16.55 3.05 2.60 3.45 1.57 4.78 101549 59832 132 144 150 162 174 
0017 20.18 2.18 1.22 1.40 1.73 5.60 110064 58593 138 150 159 165 175 
0018 10.12 1.47 1.78 2.68 1.80 5.13 107034 64600 126 147 156 170 175 
0019 16.00 2.80 2.37 2.85 1.03 3.95 88530 56762 112 129 141 147 160 
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#
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R
 
R
e
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o
v
e
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001 
          002 9:14 AM 9:56 AM 42 
 
186 196 185 195 186 150 
003 9:19 AM 9:47 AM 28 
 
160 167 160 183 180 123 
004 9:25 AM 9:47 AM 22 93 156 165 141 168 167 
 005 8:54 AM 9:18 AM 24 
 
160 155 161 174 172 95 
006 9:31 AM 9:51 AM 20 120 148 164 151 169 169 106 
007 9:12 AM 9:27 AM 15 143 163 164 161 178 176 110 
009 9:56 AM 10:25 AM 31 119 161 174 166 176 163 131 
0010 10:39 AM 11:06 AM 27 124 160 153 146 159 141 106 
0011 9:40 AM 10:11 AM 31 106 162 144 150 168 162 90 
0012 9:37 AM 10:06 AM 29 103 169 179 176 179 172 111 
0013 9:31 AM 9:54 AM 23 140 181 180 185 190 190 115 
0014 9:25 AM 9:52 AM 27 
 
164 164 170 176 173 118 
0015 9:28 AM 9:59 AM 31 
 
186 189 191 197 197 140 
0016 9:36 AM 10:07 AM 31 
 
162 180 180 180 186 108 
0017 9:21 AM 9:55 AM 34 131 175 184 181 188 181 107 
0018 9:33 AM 9:57 AM 24 134 162 172 170 179 180 129 
0019 9:52 AM 10:21 AM 29 110 156 156 161 166 164 100 
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#
3
 -
 D
ro
p
 J
u
m
p
s
 H
R
 
S
e
t 
#
3
 -
 L
u
n
g
e
 J
u
m
p
s
 H
R
 
S
e
t 
#
3
 -
 H
u
rd
le
 J
u
m
p
s
 H
R
 
S
e
t 
#
3
 -
 S
in
g
le
-l
e
g
 H
o
p
s
 H
R
 
S
e
t 
#
3
 -
 J
u
m
p
in
g
 J
a
c
k
s
 H
R
 
001 
           002 186 192 183 191 188 142 186 188 198 202 188 
003 157 164 160 178 175 124 160 169 159 175 159 
004 165 170 155 170 169 130 168 175 159 175 168 
005 151 157 149 175 174 115 156 159 166 171 173 
006 161 174 163 168 168 100 167 176 165 174 174 
007 170 178 180 187 186 109 170 186 188 188 189 
009 166 173 168 164 167 113 168 169 174 180 179 
0010 142 144 137 161 155 105 144 148 143 167 167 
0011 155 168 174 180 174 107 168 168 174 192 186 
0012 161 173 171 176 170 121 166 169 166 163 168 
0013 179 185 187 194 184 106 186 189 189 196 188 
0014 161 169 169 176 176 120 162 173 175 180 175 
0015 176 184 185 192 194 126 178 185 186 193 192 
0016 174 180 180 186 186 108 168 174 180 186 180 
0017 173 179 182 190 178 105 171 179 173 185 178 
0018 160 173 167 180 179 107 157 170 176 177 177 
0019 151 160 166 165 165 93 151 154 163 164 165 
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k
c
a
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T
o
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k
C
a
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 p
e
r 
k
g
 (
k
c
a
l/
k
g
) 
001 L L 4238 1 4097 1 4223 1 4050 0 2296 28 
002 R R 4110 0 4034 0 4158 1 4032 0 1766 17 
003 R R 4324 2 3969 0 4237 1 3954 0 2636 37 
004 R R 4321 2 4127 1 4405 3 4085 1 2939 33 
005 R R 4126 1 4115 1 4084 0 4106 1 1955 29 
006 R R 4042 0 3891 -1 4022 0 3890 -1 2370 27 
007 L R 4014 -1 3999 0 4118 0 4021 0 2689 35 
009 R R 4002 0 3908 -1 3974 -1 3952 0 4831 68 
0010 R R 4047 1 3989 1 4164 2 3947 0 3723 61 
0011 L R 3919 -1 3981 0 4011 -1 3864 -1 1613 18 
0012 R R 4052 0 4124 1 4156 1 4077 1 2203 31 
0013 L R 4140 1 3953 0 4176 1 3969 0 1754 21 
0014 R R 4068 0 3923 -1 4346 2 3896 -1 3367 45 
0015 R R 4022 1 3919 0 4044 1 3915 0 3118 46 
0016 R R 4039 0 3927 0 4168 2 3998 1 3187 36 
0017 R R 4159 1 3935 -1 4030 0 3858 -1 4583 63 
0018 R R 4075 0 3844 -1 4193 1 3821 -2 3451 50 
0019 R R 4076 0 3907 -1 4255 1 3900 -1 1461 17 
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T
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Z
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T
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C
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e
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001 319 83 79 1069 3 102 3493 2170 1450 277 5 0 
002 245 45 103 263 1 66 1084 2749 960 245 13 0 
003 284 92 173 1215 6 239 3905 3559 1561 359 10 120 
004 281 136 167 1409 13 431 3146 5439 2885 787 23 0 
005 368 37 64 776 3 120 1541 4521 1201 546 9 1 
006 387 43 126 1580 2 94 2105 5185 1958 768 14 0 
007 395 79 123 875 4 116 875 4587 1729 597 12 107 
009 602 230 140 1040 3 125 5330 8057 1338 466 4 17 
0010 521 124 136 1587 8 257 8955 3730 1598 388 10 118 
0011 193 49 111 681 5 229 2296 3706 1524 363 20 0 
0012 263 97 91 576 2 83 2894 1936 945 279 8 0 
0013 153 59 154 1716 9 357 2512 3027 2119 393 12 284 
0014 489 118 125 1446 7 268 3018 5352 2521 881 20 0 
0015 318 143 131 871 3 65 5096 800 1397 174 6 0 
0016 430 99 144 2455 9 363 7376 4062 2930 377 19 0 
0017 544 165 242 1657 11 427 6470 3165 2190 351 22 1 
0018 357 147 179 2273 19 811 3822 5919 2924 726 29 15 
0019 221 45 60 339 0 8 1095 1878 819 228 5 169 
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B
A
P
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μ
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) 
D
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u
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o
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a
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1
 
B
A
P
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2
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g
/L
) 
D
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u
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o
n
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a
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001 19.61 
 
24.24 
 
21.31 
 
21.22 
 
19.98 
 
18.24 
 002 17.48 
 
17.55 
 
16.51 
 
18.87 
 
14.39 
 
15.45 
 003 26.93 
 
20.65 
 
20.67 
 
20.67 
 
32.21 
 
35.03 
 004 19.05 
 
11.68 
 
13.06 
 
13.40 
 
28.32 
 
27.59 
 005 20.20 
 
17.07 
 
13.23 
 
16.66 
 
51.71 
 
56.95 
 006 20.84 
 
15.96 
 
17.61 
 
21.17 
 
19.25 
 
20.02 
 007 21.21 
 
17.78 
 
17.80 
 
17.78 
 
25.43 
 
23.65 
 009 31.73 
 
27.89 
 
22.91 
 
23.79 
 
28.54 
 
29.11 
 0010 16.74 
 
14.37 
 
24.42 
 
11.86 
 
29.61 
 
30.77 
 0011 21.34 
 
23.66 
 
14.62 
 
21.60 
 
33.31 
 
36.93 
 0012 15.06 
 
20.72 
 
10.45 
 
23.50 
 
22.32 
 
24.66 
 0013 18.15 
 
24.35 
 
13.40 
 
13.49 
 
28.70 
 
31.30 
 0014 25.96 
 
34.22 
 
25.66 
 
21.67 
 
38.43 
 
34.23 
 0015 24.28 
 
37.81 
 
33.51 
 
26.75 
 
39.53 
 
40.07 
 0016 30.77 
 
30.92 
 
23.08 
 
30.61 
 
57.07 
 
52.44 
 0017 28.94 
 
28.65 
 
25.93 
 
16.27 
 
43.92 
 
49.36 
 0018 20.42 
 
23.68 
 
21.15 
 
16.39 
 
26.89 
 
29.69 
 0019 12.49 
 
16.73 
 
12.03 
 
13.14 
 
26.32 
 
25.37 
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4
 (
p
m
o
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) 
001 20.99 
 
19.82 
 
2.46 2.76 2.68 2.21 
002 15.55 
 
19.95 
 
1.97 2.47 2.71 2.50 
003 39.19 
 
34.09 
 
4.24 3.47 4.38 4.81 
004 28.88 
 
27.78 
 
4.19 4.62 4.17 5.35 
005 59.01 
 
50.34 
 
5.35 5.99 5.08 4.09 
006 17.39 
 
18.49 
 
3.98 4.19 3.91 4.11 
007 29.51 
 
24.80 
 
3.18 3.10 3.25 2.39 
009 28.71 
 
26.09 
 
3.74 4.16 3.80 3.36 
0010 30.77 
 
32.89 
 
4.11 4.24 4.54 4.03 
0011 38.94 
 
35.74 
 
1.96 3.02 2.84 2.47 
0012 27.34 
 
28.70 
 
2.68 3.19 3.74 3.46 
0013 30.76 
 
34.96 
 
3.79 3.78 4.89 4.58 
0014 39.99 
 
41.85 
 
4.82 4.96 5.70 6.96 
0015 42.61 
 
45.46 
 
4.67 4.41 5.16 8.20 
0016 56.23 
 
55.21 
 
2.66 2.97 2.92 2.81 
0017 45.69 
 
42.75 
 
2.98 3.75 1.29 2.83 
0018 32.23 
 
33.29 
 
2.11 1.95 2.21 2.14 
0019 25.97 
 
26.98 
 
2.82 3.75 3.67 3.38 
 
 
 
  
154 
 
ID
 
R
A
N
K
L
 -
 T
1
 (
p
m
o
l/
L
) 
D
il
u
ti
o
n
 F
a
c
to
r 
1
 
R
A
N
K
L
 -
 T
2
 (
p
m
o
l/
L
) 
D
il
u
ti
o
n
 F
a
c
to
r 
2
 
R
A
N
K
L
 -
 T
3
 (
p
m
o
l/
L
) 
D
il
u
ti
o
n
 F
a
c
to
r 
3
 
R
A
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p
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D
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o
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a
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4
 
001 2.76 276.37 2.28 227.84 2.16 215.89 2.01 201.01 
002 1.44 144.38 2.00 200.31 2.68 268.18 1.71 170.78 
003 1.19 118.70 0.88 88.41 0.96 96.39 1.03 103.00 
004 4.64 463.59 7.19 719.30 2.83 283.39 3.38 337.57 
005 3.38 338.23 3.83 382.65 3.33 332.84 3.77 377.44 
006 3.68 368.00 4.73 472.98 4.83 482.87 4.64 464.03 
007 2.89 288.90 3.35 335.00 3.53 353.19 3.39 339.30 
009 3.75 375.34 4.00 400.27 3.63 362.73 3.69 369.05 
0010 3.35 335.00 3.35 335.00 3.20 319.83 3.29 328.52 
0011 5.56 555.91 4.02 402.33 3.21 320.92 3.48 347.87 
0012 1.66 165.95 1.77 177.37 1.35 134.93 2.15 214.55 
0013 0.82 82.45 0.97 97.29 0.65 65.42 0.91 90.75 
0014 7.91 321.63 9.65 346.83 9.00 280.77 8.11 305.51 
0015 5.45 544.62 6.07 607.47 5.17 517.49 4.79 478.56 
0016 0.89 89.10 1.53 152.85 1.21 121.12 1.27 127.30 
0017 4.72 472.33 3.86 386.38 4.11 410.59 4.39 438.61 
0018 4.95 495.07 5.15 515.47 3.99 398.55 5.22 521.54 
0019 3.54 353.68 4.20 420.36 3.38 337.54 2.84 283.78 
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1002 12/23/04 12/27/12 2926 8.0 1 1 1 1 0 0 0 0 0 0   
1003 01/30/02 01/03/13 3991 10.9 1 1 0 0 0 0 0 0 0 0   
1004 03/24/04 01/03/13 3207 8.8 1 1 0 0 0 0 0 0 0 0   
1006 06/05/01 01/19/13 4246 11.6 1 1 1 1 0 0 0 0 0 0   
1007 11/09/03 03/12/13 3411 9.3 1 1 1 0 0 0 0 0 0 0   
1008 08/30/01 04/13/13 4244 11.6 1 1 0  0 0 0 0 0 0   
1009 09/14/04 04/20/13 3140 8.6 1 3 0 1 0 0 0 0 0 0   
10010 07/29/01 04/20/13 4283 11.7 1 1 1 0 0 0 0 0 0 1 Adderall 1 
10011 11/22/03 05/11/13 3458 9.5 1 1 0 0 0 0 0 0 0 1   
10012 02/12/03 05/11/13 3741 10.2 1 1 0 0 0 0 0 0 0 0   
10013 07/04/03 06/21/13 3640 10.0 1 1 0 1 0 0 0 0 0 0   
10014 08/19/01 06/22/13 4325 11.8 1 4 0 0 0 0 0 0 0 0   
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1002 33.0 136.4 1.4 17.7 8.2 5.6 13.8 13.5 28.6 10.8 151.0 75.5 60.9 -3.88 1 1 
1003 39.9 148.7 1.5 18.0 9.4 4.8 14.2 13.9 34.4 9.7 149.9 74.4 74.3 -2.60 1 1 
1004 35.3 135.7 1.4 19.2 10.2 7.4 17.6 17.1 29.3 17.3 147.8 72.3 63.4 -3.74 1 1 
1006 40.5 148.1 1.5 18.5 10.6 6.8 17.4 15.2 34.3 17.7 152.4 76.9 71.2 -2.05 3 3 
1007 33.5 144.8 1.4 16.0 9.8 6.0 15.8 13.7 28.4 10.3 152.7 77.2 67.6 -3.14 1 1 
1008 41.6 146.3 1.5 19.4 14.2 7.0 21.2 18.7 33.8 19.2 153.0 77.5 68.8 -1.97 1 1 
1009 36.2 137.1 1.4 19.3 15.2 7.6 22.8 20.0 35.5 23.6 151.0 75.5 61.6 -3.57 1 1 
10010 37.8 149.7 1.5 16.9 7.8 5.2 13.0 11.0 33.6 7.1 153.2 77.7 72.0 -1.97 4 4 
10011 24.9 133.9 1.3 13.9 5.0 4.0 9.0 8.5 22.8 4.1 146.9 71.4 62.5 -3.70 1 1 
10012 31.3 139.9 1.4 16.0 7.8 4.4 12.2 10.2 28.1 7.2 147.9 72.4 67.5 -3.20 2 2 
10013 26.5 135.7 1.4 14.4 7.0 5.2 12.2 10.2 23.8 9.6 146.6 71.1 64.6 -3.50 3 2 
10014 32.2 154.5 1.5 13.5 5.8 4.8 10.6 8.5 29.5 7.1 152.7 77.2 77.3 -2.06 3 3 
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1002 9 5 2 112 5 5 2 3 3 26   7 0.4 7.5 2.9 
1003 4 5 3 70 5 5 3 3 15 27   11 1.0 7.3 7.2 
1004 2 2 6 46 5 5 3 4 21 22 15  7 1.5 7.5 11.2 
1006 7 7 6 116 2 4 4 1     11 0.7 7.3 5.4 
1007 5 4 4 77 5 5 3 5 3 18 35 24 11 0.6 7.3 4.2 
1008 2 6 7 69 4 5 3 3 21 17   8 0.8 4.0 3.3 
1009 4 1 0 41 5 2 2 2 18    27 0.4 8.3 3.1 
10010 2 3 5 48 5 5 2 4 18 17 26  11 0.5 7.3 3.6 
10011 3 1 10 62 5 5 2 5 18 3 34 35 11 2.5 7.3 18.1 
10012 2 3 5 48 4 3 2 3 18 21   7 0.8 7.5 6.2 
10013 12 2 4 130 5 5 3 4 35 24 27  11 0.5 7.3 3.6 
10014 12 0 0 108 5 5 3 3 18 37   7 0.2 7.5 1.4 
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1002 3 1.2 8.0 9.3 18 1.4 7.0 9.6 26 2.2 10.3 23.0 1.0 0.2 6.0 1.5 
1003 17 0.1 6.5 0.7 7 0.2 7.5 1.2 12 0.2 3.8 0.9 9.0 2.0 6.0 11.9 
1004 9 1.5 6.0 8.9 28 0.4 7.5 2.8 27 0.0 8.3 0.1 18.0 0.2 7.0 1.7 
1006 29 0.7 7.3 5.4 12 0.7 3.8 2.8 9 0.8 6.0 4.6 27.0 3.5 8.3 28.8 
1007 7 0.8 7.5 6.2 20 0.6 8.0 4.4 8 0.2 4.0 0.8 9.0 0.2 6.0 1.5 
1008 13 0.3 7.0 2.0 33 0.1 5.0 0.6 1 0.2 6.0 1.0 9.0 1.7 6.0 9.9 
1009 18 2.5 7.0 17.4 1 0.5 6.0 3.0         
10010 17 1.5 6.5 10.0 29 1.1 5.0 5.6 8 0.3 4.0 1.3 18.0 3.3 7.0 23.4 
10011 17 0.4 6.5 2.7 7 1.2 7.5 8.7 20 1.0 8.0 8.3 9.0 0.7 6.0 4.0 
10012 8 0.2 4.0 1.0 9 0.8 6.0 5.0 13 0.3 7.0 2.3 27.0 0.4 8.3 3.4 
10013 6 0.6 5.0 3.1 17 2.5 6.5 16.1 20 0.5 8.0 4.0 8.0 2.6 4.0 10.6 
10014 8 1.2 4.0 5.0 9 0.2 6.0 1.0 18 0.7 7.0 4.6 1.0 2.0 6.0 11.9 
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1002                 
1003 27 0.5 8.3 4.3 18 2.5 7.0 17.4 15 6.0 9.8 58.3     
1004 15 2.0 9.8 19.4 21 1.5 7.8 11.6         
1006 18 2.1 7.0 14.5 1 0.5 6.0 3.0         
1007 3 2.3 8.0 18.5 28 0.2 7.5 1.9 18 0.7 7.0 4.6 21 1.5 7.8 11.8 
1008                 
1009                 
10010 22 0.8 7.3 6.0 4 0.4 3.0 1.1 26 2.0 10.3 20.4     
10011 35 0.2 9.0 2.2 18 3.7 7.0 26.0 21 0.3 7.8 2.6 1 0.5 6.0 2.7 
10012 33 0.6 5.0 2.9 36 0.7 7.0 4.6 18 0.7 7.0 4.6 21 0.7 7.8 5.8 
10013 27 2.5 8.3 20.6 33 0.5 5.0 2.5 18 1.0 7.0 6.9 1 1.0 6.0 6.0 
10014 39 1.0 4.0 4.0             
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1002     46.3 10.0 18.3 14.2 1 7     
1003     102.0 60.3 28.1 44.2 1 14     
1004     55.7 5.8 29.5 17.6 1 7     
1006     64.6 15.9 42.0 29.0 1 13     
1007 32 0.2 4.8 0.8 78.6 17.3 69.6 43.4 1 19 32 0.2 4.8 0.8 
1008     16.8 10.5 18.3 14.4 1 2     
1009     23.4 9.7 28.8 19.2 1 6     
10010     71.6 26.6 70.2 48.4 1 14     
10011     83.2 8.6 26.7 17.6 1 12     
10012 26 1.8 10.3 18.7 56.1 17.6 65.4 41.5 1 6 26 1.8 10.3 18.7 
10013 38 0.2 5.5 1.4 75.2 18.7 57.0 37.8 1 13 38 0.2 5.5 1.4 
10014     27.9 23.4 28.0 25.7 1 9     
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1002 9.0 1.1  4.3 2.3 4.4 77293 47526 173 169 181 190 202 
1003 13.3 0.5  3.3 1.7 4.3 70301 34942 162 177 200 193 199 
1004 10.1 1.2  5.2 1.5 3.9 68499 40540 174 189 195 204 206 
1006 10.6 0.8  3.8 1.8 4.1 74433 35426 133 152 171 169 178 
1007 12.3 1.2  4.9 1.7 3.9 72115 42372 148 151 156 167 178 
1008 11.5 1.8  6.4 2.5 4.9 96217 54354 137 134 151 162 173 
1009 6.4 1.5  6.3 1.7 4.4 78929 65378 142 167 153   
10010 8.4 1.0  2.8 0.9 4.9 81099 45095 168 166 175 180 186 
10011 11.1 1.6  7.9 2.5 5.9 112467 59269 170 183 188 191  
10012 14.5 0.9  5.2 2.3 4.5 81284 59722 157 161 175 187 196 
10013 5.4 1.9  5.4 2.2 5.1 88791 62383 126 139 139 150 186 
10014 6.9 1.5  5.0 1.4 4.9 92651 51936 154 165 175 186 197 
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1002 9:43 AM 10:03 AM 20 130 176 179 165 192 188 128 
1003 9:56 AM 10:18 AM 22 126 176 193 180 189 190 113 
1004 10:02 AM 10:23 AM 21 130 189 192 188 202 198 135 
1006 10:58 AM 11:18 AM 20 140 180 183 183 193 190 118 
1007 9:27 AM 9:52 AM 25 81 127 144 152 167 158 113 
1008 10:00 AM 10:26 AM 26 125 163 178 173 180 181 101 
1009 9:19 AM 9:40 AM 21 108 165 172 170 173 159 105 
10010 10:15 AM 10:31 AM 16 120 183 189 177 191 190 130 
10011 10:15 AM 10:43 AM 18 135 168 170 167 181 179 135 
10012 10:21 AM 10:49 AM 28 130 173 175 163 186 193 116 
10013 11:37 AM 11:56 AM 19 120 158 164 170 172 177 109 
10014 9:59 AM 10:19 AM 21 146 181 192 190 174 157 120 
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1002 170 172 176 189 181 131 173 188 178 191 193 
1003 178 194 181 188 186 109 181 199 190 198 198 
1004 188 183 185 192 185 131 190 194 183 190 189 
1006 178 185 177 193 190 124 182 187 190 196 195 
1007 152 148 141 161 162 117 149 156 153 164 157 
1008 160 178 169 175 178 108 159 176 166 178 177 
1009 173 187 177 173 168 120 181 192 186 178 167 
10010 181 196 192 192 193 129 186 189 180 189 191 
10011 168 174 170 187 183 92 164 170 172 181 181 
10012 162 171 163 188 180 120 155 155 153 183 180 
10013 173 159 165 181 181 123 174 158 144 177 173 
10014 182 190 191 200 195 121 182 191 193 200 196 
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1002 R R 3743 0 3745 1 3754 0 3738 1 2447 74 
1003 R R 3767 0 3755 1 3821 0 3709 0 1748 44 
1004 R R 3655 -1 3705 0 3599 -2 3698 0 2004 57 
1006 R R 3840 0 3790 1 3889 1 3758 1 1240 31 
1007 R R 3801 0 3857 2 3909 1 3805 2 2065 62 
1008 R R 3726 -1 3737 1 3726 -1 3705 0 1560 37 
1009 R R 3854 1 3694 0 4023 2 3691 0 2620 72 
10010 R R 3775 0 3594 -1 3766 0 3613 -1 2069 55 
10011 R R 3720 -1 3625 -1 3751 0 3693 0 2093 84 
10012 R R 3699 -1 3621 -1 3640 -2 3647 0 1513 48 
10013 R R 3879 1 3757 1 3825 0 3835 2 1581 60 
10014 L L 3809 1 3653 1 3831 1 3584 0 1718 53 
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1002 297 95 106 650 5 169 3231 2672 1208 282 8 0 
1003 262 54 62 1075 6 258 2535 2219 1108 266 14 3 
1004 299 62 76 1319 7 307 2936 2952 1304 358 11 1 
1006 177 46 37 655 2 63 1853 843 339 79 2 0 
1007 286 72 79 1195 7 295 3170 1719 1294 214 10 2 
1008 294 22 53 426 1 58 1518 2358 707 180 4 0 
1009 366 95 83 858 4 115 2558 2630 952 217 6 0 
10010 227 99 76 1314 13 421 2607 3251 1654 301 10 1 
10011 392 35 79 1099 5 185 1468 4901 1489 421 10 1 
10012 261 32 53 897 7 308 1880 3227 1029 283 6 2 
10013 222 57 55 429 1 36 2474 1131 707 167 6 2 
10014 293 35 63 824 5 187 1555 2256 1014 238 6 0 
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1002 20.53 61.60 25.28 75.85 19.65 58.94 22.43 67.29 15.55 46.66 19.95 59.85 
1003 23.23 69.69 23.67 71.02 17.50 52.49 14.46 43.37 38.81 116.43 42.77 128.31 
1004 12.08 36.25 15.26 45.78  64.23 14.11 42.34 42.59 127.77 40.48 121.45 
1006 22.12 66.35 16.92 50.76 24.35 73.05 29.92 89.75 71.18 111.90 65.48 105.12 
1007 18.13 54.38 26.68 80.05 19.98 59.93 16.20 48.60 25.16 75.49 21.99 65.98 
1008 13.50 40.49 26.27 78.81  64.23  58.58 34.37 103.12 22.63 67.88 
1009 14.77 44.32 14.94 44.82 18.56 55.68 11.92 35.76 50.03 150.08 52.11 156.33 
10010 20.13 60.40 19.52 58.55 19.36 58.07 21.56 64.68 40.07 120.22 39.78 119.33 
10011 8.40 25.20 13.30 39.90 13.43 40.29 16.25 48.75 47.11 141.32 49.45 148.34 
10012 14.72 44.16 4.86 14.58 26.46 79.38 19.70 59.10 43.64 130.91 19.17 57.52 
10013 14.92 44.77 37.55 112.64 33.41 100.22 28.72 86.17 30.36 91.09 32.60 97.80 
10014 52.61 49.78 16.89 61.16 19.86 64.23 18.26 58.58 42.61 127.82 44.52 133.57 
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1002 27.17 81.51 36.02 108.05 3.05 2.97 2.67 3.22 
1003 47.68 143.05 41.48 124.43 2.21 2.65 2.28 1.82 
1004  116.55 41.69 125.06 3.92 3.39 4.21 3.08 
1006 60.00 116.55 66.48 131.95 3.61 3.79 4.10 3.89 
1007 22.48 67.44 25.77 77.31 3.38 4.08 3.87 4.31 
1008  116.55  131.95 2.73 3.59 4.21 3.90 
1009 54.43 163.28 56.79 170.37 5.11 6.18 5.33 5.37 
10010 10.20 30.60 35.86 107.59 3.26 4.14 4.42 3.75 
10011 52.80 158.39 60.34 181.02 5.25 5.86 6.55 5.83 
10012 59.68 179.04 58.14 174.43 4.05 5.69 4.75 4.85 
10013 37.01 111.04 45.69 137.06 3.99 3.68 4.59 4.08 
10014 38.19 114.56 38.05 114.14 3.77 3.44 3.53 2.64 
 
 
 
 
 
 
  
168 
 
ID
 
R
A
N
K
L
 -
 T
1
 (
p
m
o
l/
L
) 
D
il
u
ti
o
n
 F
a
c
to
r 
1
 
R
A
N
K
L
 -
 T
2
 (
p
m
o
l/
L
) 
D
il
u
ti
o
n
 F
a
c
to
r 
2
 
R
A
N
K
L
 -
 T
3
 (
p
m
o
l/
L
) 
D
il
u
ti
o
n
 F
a
c
to
r 
3
 
R
A
N
K
L
 -
 T
4
 (
p
m
o
l/
L
) 
D
il
u
ti
o
n
 F
a
c
to
r 
4
 
1002 5.45 544.65 6.21 620.88 5.71 571.45 5.60 560.12 
1003 4.32 432.41 3.32 331.73 3.72 372.31 4.41 440.78 
1004 4.36 435.76 3.27 327.37  323.02 3.39 338.69 
1006 1.72 172.45 1.88 187.70 1.24 123.60 1.54 154.11 
1007 8.57 317.43 6.75 317.58 7.78 323.02 7.32 340.71 
1008 2.88 287.70 2.24 224.21  323.02  340.71 
1009 1.06 105.52 1.41 141.41 1.94 194.32 1.50 150.21 
10010 4.35 434.93 3.85 385.12 4.72 471.56 5.90 590.15 
10011 4.69 469.07 5.00 500.44 4.67 466.58 4.44 444.12 
10012 0.70 70.29 1.23 122.76 1.19 118.66 0.94 93.54 
10013 0.49 49.13 0.61 61.33 0.37 36.65 0.41 41.37 
10014 4.90 489.78 5.90 590.39 5.52 552.06 5.94 594.00 
 
 
